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Date

Code

User

10/1/2009

LOCT

DCANO

CR

Peter D. McDermott

NCPI

DCANO

New Case Filed-Personal Injury

Peter D. McDermott

SMIS

DCANO

Summons Issued

Peter D. McDermott

COMP

DCANO

Verified Complaint and Demand for Jury Trial
Filed

Peter D. McDermott

DCANO

Filing: A - All initial civil case filings of any type not Robert C. Naftz
(Magistrate)
listed in categories B-H, or the other A listings
below Paid by: cooper and larsen Receipt
number: 0036486 Dated: 10/1/2009 Amount:
$88.00 (Check) For:

JANA

Plaintiff: Nield, Judy Attorney Retained Reed W
Larsen

Peter D. McDermott

10/26/2009

CAMILLE

Affidavit of return; srvd on Pocatello Health
services inc. thru Gard Skinner on 10-16-09

Robert C Naftz

11/12/2009

MEGAN

Filing: 11 - Initial Appearance by persons other
Robert C Naftz
than the plaintiff or petitioner Paid by: Hall Farley
Oberrecht & Blanton P.A. Receipt number:
0041727 Dated: 11/12/2009 Amount: $58.00
(Check) For: Pocatello Health Services, Inc.
(defendant)

CAMILLE

Def Pocatello Health services, inc Pocatello care Robert C Naftz
and Rehabilitation centers Answer to Plntts
Verified complaint and demand for Jury Trial;
aty Keely Duke for def Pocatello Health

CAMILLE

Defendant: Pocatello Health Services, Inc.
Attorney Retained Keely E Duke

CAMILLE

Notice of service - Def Pocatello Health services, Robert C Naftz
Inc. dba Pocatello care and rehabilitation centers
first set of Interrog. and requests for production of
documents to plntt: aty Keely Duke for def

1/16/2009

CAMILLE

Notice of Depo of Judy Nield on 1-12-2010 @
9am: aty Chris Comstock for def

i/19/2009

CAMILLE

Order for submission of information for
Robert C Naftz
scheduling Order; Plntt shall submit to the court,
within 14 days of the date of this Order, a
Stipulated statement: J Naftz 11-19-09

12012009

CAMILLE

Notice of sevice - Plntts First set of Discovery to
Def Pocatello Health Services, Inc.
aty Reed
larsen for plntt

1412009

CAMILLE

Stipulated Statement;

HRSC

NICOLE

Hearing Scheduled (Jury Trial 11/16/201009:00 Robert C Naftz
AM) 10-12 days requested

HRSC

NICOLE

Hearing Scheduled (Jury Trial 02/15/2011 09:00 Robert C Naftz
AM) 10 - 12 days requested

DCANO

Scheduling Order, Notice of Trial Setting and
Initial Pretrial Order

ATTR

ATTR

18/2009

Judge

Robert C Naftz

Robert C Naftz

Robert C Naftz

aty Reed Larsen for plntt Robert C Naftz

Robert C Naftz
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Judy Nield vs. Pocatello Health Services, Inc.

Judy Nield vs. Pocatello Health Services, Inc.
Date

Code

User

Judge

12/14/2009

CAMILLE

Notice of service - Plntfs Discovery Responses to Robert C Naftz
Def Pocatello Health Care: aty Reed larsen for
plntf

12/21/2009

CAMILLE

Notice Vacating Depo of Judy Neild; aty Keely
Duke for defs

Robert C Naftz

12/29/2009

CAMILLE

Amended Notice of Depo of Judy Nield on
2-18-2010: aty Chris Comstock

Robert C Naftz

12/30/2009

CAMILLE

Notice of service - Answers to Plntfs First set of Robert C Naftz
Interrog and REq for Production of Documents wi
this notice of service: aty Keely Duke for defs

1/4/2010

CAMILLE

Notice of Service - Plntfs Supplemental Discovery Robert C Naftz
Responses to Def Pocatello Health Services, Inc;
aty Reed Larsen for pInt

1/8/2010

CAMILLE

Second Amended Notice of Depositoin; set for
2-24-2010 @ 9am: aty Chris Comstock

4/21/2010

CAMILLE

Plaintiffs witness Disclosures;
for Plaintiff

6/212010

CAMILLE

Notice of service - Plntfs Second Supplemental
Robert C Naftz
Discovery Responses to def Pocatello Care &
Rehabilitation Centers First set of Interrog and req
for production of Documents to plntf: aty Reed
Larsen for plntf

6/10/2010

CAMILLE

Stipulation to Amend Scheduling Order; aty
Keely Duke for Def Pocatello Health Service

Robert C Naftz

6/11/2010

CAMILLE

Notice of Service - Plntfs Third Supplemental
Discovery Responses to Defendant Pocatello
Health Services, Inc. and this Notice: aty
Reed Larsen for p Intf

Robert C Naftz

6/16/2010

CAMILLE

Order granting Stipulation to Amend Scheduling
Order;
sl Judge Naftz 6-16-2010

Robert C Naftz

6/29/2010

CAMILLE

Robert C Naftz

aty Reed Larsen Robert C Naftz

Notice of Deposition of Mary Akina on 7-12-2010 Robert C Naftz
aty Reed Larsen for plntf

@ 8:30 am:
CAMILLE

Notice of Deposition of Melody Lee on 7-12-2010 Robert C Naftz
@ 10:30 am: aty Reed Larsen for plntf

CAMILLE

Notice of Deposition of Wendy Sneddon on
7-12-2010 @ 1:30 pm: aty Reed Larsen

Robert C Naftz

CAMILLE

Notice of Deposition of DAna Camphouse on
7-12-2010 @ 3:30 pm: aty Reed Larsen fo
rplntf

Robert C Naftz

CAMILLE

Notice of Deposition of Lachelle Pratt on
Robert C Naftz
7-13-2010 @ 8:30 am: aty Reed Laren for plntf

CAMILLE

Notice of Deposition fo Jill Schuette on 7-13-2010 Robert C Naftz
@ 10:30 am: aty Reed Larsen for plntf

CAMILLE

Notice of Deposition of TAra Tanner on
Robert C Naftz
7-13-2010 @ 1:30 pm: aty Reed Larsen for plntf

CAMILLE

Notice of DepOSition of Connie Funk on
Robert C Naftz
7-13-2010 @ 3:30 pm: aty Reed Larsen for plntf
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Case: CV-2009-0003869-PI Current Judge: Robert C Naftz
Judy Nield vs. Pocatello Health Services, Inc.

Judy Nield
Date

VS.

Pocatello Health Services, Inc.
Code

User

Judge

6/29/2010

CAMILLE

Notice of Depositon of Debra Cheatum on
7-14-2010 @8:30 am: aty Reed Larsen

7/212010

CAMILLE

Notice of service - First Supplemental Answers to Robert C Naftz
Plntfs First set of Interrog and requests for
Production of Documents and this Notice: aty
Keely Duke

7/8/2010

CAMILLE

Amended Notice of Deposition of connie Funk on Robert C Naftz
7-13-2010 @ 1pm: aty Reed Larsen for plntf

CAMILLE

Amended Notice of Deposition of Debra
Cheatum; set for 7-13-2010 @ 2pm: aty Reed
larsen for plntf

Robert C Naftz

CAMILLE

Amended Notice of Deposition of Melody Lee on
7-13-2010 @ 3pm: aty Reed Larsen for plntf

Robert C Naftz

CAMILLE

Amended Notice of Deposition of Lachelle Pratt Robert C Naftz
on 7-14-2010 @ 8am: aty Reed Larsen for plntf

CAMILLE

Amended Notice of Deposition of Dana
Camphouse on 7-14-2010 @ 9am: aty Reed
Larsen for plntf

Robert C Naftz

CAMILLE

Amended Notice of Deposition of Mary Akina on
7-14-2010 @ 10am: aty Reed Larsen for plntf

Robert C Naftz

CAMILLE

Amended Notice of Deposition of Wendy
Sneddon on 7-14-2010 @ 11am: aty Reed
Larsen for plntf

Robert C Naftz

CAMILLE

Amended Notice of Deposition of Jill Schuette on Robert C Naftz
7-14-2010 @ 1:30 pm: aty Reed Larsen for plntf

CAMILLE

Amended Notice of Deposition of Tara Tanner on Robert C Naftz
7-14-2010 @ 2:30 pm: aty Reed Larsen for plntf

7/22/2010

CAMILLE

Defendants Pocatello care and Rehabilitation
Centers expert witness disclosure: aty Keely
Duke

7/26/2010

CAMILLE

Motion for stay of Proceedings;
for plntf

CAMILLE

Affidavit of Reed Larsen in Support of Motion to
Stay Proceedings; aty Reed Larsen for pltnf

Robert C Naftz

CAMILLE

Notice of service - Def Pocatello I-iEtalth services
Inc. Pocatello Care and Rehabilitation Centers
Answers to Plntfs First set of Interog. aty Keely
Duke for def

Robert C Naftz

NICOLE

Hearing Scheduled (Motion for Summary
Judgment 09/13/201001:30 PM)

Robert C Naftz

CAMILLE

Notice of Hearing; set for Plntfs Motion for Stay
of Proceedings: on 8-23-2010 @ 1:30 pm: aty
Reed Larsen for plntf

Robert C Naftz

NICOLE

Hearing result for Motion for Summary Judgment Robert C Naftz
held on 09/13/201001:30 PM: Hearing Vacated
upon request of Defendant

3/412010

HRSC

3/6/2010

3/20/2010

HRVC

Robert C Naftz

Robert C Naftz

aty Reed Larsen Robert C Naftz

•_ _ .. _.
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Case:

Current Judge: Robert C Naftz

Judy Nield vs. Pocatello Health Services, Inc.

Judy Nield vs. Pocatello Health Services, Inc.
Date

Code

User

8/2012010

HRVC

NICOLE

Hearing result for Motion held on 08/23/2010
01 :30 PM: Hearing Vacated Motion for Stay of
Proceedings upon request of Plaintiff

Robert C Naftz

CAMILLE

Stipulation to Vacate; aty Reed Larsen for plntf

Robert C Naftz

NICOLE

Hearing result for Jury Trial held on 11/16/2010
09:00 AM: Hearing Vacated 10-12 days
requested

Robert C Naftz

CAMILLE

Order granting Stipulation to Vacate Trial; sl
Robert C Naftz
Judge Naftz 8-20-2010 (this matter shall be reset
to 2-15-28, 2011)

NICOLE

Hearing Scheduled (Motion for Summary
Judgment 11/08/201001:30 PM)

CAMILLE

Defendant Pocatello Health services, Inc DBA
Robert C Naftz
Pocatello care and rehabiltation centers Motin for
Summary Judgment; aty Keely Duke for def

CAMILLE

Memorandum in Support of Def Pocatello Health Robert C Naftz
Services, Inc DBA Pocatello Care and
Rehabilitation Centers Motion for summary
Judgment; aty Keely Duke

CAMILLE

Affidavit of Keely Duke in Support of Defendant
Pocatello care and Rehabilitation centers Motion
for Summary Judgment; aty Keely Duke for def

DCANO

Affidavit of Thomas J. Coffman, MD, in Support of Robert C Naftz
Defendant Pocatello Health Services, Inc. D/B/A
Pocatello Care and Rehabilitation Centers Motion
for Summary Judgment; Keely E. Duke, Attys for
Dfdts.

NICOLE

Continued (Motion for Summary Judgment
12/13/2010 01 :30 PM) Defendant's Motion upon
request of defense

Robert C Naftz

Notice of Deposition of Laree Dun on 11-9-2010

Robert C Naftz

8/23/2010

8/24/2010

HRVC

HRSC

10/8/2010

10/21/2010

10/28/2010

CO NT

CAMILLE

Judge

Robert C Naftz

Robert C Naftz

@ 9am: aty Javier Gabiola
CAMILLE

Notice of Deposition of Joyce Maxfield on
11-9-2010 @ 1pm: aty Javier Gabiola for plntf

Robert C Naftz

CAMILLE

Notice of Deposition of Thomas Coffman MD:
on 11-11-2010 @ 9:30am:
aty Javier Gabiola
for plntf

Robert C Naftz

CAMILLE

Notice of Deposition Derick Glum on 11-16-2010 Robert C Naftz
@ 9:30 am: aty Javier Gabiola for plntf
Notice of Depositon of Marji Brim on 11-19-2010
aty Javier Gaboiola for plntf

Robert C Naftz

CAMILLE

Stipulation to vacate trial and amend scheduling
order; aty Keely Duke

Robert C Naftz

CAMILLE

Amended Notice of Deposition of Thomas J
Coffman, MD: (11-19-20109am)
aty Javier
Gabiola for plntf

Robert C Naftz

CAMILLE

@ 1:30pm:
11/15/2010

uate: til12/2011

I'ldicial District Court - Bannock

Time: 09:36 AM
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Case: CV-2009-0003869-PI Current Judge: Robert C Naftz
Judy Nield vs. Pocatello Health Services, Inc.

Judy Nield vs. Pocatello Health Services, Inc.
Date

Code

11/15/2010

11/18/2010

11/29/2010

11/30/2010

12/112010

21212010

HRSC

User

Judge

CAMILLE

Amended Notice of Deposition of Joyce Maxfield; Robert C Naftz
set for Joyce Maxfield on 11-17-2010 1pm): aty
Javier Gabolia for plntt

CAMILLE

Amended Notice of Deposiiton of Derrick Glum;
on 11-16-2010 @ 8:30 am: atyJavier Gabolia
for plntt

Robert C Naftz

CAMILLE

Amended Notice of hearing; set for 12-13-2010
@ 1:30 pm: aty Keely Duke for Def.

Robert C Naftz

CAMILLE

Defendant Pocatello care and rehabilitation
centers first supplemental expert witness
disclosure; aty Keely Duke

Robert C Naftz

CAMILLE

Amended Notice of Deposition ofTaree Dunn on Robert C Naftz
11-17-2010 @ 9am: aty Javier Gabiola for p Intt

CAMILLE

Memorandum in support of Plaintiffs Motion to
Strike the Affidavit of Dr. Coffman:
aty Reed
Larsen for plntt

Robert C Naftz

CAMILLE

Motion to continue hearing on Summary
Judgment or in the Alternative Additional time to
suppplement the record: aty Reed Larsen for
plntt

Robert C Naftz

CAMILLE

Memorandum in support of pints motion to
continue hearing on summary judgment or in the
alternative additional time to supplement the
record; aty Reed Larsen for plntt

Robert C Naftz

CAMILLE

Memorandum in opposition to defendants motion Robert C Naftz
for summary judgment; aty Reed Larsen for
plntt

CAMILLE

Affidavit of Reed Larsen in support of plntts
Robert C Naftz
opposition to defs motion for summary judgment;
aty Reed Larsen for plntt

NICOLE

Hearing Scheduled (Motion 12/13/201001:30
PM) Motion to Strike Affidavit of Dr. Coffman

Robert C Naftz

CAMILLE

Affidavit of Suzanne Frederick; aty Suzann
Frederick for plntt

Robert C Naftz

CAMILLE

Motion to strike the Affidavit of Dr. Coffman; aty Robert C Naftz
Reed Larsen for plntt

CAMILLE

Affidavit of Javier Gabiola in support of plntts
Robert C Naftz
motion to continue hearing on summary judgment
or in the alternative additional time to
supplemental the record: aty Reed Larsen for
plntt

CAMILLE

Affidavit of Hughes Selznick, MD; aty Reed
Larsen for plntt

Robert C Naftz

CAMILLE

Affidavit of Sidney Gerber;

Robert C Naftz

CAMILLE

Notice of hearing; set for 12-13-2010 @ 1:30
pm: aty Reed Larsen for plntt

Robert C Naftz
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Case: CV-2009-0003869-PI Current Judge: Robert C Naftz
Judy Nield vs. Pocatello Health Services, Inc.

Judy Nield vs. Pocatello Health Services, Inc.
Date

Code

12/6/2010

218/2010

CO NT

2/9/2010

U17/2010

21/2011

HRVC

User

Judge

CAMILLE

Motion to strike portions of the affidavit s of Hugh Robert C Naftz
Selznick, MD Suzanne Frederick and Sidney
Gerber; aty Keely Duke for def

CAMILLE

Memorandum in Opposition to plntfs Motion to
Robert C Naftz
continue hearing on summary Judgment or in the
Alternative Additional time to supplement the
record: aty Keely Duke for def

CAMILLE

Motion to Shorten Time Regarding Motin to Strike Robert C Naftz
Portions of the Affidavits of Hugh Selznick, MD
Suzanne Frederick and Sidney Gerber; aty
Keely Duke for def

CAMILLE

Notice of Hearing regarding motion to strike
portions of the affidavit s of Hug Selznick, MD
Suzann Frederick and Sidney Gerber: aty
KeelyDuke for def

Robert C Naftz

CAMILLE

Memorandum in Opposition t oplntf to plntfs
motion to strike the affidavit of Dr. Coffman; aty
Keely Duke for def

Robert C Naftz

CAMILLE

Reply Memorandum in support of def pocatello
Health services, Inc DBA Pocatello care and
rehabiliation centers motion for summary
judgment. aty Keely Duke for Def

Robert C Naftz

CAMILLE

Memorandum in support of motion to strike
portions of the affidavit of Hugh Selznick, MD
Suzanne Frederrick and Sidney Gerber; aty
Keely Duke

Robert C Naftz

NICOLE

Continued (Jury Trial 10/25/2011 09:00 AM)
10-12 days requested; 9 scheduled

Robert C Naftz

CAMILLE

Order granting stipulation to amend scheduling
order; sl Judge Naftz 11-22-2010

Robert C Naftz

CINDYBF

Reply Memorandum in Support of Plaintiffs
Robert C Naftz
Motion to Continue Hearing on Summary
Judgment or in the Alternative Additional Time to
Supplement the Record- by PA Larsen.

CINDYBF

Reply Memorandum in Support of Plaintiffs
Motion to Strike the Affidavit of Dr. Coffman- by
PA Larsen.

CINDYBF

Memorandum in Opposition to Defendant's
Robert C Naftz
Motion to Strike Portions of the Affidavits of Hugh
Selznick, MD, Suzanne Frederick and Sidney
Gerber- by PA Larsen.

CAMILLE

Notice of service - Plaintiffs Second set of
Discovery to Defendant: aty Javier Gabiola for
plntf

NICOLE

Hearing result for Motion held on 12113/2010
Robert C Naftz
01 :30 PM: Hearing Vacated Motion to Continue
Hearing on Summary Judgment; withdrawn by
Plaintiff

Robert C Naftz

Robert C Naftz

";IALII ""'UI'->Ii:U UI5trlCt lOOUn -
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Case:

Current Judge: Robert C Naftz
Judy Nield

Judy Nield

VS.

VS.

Pocatello Health Services, Inc.

Pocatello Health Services, Inc.

Date

Code

User

1/21/2011

DCHH

NICOLE

Hearing result for Motion held on 12/13/2010
01 :30 PM: District Court Hearing Held
Court Reporter: Stephanie Davis
Number of Transcript Pages for this hearing
estimated: less than 100 pages
Motion to Strike Affidavit of Dr. Coffman

DCHH

NICOLE

Hearing result for Motion for Summary Judgment Robert C Naftz
held on 12/13/201001:30 PM: District Court
Hearing Held
Court Reporter: Stephanie Davis
Number of Transcript Pages for this hearing
estimated: less than 100 pages
Defendant's Motion

CAMILLE

Memorandum Decision and Order; Defendants
Motion for Summary Judgment is hereby
GRANTED: sl Judge Naftz 1-21-2011

Robert C Naftz

CAMILLE

Plaintiffs motion for reconsideration;
Larsen for plntf

aty Reed

Robert C Naftz

CAMILLE

Memorandum in support of Plaintiffs Motion for
Recosnsideration; aty Reed Larsen for plntf

Robert C Naftz

NICOLE

Hearing Scheduled (Motion 02/28/2011 01 :30
PM) Motion for Reconsideration (Plaintiff)

Robert C Naftz

2/9/2011

CAMILLE

Notice of hearing; set for plntf motion for
reconsideration on 2-28-2011 @ 1:30 pm: aty
Javier Gabiola for plntf

Robert C Naftz

2/18/2011

CAMILLE

Pocatello Health services, inc dba Pocatello care Robert C Naftz
and rehabilitation centers Memorandum in
opposition to plntfs motion for reconsideration;
aty Keely Duke for def

2/412011

2/8/2011

HRSC

Judge
Robert C Naftz

212412011

STIP

DCANO

Stipulation to Vacate Hearing on Motion for
Reconsideration; Keely E. Duke, Atty for Dfdts.

Robert C Naftz

U25/2011

CO NT

NICOLE

Robert C Naftz
Continued (Motion 03/28/2011 01 :45 PM)
Motion for Reconsideration (Plaintiff) per stipulatin

CAMILLE

Reply Memorandum in support of plaintiffs motion Robert C Naftz
for reconsideration; aty Reed Larsen

11312011

OR DR

DCANO

Order Granting Stipulation to Vacate Hearing on
Plaintiffs Motion for Reconsideration; Javier L.
Gabiola, Atty for Plntfs.

Robert C Naftz

128/2011

INHD

BRANDY

Hearing result for Motion held on 03/28/2011
01 :45 PM: Interim Hearing Held Motion for
Reconsideration (Plaintiff)

Robert C Naftz

1312011

HRVC

BRANDY

Hearing result for Jury Trial held on 10/25/2011
09:00 AM: Hearing Vacated 10-12 days
requested; 9 scheduled

Robert C Naftz

CAMILLE

Memorandum Decision and Order; Plaintiffs
Motion for rexonsideration is hereby DENIED;
court will prepare judgment: sl Judge Naftz

Robert C Naftz

Udlt::.
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Case: CV-2009-0003869-PI Current Judge: Robert C Naftz
Judy Nield vs. Pocatello Health Services, Inc.

Judy Nield vs. Pocatello Health Services, Inc.
Date

Code

User

5/3/2011

JDMT

CAMILLE

Judgment; court DENIED the plntf Motion for
reconsideration, court is hereby ordered and
adjudged that all of the plntfs claims against the
def in this matter are dismissed withprej: sl
Judge Naftz 5-3-2011

Robert C Naftz

CSTS

CAMILLE

Case Status Changed: Closed

Robert C Naftz

NOELIA

Filing: L4 - Appeal, Civil appeal or cross-appeal to Robert C Naftz
Supreme Court Paid by: Larsen, Reed W
(attorney for Nield, Judy) Receipt number:
0016659 Dated: 5/12/2011 Amount: $101.00
(Check) For: Nield, Judy (plaintiff)

APSC

DCANO

Appealed To The Supreme Court

Robert C Naftz

NOTC

DCANO

Notice of Appeal: Javier L. Gabiola, Atty for
Plaintiff

Robert C Naftz

MISC

DCANO

Received Check #27668 for $101.00 filing fee on Robert C Naftz
Appeal and Check # 27669 for $100.00 for
Deposit of Clerk's Record.

CAMILLE

Pocatello Health Services, Inc. dba Pocatello care Robert C Naftz
and rehabilitation centers motion for costs; aty
Keely Duke for Oef.

CAMILLE

Pocatello Health services, Inc dba Pocatello care Robert C Naftz
and rehailitation centers verified Memorandum of
costs; aty Keely Duke for def

CAMILLE

Affidavit of ocunsel in support of Memorandum for Robert C Naftz
fees and costs; aty Keely Duke for def

CAMILLE

Pocatello Health services, Inc's Memorandum in Robert C Naftz
support of Motion to amend Judgment; aty Keely
Duke for def

CAMILLE

Pocatello Health services, Inc's Motion to Amend Robert C Naftz
Judgment; aty Keely Duke

HRSC

NICOLE

Hearing Scheduled (Motion 06/13/2011 02:00
PM) Motion for Costs
Motion to Amend Judgment

Robert C Naftz

CSTS

NICOLE

Case Status Changed: Closed pending clerk
action

Robert C Naftz

MISC

DCANO

CLERK'S CERTIFICATE OF APPEAL: Signed
and Mailed to Counsel and SC on 5-24-11.

Robert C Naftz

CAMILLE

Notice of hearing; aty Keely Duke for def

Robert C Naftz

CAMILLE

Defendant Pocatello Health services, Inc's
requests for additions to the clerks record; aty
Keely Duke

Robert C Naftz

CAMILLE

Plaintiff's Memorandum i n Opposition to Def
Robert C Naftz
Pocatello Health services, Inc. dba Pocatello care
and rehabilitation centers motion to amend
judgment and motion for costs; aty Reed larsen

5/12/2011

5/17/2011

5/18/2011

5/19/2011

5/24/2011
5/25/2011

3/26/2011

Judge
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Case: CV-2009-0003869-PI Current Judge: Robert C Naftz
Judy Nield vs. Pocatello Health Services, Inc.

Judy Nield vs. Pocatello Health Services, Inc.
Date

Code

User

Judge

CAMILLE

Affidavit of Javier Gabiola in support of plaintiffs
Memorandum in opposition to defs pocatello
health services, Inc dba pocatello care and
rehabilitation centers motion to amend judgment
and motion for costs; aty Reed larsen

DCANO

IDAHO SUPREME COURT; Notice of Appeal
Robert C Naftz
received in SC on 5-26-11. Docket Number #
38823-2011. Clerk's Record and Reporter's
Transcripts must be filed in SC on 8-3-11.
(6-30-11 5 weeks prior). The following Transcritps
to be lodged: Motion for Summary Judgment
12-13-10 and Reconsideration 3-28-11.

DCANO

IDAHO SUPREME COURT; Clerk's Certificate
filed with SC. Examine Title of Cert. if any
corrections contact Dist. Clerk. Title in the Cert.
must appear on all documents filed with SC.

Robert C Naftz

DCANO

Pocatello Health Services, Inc. dba Pocatello
Care and Rehabilitation Center's Reply
Memorandum in Support of Motion for Costs;
Keely E. Duke, Atty for Defendants.

Robert C Naftz

DCANO

Defendant Pocatello Health Services, Inc.'s
Second Request for Additions to the Clerk's
Record.! Keely E. Duke, Atty for Defendants.

Robert C Naftz

DCANO

Pocatello Health Services, Inc.'s Reply
Memorandum in Support of Motion to Amend
Judgment; Keely E. Duke, Atty for Defendants.

Robert C Naftz

DCANO

Pocatello Health Services, Inc. dba Pocatello
Care and Rehabilitation Center's Amended
Verified Memorandum of Costs; Keely E. Duke,
Atty. for Defendants.

Robert C Naftz

6/10/2011

CAMILLE

3/16/2011

CAMILLE

Affidavit of counsel in support of Pocatello health Robert C Naftz
services, inc. dba Pocatello care and
rehabilitation centers reply memorandum in
support of motion for costs: aty Keely Duke for
def
Robert C Naftz
Plaintiffs request for additions to clerks record;
aty Reed Larsen
Robert C Naftz
Hearing result for Motion held on 06/13/2011
02:00 PM: District Court Hearing Held
Court Reporter: Stephanie Davis
Number of Transcript Pages for this hearing
estimated: less than 100 pages
Motion for Costs
Motion to Amend Judgment

5/27/2011

6/2/2011

MISC

6/9/2011

3/17/2011

:;/20/2011

DCHH

NICOLE

CAMILLE

Minute Entry and Order; Plntfs Motion to Amend
Judgment and Motion for costs are DENIED:
sl Judge Naftz 6-20-2011

Robert C Naftz

Robert C Naftz
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Case: CV-2009-0003869-PI Current Judge: Robert C Naftz
Judy Nield vs. Pocatello Health

~ervices.Jnc.

Judy Nield vs. Pocatello Health Services, Inc.
Date

Code

User

7/7/2011

MISC

DCANO

IDAHO SUPREME COURT; Documents filed in
Robert C Naftz
SC. Defendant Pocatello Helath Serivces, Inco's
Request for Additions to the Clerk's Record and
Defendant Poctello Haelth Service, Inc.'s Second
Request for Additions to the Clerk's Record.

DCANO

REPORTER'S TRANSCRIPTS received in Court Robert C Naftz
Records on 7-26-11 from Stephanie Davis for the
following hearings: Dfdts. Motn Summary Judge,
Motion to Strike, Plntts Motion to Strike and Motn
to Continue held 12-13-10. Pltnfs. Motion to
Reconsider held 3-28-11.

DCANO

CLERK'S RECORD RECEIVED IN Court
Records on 8-12-11.

7/26/2011

8/12/2011

MISC

Judge

Robert C Naftz

Keely E. Duke

A!4

ISB #6044; ked@hallfarley.com

.t';IO: 0 I

Chris D. Comstock
ISB #6581; cdc@hallfarley.com

HALL, FARLEY, OBERRECHT & BLANTON, P.
702 West Idaho, Suite 700
Post Office Box 1271
Boise, Idaho 83701
Telephone:
(208) 395-8500
Facsimile:
(208) 395-8585
W:\4\4-568.! \Pleadings\MSJ-HFOB Noh.doc

Attomeys for Defendant Pocatello Health Services, Inc. d/b/a Pocatello Care and Rehab

IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,
Case No. CV 09 3869 PI
Plaintiff,
NOTICE OF HEARING
vs.
POCATELLO HEALTH SERVICES, INC., a
Nevada corporation, d/b/a POCATELLO
CARE AND REHAB, and JOHN DOES I-X,
acting as agents and employees of
POCATELLO HEALTH SERVICES, INC.,
d/b/a Pocatello Care and Rehab,

ORIGINAL

Defendants.

PLEASE TAKE NOTICE, defendant Pocatello Health Services, Inc., d/b/a Pocatello
Care and Rehab ("Pocatello Care and Rehab"), by and through its counsel of record, has set
before this Court to be heard a Motion for Summary Judgment. Said motion shall be heard on
the 8th day of November, 2010 at the hour of 1:30 p.m. before the Honorable Robert c. Naftz.

NOTICE OF HEARING - 1

448

DATED this

113, day of October, 2010.
HALL, FARLEY, OBERRECHT &
BLANTON, P.A.

I,

BY:-p-:M4qpt:..-¥--=_~~~_ _ __

K ely E. uke - 0 the Firm
Chris D. Comstock - Of the Firm
Attorneys for Defendant Pocatello Health
Services, Inc. d/b/a Pocatello Care and Rehab

CERTIFICATE OF SERVICE

}"fJ.

I HEREBY CERTIFY that on the
day of October, 2010, I caused to be served a
true copy of the foregoing NOTICE OF HEARING, by the method indicated below, and
addressed to each of the following:
Reed W. Larsen
COOPER & LARSEN, CHARTERED
151 North 3rd Avenue, 2nd Floor
P.O. Box 4229
Pocatello, ID 83205-4229
Fax: (208) 235-1182
Attorneys for Plaintiff

D

U.S. Mail, Postage Prepaid
~Hand Delivered
D Overnight Mail
D Telecopy

NOTICE OF HEARING - 2

449

Keely E. Duke
ISB #6044; ked@hallfarley.com

Chris D. Comstock
ISB #6581; cdc@hallfarley.com

HALL, FARLEY, OBERRECHT & BLANTON, P.A.
702 West Idaho, Suite 700
Post Office Box 1271
Boise, Idaho 83701
Telephone:
(208) 395-8500
Facsimile:
(208) 395-8585
W:\4\4-568.1 \Discovery\Defendant's Expert Disclosure.First Supplemental.doc
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IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,
Case No. CV 09 3869 PI
Plaintiff,

DEFENDANT POCATELLO CARE
AND REHABILITATION CENTER'S
FIRST SUPPLEMENTAL EXPERT
WITNESS DISCLOSURE

vs.
POCATELLO HEALTH SERVICES, INC., a
Nevada corporation, d/b/a POCATELLO
CARE AND REHABILITATION CENTER,
and JOHN DOES I-X, acting as agents and
employees of POCATELLO HEALTH
SERVICES, INC., d/b/a POCATELLO CARE
AND REHABILITATION CENTER,
Defendants.

COMES NOW defendant Pocatello Health Services, Inc., d/b/a Pocatello Care and
Rehabilitation Center ("the Center") by and through its counsel of record Hall, Farley, Oberrecht
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& Blanton, P.A., and hereby makes the following disclosures pursuant to Rule 26(b)(4) of the

Idaho Rules of Civil Procedure related to experts who may be called to testify at trial:
SUPPLEMENTAL DISCLOSURES
Without waiving such objections, and subject to such reservations, the Center makes the
following supplement to its Expert Disclosure provided on July 21, 2010:
Thomas J. Coffman, M.D.
125 E. Idaho Suite 203
Boise, Idaho 83712
•

Dr. Coffman may testify regarding causation of Ms. Nield's left below knee
amputation. Specifically, Dr. Coffman may testify that Ms. Nield's comorbidities
including but not limited to:

poorly controlled diabetes; chronic non healing

ulcers caused by leukocytoclastic vasculitis and severe neuropathy of the left
lower extremity may have eventually required a below left knee amputation
regardless of whether or not she was MRSA colonized.
•

Dr. Coffman may testifY that Ms. Nield's left leg below knee amputation was
more likely required as a result of her leukocytoclastic vasculitis as opposed to
her MRSA colonization. Dr. Coffman will testify regarding the characteristics,
causes, symptoms and effects of leukocytoclastic vasculitis and the effect Ms.
Nield's leukocytoclastic vasculitis had on her. Dr. Coffman will explain how Ms.
Nield's leukocytoclastic vasculitis interacted with her MRSA colonization.

•

Dr. Coffman will testify that if Ms. Nield had contracted MRS A in the Center, it
would be expected that she would have contracted a hospital acquired strain of
MRSA, as opposed to a community acquired strain. Dr. Coffman will testify that
the strain of MRSA Ms. Nield was identified with is a mixture of hospital
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acquired and community acquired MRSA, that is more closely associated with
community rather than hospital acquired MRS A based upon an antibiotic
susceptibility profile.

ARTICLES
Literature upon which Dr. Coffman may rely or testify concerning:

•
•

Methicillin-Resistant Staphylococcus aureus Disease in Three Communities, NEW
ENG. J. MED. 2005; 352:1436-1444
The Role of Nasal Carriage in Staphylococcus aureus Infections,
2005, 5: 751-62

THE LANCET

INFECTIOUS DIS.

•

Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic,
and Therapeutic Odyssey, CLINICAL INFECTIOUS DISEASES 2005; 40:562-73

•

Throat Swabs Are Necessary to Reliably Detect Carriers of Staphylococcus
aureus, CLINICAL INFECTIOUS DISEASES 2007; 45:475-7

•

Methicillin-Resistant Staphylococcus aureus (MRSA) Nares Colonization at
Hospital Admission and Its Effect on Subsequent MRSA Infection, CLINICAL
INFECTIOUS DISEASES 2004; 39:776-82

•

Predicting the Staphylococcus aureus Nasal Carrier State: Derivation and
Validation ofa "Culture Rule ", CLINICAL INFECTIOUS DISEASES 2004; 39:806-11

•

Community-Associated Methicillin-Resistant Staphylococcus aureus: The Way to
the Wound Is through the Nose, THE JOURNAL OF INFECTIOUS DISEASES 2006;
193:169-71

•

Predicting the Staphylococcus aureus Nasal Carrier State: Derivation and
Validation of a "Culture Rule ", CLINICAL INFECTIOUS DISEASES 2004; 39:80611.
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Discovery in this matter is still underway, and the Center reserves the right to supplement
these opinions based upon its experts' review of depositions in this case that have not yet been
taken and any other additional discovery, including additional documents that are provided to
them.
DATED this

{"'~ay of November, 2010.
HALL, FARLEY, OBERRECHT &
BLANTON, P.A.

By.~~~~~~~~_ _ _ __

Keely E. Duke - Of the Firm
Chris D. Comstock - Of the Firm
Attorneys for Defendant Pocatello Health
Services, Inc. d/b/a Pocatello Care and
Rehabilitation Center
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on the Ib;-day of November, 2010, I caused to be served a
true copy of the foregoing POCATELLO CARE AND REHABILITATION CENTER'S
FIRST SUPPLEMENTAL EXPERT WITNESS DISCLOSURE, by the method indicated
below, and addressed to each of the following:
Reed W. Larsen
COOPER & LARSEN, CHARTERED
151 North 3rd Avenue, 2nd Floor
P.O. Box 4229
Pocatello, ID 83205-4229
Fax: (208) 235-1182
Attorneys for Plaintiff
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Keely E. Duke

DEFENDANT POCATELLO CARE AND REHABILITATION CENTER'S FIRST SUPPLEMENTAL EXPERT WITNESS
DISCLOSURE -5

454

I

_

A

I;~"h..trc.. ~,~

The NEW ENGLAND JOURN

I~I

_________________

O
__R_I_G_I_N_A
__L_A_R_._T_I_C_L_E________________

~II

Methicillin-Resistant Staphylococcus aureus
Disease in Three Communities
Scott K. Fridkin, M.D., Jeffrey C. Hageman, M.H.S .. Melissa Morrison, M.P.H.,
Laurie Thomson Sanza. R.N., Kathryn Como·Sabetti, M.P.H.,
John A.Jernigan, M.D., Kathieen Harriman, Ph.D., Lee H. Harrison, M.D.,
Ruth Lynfield, M.D., and Monica M. Farley. M.D., for the /\ctivc Bacterial Core
Surveillance Program oftne Emerging Infections Prograrn Network

ABSTRACT

BACKGROUND

From the Division of Bacterial and Mycotic
Diseases (S.K.F.) and Division of Health·
care Quality Promotion U.C.H., M.M.,
J.A.J.), National Center for Infectious Dis·
eases, Centers for Disease Control and Pre·
vention, Atlanta; Emory University School
of Medicine and the Veterans Affairs Med·
ical Center, Atlanta (M.M.,J.A.J., M.M.F.);
Johns Hopkins University Bloomberg
School of Public Health, Baltimore (L.T.S.,
L.H.H.); and the Minnesota Department
of Health, Minneapolis (K.C.·S., KH.,
R.L.). Address reprint requests to Dr. Frid·
kin at the CDC, NCID, DBMD, MDB, MS
C·09, 1600 Clifton Rd., NE, Atlanta, GA
30333, or at skfO@cdc.gov.
N Engl J Med 2005;352:1436·44.
Copyright © 2005 Mass.,husens Medical Society.

Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in patients who
do not have the established risk factors. The national burden and clinical effect of this
novel presentation of MRS A disease are unclear.
METHODS

We evaluated MRSA infections in patients identified from population-based surveillance
in Baltimore and Atlanta and from hospital-laboratOly-based sentinel surveillance of
12 hospitals in Minnesota. Information was obtained by interviewing patients and by
reviewing their medical records. Infections were classified as community-acquired
MRSA disease if no established risk factors were identified.
RESULTS

From 2001 through 2002, 1647 cases ofcommunity-acquired MRSA infection were reported, representing between 8 and 20 percent ofall MRSA isolates. The annual disease
incidence varied according to site (25.7 cases per 100,000 population in Atlanta vs.
18.0 per 100,000 in Baltimore) and was significantly higher among persons less than
two years old than among those who were two years ofage or older (relative risk, 1.51;
95 percent confidence interval, 1.19 to 1.92) and among blacks than among whites in
Atlanta (age-adjusted relative risk, 2.74; 95 percent confidence interval, 2.44 to 3.07).
Six percent ofcases were invasive, and 77 percent involved skin and soft tissue, The infecting strain of MRSA was often (73 percent) resistant to prescribed antimicrobial
agents. Among patients with skin or soft-tissue infections, therapy to which the infecting strain was resistant did not appear to be associated with adverse patient-reported
outcomes. Overall, 23 percent of patients were hospitalized for the MRSA infection.
CONCLUSIONS

Community-associated MRSA infections are now a common and serious problem.
These infections usually involve the skin, especially among children, and hospitalization is common.
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N THE UNITED STATES, STAPHYLOCOCCUS

percent of the licensed hospital beds in the state).

aureus is the most common cause of skin and Laboratories served both outpatient clinic networks
soft-tissue infections, as well as ofinvasive infections acquired in hospitals.1,2 Treatment ofserious S. aureus infections can be challenging, and the
associated mortality rate remains 20 to 25 percent
despite the availability of highly active antimicrobial
agents. 3,4 However, most antistaphylococcal agents
are ineffective against methicillin-resistant S. aureus
(MRSA), which was first identified as a hospitalacquired pathogen in the 1960s. 2,3,5,6
Over the past 40 years, MRSA infections have
become endemic in most U.S. hospitals1,2 and hospitals worldwide, 7 striking, with rare exception,
only patients with established risk factors. 8,9 More
recently, however, MRSA infections have been described in patients without established risk factors
who are living in the community.10-19 The current
approach to suspected cases of community-associated (also referred to as community-acquired)
S. aureus infections (suggested by findings offurunc1es, abscesses, or cellulitis) commonly includes
empirical treatment with f3-lactam antibiotics. This
approach may need to be reconsidered if community-associated MRSA becomes a clinically significant pathogen.
The Centers for Disease Control and Prevention
(CDC) and three sites participating in the Emerging Infections Program began a specialized MRSA
surveillance project in 2001 using the Active Bacterial Core Surveillance program, a population-based
surveillance component ofthe Emerging Infections
Program Network designed to study the epidemiologic features of invasive bacterial disease and to
track drug resistance in the United States. We used
these data to evaluate the incidence of endemic
community-associated MRSA infection, racial disparities in the incidence, patterns of antimicrobial
susceptibility, and clinical outcomes in several areas
in the United States.
METHODS
SURVEILLANCE POPULATION

The MRSAActive Bacterial Core Surveillance project
monitored all MRSA isolates from all body sites
from patients in 11 Baltimore hospitals serving a
population of700,000; Health District 3 in greater
Atlanta, comprising eight counties with a total population of 3.3 million; and 12 sentinel hospitalbased laboratories representative of the state in
Minnesota (6 rural and 6 urban, representing 16

N ENGl J MED 352;14

and hospital inpatients; sites in Atlanta included
several referral laboratories serving predominantly ambulatory care settings. Surveillance was performed consecutively for 12 months in Baltimore
(beginning February 2002), 18 months in Atlanta
(beginning July 2001), and 24 months in Minnesota (beginning January 2001). In Baltimore, 1 of
12 eligible hospitals declined to participate in the
MRSA study; however, this omission would be unlikely to have a substantial effect. The laboratory in
that hospital historically reports only about 5 percent of the cases ofinfections with other pathogens
under surveillance as part of the Active Bacterial
Core Surveillance system in Baltimore.
CASE DEFINITIONS AND ASCERTAINMENT

A community-associated MRSA isolate was defined
as an MRSA isolate recovered from a clinical culture from a patient residing in the surveillance area
who had no established risk factors for MRSA infection. Established risk factors included the isolation of MRSA two or more days after hospitalization; a history of hospitalization , surgery, dialysis,
or residence in a long-term care facility within one
year before the MRSA-culture date; the presence of
a permanent indwelling catheter or percutaneous
medical device (e.g., tracheostomy tube, gastrostomy tube, or Foley catheter) at the time ofculture;
or previous isolation of MRSA. We reviewed the
medical records ofpatients with suspected community-associated MRSA isolates to identifY risk factors for infection. We attempted to interview by telephone all patients for whom no risk factors were
identified to confirm the absence of established
risk factors and to obtain a brief history of the clinical outcome. At least 15 attempts were made, after
which suspected community-associated MRSA isolates were classified as confirmed in the case of
patients who were successfully interviewed and confirmed to have no established risk factors or as
probable in the case ofpatients who were not interviewed but who had no established risk factors on
a review of medical records. The remaining isolates
were classified as either health care-associated
when established risk factors were identified or indeterminate if no information on the patient could
be obtained.
A case of community-associated MRSA disease
was defined as illness compatible with staphylococcal disease in a patient residing in the surveillance
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areas and isolation ofcommunity-associated MRSA
from a clinically relevant site. Only a subgroup of
patients with community-associated MRSA isolates
had actual disease and achieved case status.
To identifY cases, surveillance personnel routinely contacted all clinical microbiology laboratories
serving residents of each catchment area regarding
MRSA isolated from clinical cultures (infectioncontrol surveillance cultures were excluded). Periodic audits oflaboratory records were conducted by
surveillance personnel to identifY any unreported
cases and ensure the completeness of reporting.
Surveillance personnel collected information on patients using a standardized questionnaire that included demographic and isolate data on all MRSA
isolates; information on antimicrobial-susceptibility testing (with results characterized as susceptible, intermediate, or resistant) and clinical characteristics were obtained from available medical
records (e.g., emergency room, primary care, or
hospital) only for patients with confirmed or probable community-associated MRSA isolates. The collection of additional data on disease outcome,
employment status, household structure, socioeconomic status, and level of education was limited to
patients with confirmed cases of community-associated MRSA disease.
The study was approved by the appropriate institutional review boards at the participating sites,
including all participating Baltimore hospitals, the
Maryland Department of Health and Mental Hygiene, lohns Hopkins University Bloomberg School
of Public Health, the Georgia Department ofHuman Resources, Emory University School ofMedicine, the Minnesota Department of Health, and the
CDC. Oral informed consent was obtained from all
those who were interviewed.
STATISTICAL ANALYSIS

Statistical analysis was conducted with SAS software (SAS Institute). Annual cumulative incidence
rates were calculated, after adjustment for the study
period at each site, with the use of projections of
the 2001 and 2002 population from the Census Bureau. Initial therapy was categorized as active if the
patient received an antimicrobial agent with activity
against S. aureus and to which the MRSA was susceptible in vitro. Therapy was categorized as inactive if initial therapy consisted of antimicrobial
agents to which the isolate had intermediate resistance on testing or was resistant in vitro. If the results of susceptibility testing were not available for
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a prescribed agent or the patient received no antimicrobial agents, the patient was excluded from
analyses correlating inactive therapy and outcomes.
The Mantel-Haenszel chi-square test was used to
compare the incidence according to race and other
categorical data, and the t-testwas used for continuous data. All comparisons were initially stratified
according to the reporting area, and rate ratios were
pooled if there were no significant differences between areas according to the Breslow-Day test for
homogeneity of the rate ratios.
RESULTS
SURVEILLANCE

During the study period, 12,553 patients with
MRSA isolates were reported. Of these patients,
9972 (79 percent) were immediately classified as
having health care-associated MRSA infection and
did not require interviews. Interviews were attempted with 2581 patients with suspected cases ofcommunity-associated MRSA infection; 1063 of these
patients (41 percent) were interviewed, allowing 280
(11 percent) to be reclassified as having health careassociated MRSA. Among the remaining patients
with suspected cases of community-associated
MRSA infection, 2107 (17 percent) were classified
as having confirmed or probable community-associated MRSA isolates (Atlanta, 1590 of7819 [20 percent); Minnesota, 370 of 3714 [12 percent); and
Baltimore, 147 of1720 [8 percent); P<O.OOl). MRSA
isolates in 196 patients were classified as indeterminate (2 percent).
The overall incidence ofinvasive MRSA infection
(i.e., MRSA recovered from a normally sterile site),
regardless ofwhether the infection was acquired in
the community or at a health care facility, was 19.3
infections per 100,000 population in Atlanta and
40.4 infections per 100,000 in Baltimore.
Of the 2107 confirmed or probable isolates of
community-associated MRSA, 1647 (78 percent)
were associated with clinical illness and were classified as cases of community-associated MRSA
disease. Among these cases, the confirmed and the
probable community-associated MRSA isolates
were obtained from similar body sites and demonstrated similar susceptibilities to antimicrobial
agents with one exception, i.e., there was variable
sensitivity to erythromycin (details are provided in
the Supplementary Appendix, available with the full
text of this article at www.nejm.org). The annual
incidence of community-associated MRSA disease
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in the two areas that performed population-based
surveillance was 25.7 cases per 100,000 in Atlanta
and 18.0 per 100,000 in Baltimore (rate ratio, 0.70;
95 percent confidence interval, 0.58 to 0.85) (Fig.
1). In both surveillance areas, the incidence was
significantly higher among persons who were less
than two years old than among those who were two
years ofage or older (unadjusted relative risk, 1.51;
95 percent confidence interval, 1.19 to 1.92) (Fig.
1). Incidence rates were significantly higher
among blacks than whites in Atlanta among all age
groups (age-adjusted relative risk, 2.74; 95 percent
confidence interval, 2.44 to 3.07); racial differences in incidence were not significant in the Baltimore population, even in the youngest age group
(relative risk, 2.58; 95 percent confidence interval,
0.31 to 21.5).
CLINICAL CHARACTERISTICS

The type ofinfection varied slightly among the surveillance areas (Table 1); of the 1647 patients with
community-associated MRSA disease, most (1266
[77 percent]) were categorized as having skin or
soft-tissue infections. Specific types included abscess in 751 patients (59 percent), cellulitis in 528
patients (42 percent), folliculitis in 88 patients
(7 percent), and impetigo in 33 patients (3 percent).
Among the other types of infection reported, 103
(6 percent) were invasive, including bacteremia,
septic arthritis, and osteomyelitis; 157 were in
wounds (10 percent); and 31 were pneumonia
(2 percent) (Table 1).
Most patients (1333 [81 percent)) were treated

A Atlanta, 2001-2002
c

.g

80

with antimicrobial agents; specific antimicrobial
agents were documented for 1297 patients (97 percent). Among these 1297 patients, 757 (58 percent)
received f3-lactam antibiotics alone, 199 (15 percent)
received a f3-lactam with a non-f3-lactam agent,
and 341 (26 percent) received only non-f3-lactam
therapy. Among the patients whose antibiotic regimens were documented, significantly more of the
1099 patients with skin infections than of the 198
patients with other types of infection received
f3-lactam agents alone (64 percent vs. 28 percent,
P<O.OOI).
Antimicrobial susceptibilities were obtained
from the medical records of 1345 of the 1647 patients with community-associated MRSA disease
(82 percent). With -few exceptions, the patterns of
susceptibility were similar among the study areas.
However, isolates from patients in Atlanta and Baltimore were significantly less likely than those from
Minnesota to be susceptible to erythromycin and
ciprofloxacin (Table 2). Susceptibility data and documented information on empirical therapy were
available for most patients who received empirical
therapy (1215 of1297 [94 percent)); 884 (73 percent) received inactive therapy.
Limited information on the effect of the disease
was available from the medical records; 506 patients
(31 percent) were hospitalized, including 371 (23
percent) who were hospitalized specifically for
MRSA disease (Table 1). For these 371 patients,
hospitalization was unlikely to be the result of the
clinician's receiving the MRSA-culture report. The
interval between specimen collection and admis-
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Figure 1. Incidence of Community·Associated MRSA Disease in Atlanta and Baltimore, According to Race and Age Group.
The horizontal line in each graph is the overall site-specific an nual incidence. Race was determined in most cases by
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Table 1. Infections and Outcomes Associated with Community-Associated MRSA Disease, 2001-2002.
Atlanta
(N=1267)

Variable
Invasive infections -

Baltimore
(N=llS)

Minnesota
(N=265)

Total
(N = 1647)

PValue*

no. (%)1'

Bacteremia

30 (2)
1 (<1)

Meningitis

7 (6)

6 (2)

1 (1)

0

43 (3)
2 (<1)

0.66
0.84

Osteomyelitis

11 (1)

6 (5)

7 (3)

24 (1)

<0.01

Bursitis

12 (1)

0

7 (3)

19 (1)

0.04

13 (1)

0

2 (1)

15 (1)

0.52

Arthritis
Other infections -

no. (%)t

Skin and soft tissue

973 (77)

95 (83)

198 (75)

1266 (77)

0.71

Wound

136 (11)

8 (7)

13 (5)

157 (10)

<0.01

23 (2)

4 (3)

4 (2)

31 (2)

0.97

Pneumonia
Urinary tract

57 (4)

4 (3)

3 (1)

64 (4)

0.01

Sinus

60 (5)

0

1 (<1)

61 (4)

<0.01

80 (30)

744 (45)

0.08

Underlying illness - no. (%)
Hospitalization -

594 (47)

no. (%)

MRSA disease primary reasonno./total no. (%)
Intensive care unit stay -

no./total no. (%)

Discharged from hospital- no./total no. (%)
Median stay -

70 (61)

339 (27)

72 (63)

95 (36)

506 (31)

0.68

251/339 (74)

41/72 (57)

79/95 (83)

371/506 (73)

0.62

26/339 (8)

7/72 (10)

4/95 (4)

37/506 (7)

0.14

323/339 (95)

71/72 (99)

86/95 (91)

480/506 (95)

0.Q7

5

3

5

days

4

0.20

* P values were determined by means of the Cochran-Mantel-Haenszel summary statistic and indicate significant differences in infection rates among sites.

'i' Patients could have more than one infection.

Table 2. Number of Community.Associated MRSA Isolates That Were Susceptible to Selected Antimicrobial Agents,
2001-2002.*
Agent Tested

Atlanta

Baltimore

Ci profloxaci n

408/648 (63)

6/31 (19)

Clindamycin

840/970 (87)

78/92 (85)

98/907 (11)

11/94 (12)

429/444 (97)

66/71 (93)

Minnesota

Total

PValuei'

146/182 (80)

560/861 (65)

<0.001

211/239 (88)

1129/1301 (87)

0.58

110/235 (47)

219/1236 (18)

<0.001

184/188 (98)

679/703 (97)

0.59

867/887 (98)

0.21

no. ofsusceptible isolates/total no. (percent)

Erythromycin
Gentamicin
Rifampin

682/694 (98)

6/9 (67)

179/184 (97)

Tetracycline

726/814 (89)

43/70 (61)

163/179 (91)

932/1063 (88)

0.44

1016/1017 (100)

95/96 (99)

232/232 (100)

1343/1345 (100)

0.88

Vancomycin:~

Linezolid
Trimethoprimsulfamethoxazole
,~

13/13

(100)

912/943 (97)

(96)

0.30

1178/1218 (97)

0.32

0

11/12 (92)

30136 (83)

24/25

236/239 (99)

Results were obtained at local facilities.

'i' P values were determined by means of the Cochran-Mantel-Haenszel summary statistic.

:~ Two

isolates were nonsusceptible with the use of automated testing methods. but these results were not confirmed with
the use of recommended methods.'o.21
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sion was less than one day for 226 of the 371 patients (61 percent), one to two days for 115 (31 percent), and more than two days for 22 (6 percent)
(2 percent had missing data). A total of37 patients
(10 percent) required hospitalization in the intensive
care unit. Hospitalization lasted a median of four
days, and only 1 of the 37 patients who died during
hospitalization had documentation that the community-associated MRSA was causal or contributory to the death.
Information on other outcomes associated with
community-associated MRSA infection was available for 575 patients with confirmed cases (i.e., interviewed patients). Among these patients, 560 (97
percent) received some antimicrobial agents, 136
(24 percent) were hospitalized, 226 (39 percent)
underwent incision and drainage, and 176 (31 percent) required a follow-up visit with their physician.
To assess the relationship between inactive antimicrobial therapy and outcome more closely, we

attempted to identifY a homogeneous group of
patients in which to compare clinical outcomes on
the basis of empirical antimicrobial treatment. We
limited further analysis to 453 patients with confirmed cases of community-associated MRSA disease involving skin or soft-tissue infections who
received antimicrobial therapy at the time of the
isolation of community-associated MRSA and for
whom information on initial treatment and clinical
outcome was available from the interview. Neither
initial incision and drainage nor initial antimicrobial therapy that was inactive was significantly associated with an increased frequency of the following
patient-reported outcomes after the initial evaluation for illness: follow-up visits to a health care provider, subsequent incision and drainage, or subsequent change in antimicrobial therapy (Table 3).
Also, among the subgroup of patients who did
not initially undergo incision and drainage, there
were no significant differences in outcomes ac-

Table 3. Effect oflnitial Therapy on Selected Outcomes among 453 Patients with Confirmed Skin or Soft-Tissue
Infections Due to Community-Associated MRSA, 2001-2002.*

No. of
Patients

Initial Therapy

Follow-up Visit
to Health Care Provider
2:1 Times

Incision and
Drainage on
Follow-up Visit

New Antimicrobial Agent
Prescribed on
Follow-up Visit

2:2 Times

Incision and drainage
Yes-no. (%)
No-no. (%)

196

54 (28)

30 (15)

19 (10)

45 (23)

257

69 (27)

43 (17)

14 (5)

66 (26)

1.37 (1.00-1.87)

0.92 (0.71-1.18)

1.01 (0.80-1.29) 0.94 (0.70-1.27)

Rate ratio (95% CI)
Inactive therapy
Yes-no. (%)
No-no. (%)

254

59 (23)

35 (14)

15 (6)

55 (22)

199

64 (32)

38 (19)

18 (9)

56 (28)

0.80 (0.54-1.17)

0.85 (0.69-1.05)

8 (7)

16 (15)

0.81 (0.66-1.00) 0.83 (0.65-1.07)

Rate ratio (95% CI)
Incision and drainage
Inactive therapy Active therapy -

no. (%)
no. (%)

108
88

20 (19)

11 (10)

34 (39)

19 (22)

0.60 (0.41-0.87) 0.63 (0.39-1.02)

Rate ratio (95% CI)

11 (12)

29 (33)

0.75 (0.43-1.28)

0.58 (0.39-0.88)

7 (5)

39 (27)

No incision and drainage
Inactive therapy Active therapy -

no. (%)
no. (%)

Rate ratio (95% CI)

146

III

39 (27)

24 (16)

30 (27)

19 (17)

0.99 (0.78-1.26) 0.98 (0.73-1.31)

7 (6)

27 (24)

0.87 (0.51-1.49)

1.05 (0.83-1.34)

" The outcomes were reported during the interview with each patient. Only patients who were interviewed were included
in the analysis. Initial therapy was categorized as active if the patient received an antimicrobial agent with activity against
S. aureus and to which the MRSA was susceptible in vitro. Therapy was categorized as inactive if initial therapy included
only antimicrobial agents to which the isolate had intermediate susceptibility on testing or was resistant in vivo. The rate
ratio is the ratio of the rate of the outcome among the exposed group to the rate of the outcome among the group that
was not exposed. CI denotes confidence interval.
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cording to whether the initial therapy was inactive coccal disease among Pacific Islanders, American
(Table 3).
Indians, and Alaskan Natives. 16,18,22,23 Black race
was associated with increased rates of invasive
POTENTIAL EXPOSURES TO MRSA
S. aureus disease in 1998 in one population-based
Although none of the established risk factors for study in Connecticuf4 and in other studies evaluMRSA infection were documented in any patient, ating invasive pneumococcal disease. 25 -28 The in744 patients (45 percent) had underlying conditions creased prevalence of certain underlying diseases
or factors that were associated with skin infections (e.g., diabetes and HIV infection), differences in
or suggested some contact with the health care immune response, or differences in other sociosystem. Among the 1250 patients whose age was economic factors (e.g., crowding in the household
known to be at least 18 years, 653 (52 percent) or decreased access to medical care), which are
reported 1249 underlying conditions, including correlated with black race, may contribute to these
smoking (35 percent), previous skin infections (21 findings.29
percent), diabetes (19 percent), asthma (12 percent),
The differences observed in incidence rates beinfection with the human immunodeficiency virus tween Baltimore and Atlanta can probably be ex(HIV) (9 percent), intravenous drug use (7 percent), plained on the basis of the different populations
alcohol abuse (6 percent), and coronary vascular under surveillance. The lower overall incidence of
disease (5 percent). Among 345 patients who were community-associated MRSA disease in Baltimore
younger than 18 years old, 76 (22 percent) reported suggests that this surveillance population may be
90 preexisting conditions, including skin disease more likely to have established risk factors for
(42 percent), asthma (35 percent), and smoking MRSA infection. The incidence may also be falsely
(7 percent). Among the 575 patients with confirmed low, since 1 of12 eligible laboratories declined to
community-associated MRSA disease, detailed in- participate in the study. However, it is unlikely that
formation on household characteristics and em- the Baltimore surveillance underreported cases from
ployment status was obtained from the interview, the remaining laboratories, since the rates of inand several points of contact with the health care vasive MRSA disease (regardless of whether the
system exclusive of established risk factors for infection was acquired in the community or at a
MRSA infection were identified (Table 4).
health care facility) were higher in Baltimore (40
per 100,000) than Atlanta (19 per 100,000). The
Atlanta
surveillance area encompassed an eightDISCUSSION
county urban and suburban area and included a
In this study, 8 to 20 percent of all MRSA isolates large referral laboratory; the Baltimore surveillance
collected as part of prospective population-based area was limited to urban hospital-based laborasurveillance were not associated with traditional risk tories likely to serve persons with more frequent
factors and were classified as community-associat- contact with the hospitals.
Our large, prospective series of communityed MRSA. Most of these isolates were associated
with clinically relevant infections that required treat- associated MRSA infections identified with the use
ment. The most common infections involved skin of standardized methods to measure rates of enand soft tissues; however, 6 percent were consid- demic disease allows for an accurate description of
ered invasive. Attributable mortality was low, but the clinical course and effect ofthese infections. In a
23 percent of patients were hospitalized for these manner consistent with previous reports from outbreaks and smaller surveillance studies, we found
infections.
The incidence ofclinically relevant community- that most patients who were treated empirically reassociated MRSA disease varied between the Atlanta ceived f3-lactam antimicrobial agents. Measuring
surveillance area (25.7 per 100,000) and the Balti- the effect ofinactive therapy on these infections has
more surveillance area (18.0 per 100,000), and we been difficult owing to the small numbers of casfound marked disparity in the incidence of com- es and imprecise outcome measurements. 30-35 Almunity-associated MRSA disease between blacks though we relied on self-reported measures, our
and whites in Atlanta but not in Baltimore, even data suggest that patients with community-associamong the youngest age group. Several reports have ated MRSA skin or soft-tissue disease who initially
highlighted the increased incidence of staphylo- receive inactive antimicrobial therapy have out-
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comes similar to those among patients who are
treated with antimicrobial agents to which the organism is susceptible in vitro. Prospective evaluations with more objective measurements are needed to clarifY whether the addition of active systemic
therapy to topical agents or surgical drainage increases the beneficial effect in patients with community-associated MRSA infections involving the
skin and soft tissues.
Our report reflects the results of one to two
years ofactive surveillance in three large and diverse
geographic areas. However, certain limitations
should be borne in mind. First, we were unable to
perform population-based estimates in Minnesota,
where sentinel surveillance was conducted. However, the descriptive data probably reflect the patient mix in that state. Second, our surveillance required isolation of MRSA from a clinically relevant
culture; since S. aureus skin disease is often treated
empirically without a diagnostic test, our results
probably underestimate the true burden ofdisease.
Some caution must be taken in generalizing our
findings to the U.S. population. First, we were able
to interview only 41 percent of eligible patients,
eliminating a majority ofpatients from the outcome
analysis. Second, although there were rarely significant differences among the reporting areas, the
majority ofcases were reported in the Atlanta area.
Also, patients who could not be interviewed may
have been misclassified as having communityassociated MRSA infection, since no interview data
were available. However, we believe pooling the patients with probable and confirmed cases of community-associated MRSA disease was justified on
the basis of the similarities between both patients'
and isolates' characteristics, reflecting a pattern
typically seen in previously reported outbreaks of
community-associated MRSA infection. 10,1l,15,36-38
To avoid clinical complications from community-acquired MRSA infections, clinicians should
now consider MRSA as a potential pathogen in patients with suspected S. aureus infections in the
community setting. Clinicians should obtain appropriate material for bacterial culture; should follow up on the results of susceptibility testing of all
S. aureus isolates, since by definition MRSA organisms are not susceptible to l3-lactam antibiotics;
and should recommend surgical drainage ofinfections when feasible. The choice ofappropriate antimicrobial agents for suspected S. aureus infections
ofskin and soft tissue in patients in the community

N ENGLJ MEO 352;14

Table 4. Frequency of Characteristics Potentially Related to Infection
among 575 Patients with Confirmed Community-Associated MRSA Disease,
2001-2002.*
Potential Risk Factor

No. of Patients (%)

Any visit to a physician's office in past yr

357 (62)

Receipt of any antimicrobial agents in past yr

224 (39)

Chronic noninfectious skin disease

190 (33)

Stayed >2 wk in non-health care high-risk setting in past
5 yr"j
Health care-related employment in past 5 yr
Health care provider or direct care

10 (2)

69 (12)
23 (4)

Health care-delivery support services

26 (5)

Other type of health care

46 (8)

Acute care or skilled-nursing facility

30 (5)

Clinic or ambulatory care facility
Crowded household (>1 person/bedroom»),:

12 (2)
121 (51)

",1 Household member ,;;2 yr old

132 (23)

",1 Household member >60 yr old

109 (19)

",1 Household member with established risk factor for
MRSA infection

92 (16)

Job in the health care setting

69 (12)

Attendance at day care~

52 (9)

History of MRSA infection

35 (6)

Receipt of home care services

17 (3)

Self-reported annual income,
<$20,000

144 (29)

$20,000--$50,000

178 (36)

>$50,000

173 (35)

Receipt of public assistance

92 (16)

* The categories are not mutually exclusive.
l' A high-risk setting was defined as a department-of-corrections facility or military barracks.
),: Data on crowding were available for 236 of the 575 interviewed patients.
§ Day-care attendance among household members was for a median of20 hours
per week (range, 20 to 60).
, Data on income were available for 495 interviewed patients.

must now take into account the emergence of
community-associated MRSA; providers should
be aware that several available antimicrobial agents
should be effective in treating these infections.
Supported by the CDC Emerging Infections Program. (The use of
product names in this article does not imply their endorsement by
the Public Health Service or the Department of Health and Human
Services.)
We are indebted to Virginia Rego, Wendy Baughman, Christina
Payne, Matthew Johns, Margaret Pass, Elizabeth Hopewell, Chris
Van Beneden, Tami Hilger, Anne Schuchat, and personnel in hospitals and laboratories participating in the Community-Associated
MRSA Special Project of the Active Bacterial Core Surveillance program for their contributions to this project.
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Methicillin-Resistant Staphylococcus aureus Disease
in Three Communities
Methicillin-Resistant Staphylococcus aureus Disease in Three Communities. In the Abstract on page 1436, the Methods and Results
sections should have referred to "community-associated" infection,
rather than "community-acquired" infection, as printed. We regret
the error.
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The role of nasal carriage in Staphylococcus aureus infections
Heiman F I. Wertheim, Damian CMe/les, Margreet CVas, Wit/em van l.eelJwen, Alex van BelkulTI, Henri AVerbrugh,Jan LNouwen

Staphylococcus aureus is a frequent cause of infections in both the community and hospital. Worldwide, the increasing
resistance of this pathogen to various antibiotics complicates treatment of S aureus infections. Effective measures to
prevent S aureus infections are therefore urgently needed. It has been shown that nasal carriers of S aureus have an
increased risk of acquiring an infection with this pathogen. The nose is the main ecological niche where S aureus resides
in hurnan beings, but the determinants of the carrier state are incompletely understood. Eradication of S aureus from
nasal carriers prevents infection in specific patient categories-eg, haemodialysis and general surgery patients.
However, recent randomised clinical trials in orthopaedic and non-surgical patients failed to show the efficacy of
eliminating S aureus from the nose to prevent subsequent infection. Thus we must elucidate the mechanisms behind
S aureus nasal carriage and infection to be able to develop new preventive strategies. We present an overview of the
current knowledge of the determinants (both human and bacterial) and risks of S aureus nasal carriage. Studies on the
population dynamics of S aureus are also summarised.

Introduction
Staphylococcus aureus is both a human commensal and a
frequent cause of clinically important infections
(figure 1).' Although the prevalence of me ticill in-resistant
S aureus (MRSA) is still very low in northern European
countries,' there is a worldwide increase in the number of
infections caused by MRSA. Vancomycin is one of the last
therapeutic options available for MRSA infections. TIle
recent isolation of vancomycin-resistant MRSA strains in
the USA is a major cause for concern: Therefore, the
prevention of staphylococcal infections and reduction of
the spread and emergence of MRSA are essential.
The association between S aureus nasal carriage and
staphylococcal disease was first reported by DanboIt in
1931, who studied furunculosis. 4 The increasing incidence
of penicillin-resistant S aureus hospital infections since
1947 emphasised the need for a better understanding of
the pathogenesis of staphylococcal disease. Subsequently,
numerous studies confirmed Danbolt's finding."") A
causal relation between S aureus nasal carriage and
infection is supported by the fact that the nasal S aureus
strain and the infecting strain share the same phage type
or genotype."'" Furthermore, nasal application of an
antistaphylococcal drug temporarily decolonises the nose
and other body sites, which prevents infection.ll
Our knowledge of the mechanisms, risks. and treatment
of S aureus nasal carriage has greatly expanded over the
past decade. Table 1 presents an overview of major events
in S aureus research. Here, we focus on the latest insights
into the determinants of S aureus nasal carriage and the
risks of infection associated with S aureus nasal carriage.
Most studies were done in western cotmtries, so
conclusions drawn can not always be generalised.

include the skin, perineum, and pharynxY<-1S Other
carriage sites including the gastrointestinal tract, \,"
vagina.'7 and axi1lae"""" harbour S aureus less frequently
(figure 2).
Most studies on S aureus nasal carriage have used a
cross-sectional design with a single nasal culture to
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Determinants of nasal carriage of S aureus
5 aureus nasal carriage patterns
S aureus colonises the skin and mucosae of human beings
and several animal species. I Although multiple body sites
can be colonised in human beings, the anterior nares of
Lhe nose is the most frequent carriage site for S aureus.;
Extra-nasal sites that typically harbour the organism
http://infection,thelancet.com VolS December 2005

Figllfel: Large diversity in 5 aurellS infections
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Event

1880

Alexander Ogston identities micrococci in putulent infections"

1931
1934
1944
1947
1951

Popularisation of the coagulase test for the identification of S aureus'
Introduction of phage typing"
Penicillin-resistant 5 aureus reported"

1961
1991
1994
2000

2001
2001

2001
2002

Association between nasal (olonisation and furunculosis di5covered~

As~ociation

between nasal colonisation of S l1ureus and infection with the same stram

determined by phage typing"'"
Meticillin-resistant S aureus (MRSA) reported"
Pulsed field gel electrophoresi' "sed for genotyping 5 aur'tls"
Identification of microbial surface components recognising adhesive matrix molecules

(MSCRAMMs)"
Mukilocus sequence typing developed for studying clon.lity of 5 aureus'"
Whole genome of 5 aureus sequenced"
80% of bacteraerni( S aureus isolates are endogenousll
Increase in cornmunity~onset MRSA infections"
Van(Qmycin~resistant Saureus reported))

Table 1: Major events in S aureus research

classifY an individual as a carrier or not. However.
longitudinal studies distinguish at least three S aureus
nasal carriage patterns in healthy individuals: persistent
carriage. intermittent carriage. and non-carriage.',6.1l",!O
Some studies make a further distinction between
occasional and intermittent carriers.'''''! Therefore, a
patient classified as a carrier in cross-sectional studies
could either be a persistent or an intermittent carrier. This
distinction is important because persistent carriers have
higher S aureus loads and a higher risk of acquiring
General population

5 aureus nasal carriers

Figure 2: 5 aurevs carriage rates per body site in adults
There is all increase in carriage rates at extra-nasal sites within nasal S aureus carriers. The mentioned rates are
approximations using data from the literature cited in the text

752

466

S aureus infection. n .ll Likewise. non-carriers in a crosssectional study may actually be intermittent carriers.
TIle definition of persistent carriage varies from study to
study. There is no general consensus on how many
cultures should be taken and how many cultures should
be positive to define persistence. One study concludes that
a "cUlture rule" that combines qualitative and quantitative
results of two nasal swabs taken with a week interval can
accurately classifY S aureus nasal carriage." Since
adequate. internationally accepted definitions are needed.
the so-called culture rule is an improvement for those
studying determinants and risks of S aureus nasal
carriage.
Longitudinal studies show that about 20% (range
12-30%) of individuals are persistent S au reus nasal
carriers, approximately 30% are intermittent carriers
(range 16-70%). and about 50% (range 16-69%) noncarriers"·""·lI The very wide ranges found in the
proportions of intermittent and non-carriers are the result
of the use of different culture techniques. different
populations being studied. and the use of different
interpretation guidelines.'" Although at least seven nasal
swab cultures are necessary to segregate non-carriers from
intermittent carriers. the more nasal cultures are analysed.
the higher the chance of identifYing an intermittent
carrier."
Children have higher persistent carriage rates than
adults.21.J637 Rates vary substantially with age, falling from
approximately 45% during the first 8 weeks to 21% by
6 months. JS More than 70% of newborn babies have at
least one positive nasal culture with S aureus.18 There is a
transition from persistent carriage to intermittent or noncarriage states during adolescence (figure 3)Y' Crosssectional surveys of healthy adult populations have
reported S aurcus nasal carriage rates of approximately
27% since 2000?')!'>-l(, This rate is much lower than the
earlier reported prevalence 005%, which included studies
since 1934.(' Plotting the carriage rates of either healthy
populations or a general hospital population clearly
illustrates a substantial decline in the S aureus nasal
carriage rate in time (figure 4. patient categories with
known higher S aureus nasal carriage rates, like dialysis
patients. were excluded). Explanations for this decline
include improved personal hygiene. changes in
socioeconomic class. n and smaller families.'"

Determinants of S aureus nasal carriage
Although the reasons remain unknown. the basic
determinants of persistent and intermittent carriage are
thought to be different. Persistent carriers are often
colonised by a single strain of S aureus over long time
periods. whereas intermittent carriers may carry different
strains over time."''''''! Furthermore. the load of S aureus is
higher in persistent carriers. resulting in increased
dispersal and a higher risk of infection. H." Nasal caniers
who are also perineal carriers have higher S aureus loads
and disperse more S aureus.'·21 ...
http://infection,thelancetcom VolS December 2005
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The mechanisms leading to S aureus nasal carriage are
multifactorial. A recent study in which volunteers (noncarriers and persistent carriers) were artificially inoculated
with a mixture of S aureus strains showed that noncarriers quickly eliminated the inoculated S aureus strains,
whereas most persistent carriers selected their original
resident S aureus strain from the inoculation mixture.'o
The investigators concluded that host characteristics
substantially co-determine the S aureus carrier state and
that an optimal fit between host and bacteria seems to be
essential. so
This view is further supported by the fact that S aureus
carriage rates vary between different ethnic groups, with
higher rates in white peoples", and in men,s..,.S} and depend
on age. lJ •l •• " Patients with diabetes mellitus (both insulin
dependent and non-insulin dependent);" patients
tmdergoing haemodialysis"'5S or continuous peritoneal
dialysis for end stage renal disease,l" patients with end
stage liver disease;,7." patients with HIV;"'''' patients with
S aureus skin infections and skin disease (eg, eczema or
psoriasis),"}-('} and obesity and a history of cerebrovascular
accident" have been shown to have higher S aureus nasal
carriage rates. Most studies are hospital or outpatientclinic based and need confirmation from communitybased surveys. In one community-based study, Boyko and
co-workers'A found similar S aureus carriage rates in
diabetics and non-diabetics, by contrast with an earlier
clinic-based study."
Nasal colonisation of S aureus can be seen as the net
result of repellent and attracting forces. There are four
prerequisites to becoming a nasal carrier of S aureus. First,
the nose has to come in contact with S aureus. Second,
S aureus needs to adhere to certain receptors in the nasal
niche. Third, S aureus needs to overcome the host
defences. Finally, S aureus should be able to propagate in
the nose. We will discuss these issues separately (table 2).
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Figure 3: Rates of 5 aur.us nasal carriage according to age

shown to be an important risk factor.7o Furthermore, it
seems that S aureus carriers can "impose" their carrier
state upon other household members. Recently, Peacock
and colleagues" found concordant carrier states between
mothers and their children. Also, Bogaert and co-workers"
found large households (;;.five members) to be positively
assodated with S aureus nasal carriage. Most mothers
carry the same strain as their children. indicating that
carriage strains are transmitted to close contacts.]" A study
among an elderly population demonstrated that not only
persistent but also non-carriage or intermittent S aureus
nasal carrier states are shared among household
members.71 Up to 65% of people with positive cultures
living within one household shared genotypically identical
strains. 71 Intrafamilial spread of MRSA from and to
health-care workers has also been shown to be an

How does S aureus reach the nose?
S aureus cells can survive for months on any type of
surface."" Hands are the main vector for transmitting
S aureus from surfaces to the nasal niche-eg, nose
picking.'" S aureus cells are principally found in the
anterior nares (vestibulum nasi or "nose picking area"),
and S aureus nasal carriage and hand carriage are strongly
correlated.' Some studies find higher carriage rates more
proximal in the nose, but these studies are rare and
probably reflect a chance finding.,·7 S aureus may also reach
the nose directly through the air, but this probably occurs
less frequently."" However, airborne transmission is
important for the dispersal of staphylococci to many
different reservoirs, from where, via the hands, they can
reach the nose. S aureus nasal carriers with rhinitis can
disperse high loads of S aureus into the environment and
may be the source of an outbreak of S aureus infectionsthe so called "cloud" individual.'"
Environmental factors can also influence the S aureus
nasal carriage state. Hospitalisation, for example, has been
http://infectiol1.thelancet.com Vol 5 December 2005
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Figure 4: Reported S aureus nasal carriage rates through the years
There is a Significant negative correlation between the year of reporting and the
reported carriage rate (correlation coefficient -0·55; p<O·OOl).
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TobIe 2: Overview of mechanisms associated with Saureus nasal carriage

important risk factor for the re-introduction of MRSA into
hospitals. 71 Furthermore. Herwaldt and colleagues71
demonstrated that in 21% of patients receiving
continuous peritoneal dialysis. the source of newly
acquired nasal S aureus strains were their respective
family members.
Activities leading to skin lesions are also correlated with
higher S aureus nasal carriage rates. These include river
rafting." football." and (pig-)farming,7(. Repeated skin
ptmctures in drug users and diabetics were thought to
explain higher S aureus nasal carriage rates." However.
recent studies do not support this theory: intravenous
drug users have a lower prevalence of S aureus nasal
carriage compared with drug users on an oral methadone
programme,?' and S aureus nasal carriage rates are not
different between diabetic patients injecting insulin and
those using oral glucose-lowering medication."·M
There is no relation between carriage rate and seasonality, temperature, or relative humidityY'" A populationbased cohort of children and adolescents showed that
active cigarette smoking is associated with a lower S aureus
nasal carriage rate. whereas passive smoking is associated
with a higher S aureus nasal carriage rate," The
aetiological basis of this observation is unknown.
How does 5 aureus withstand and evade the host immune
response?
Nasal secretions have a prominent role in the innate host
defence. Components of nasal secretions that contribute
to the innate immune response include immunoglobulin
A and G, lysozyme, lactoferrin, and antimicrobial
754
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peptides."" S aureus nasal carriers may have a
dysregulation of these innate humoral factors in their
nasal secretions." Such people have raised concentrations
of the alpha-defensins (eg, human neutrophil peptide
[HNP] 1, 2, and 3) and human beta-defensin 2 (HBD2),
indicative of the presence of both neutrophil-mediated
and epithelial-mediated inflammation." lipoteichoic acid,
present in the S aureus cell wall, is a strong stimulus for
neutrophil recruitment."' Therefore, this inflammatory
response could be induced by S aureus colonisation,
However, studies have shown that HNPl, 2, and 3, and
HBD2 are not microbicidal against S aureus in vitro,
suggesting that the host response is ineffective and
insufficient to prevent S aureus nasal carriage.'" The role of
the cellular response is unclear. The previously
established relation between glycaemic control and
S aureus carriage rate in diabetics lJ could be seen as the
result of hyperglycaemia-related reduced phagocytic
activation."
Several studies have found that certain antimicrobial
peptides have no or little activity against S aureus or that
other peptides are needed to enhance their activity, ..··1
The inability of nasal antimicrobial peptides to clear
S aureus from the nose may be explained by (1) the
anatomy of the nose in relation to S aureus nasal carriage
and (2) resistance of S aureus to many antimicrobial
peptides.'o.•• S aureus predominantly colonises an area in
the vestibulum nasi that is devoid of cilia and relatively
free from nasal mucous secretions that contain
antimicrobial peptides and immunoglobulins.'" It is
nevertheless possible that the innate immune response
prevents S aureus from invading the mucosa and
causing more extensive forms of colonisation or even
infection.
In-vitro studies have shown that S aureus is able to resist
certain cationic antimicrobial peptides by reducing the net
negative charge of its cell wall and cell membrane. or
perhaps by using efflux pumps or by releasing proteases."·
S aureus has
several mechanisms-including
staphylokinase87 and membrane lipid modification88through which it can withstand an attack by cationic
antimicrobial peptides, including defensins and
cathelicidins, which are present in nasal secretions.""'"
Whether the resistance of S aureus to defensins and other
cationic antimicrobial peptides is a determinant of
S ~u1"eus nasal carriage is currently not known.
Cathelicidin can synergistically work with defensins to
exert a bactericidal effect on S aureus." Furthermore. all
S aureus strains are lysozyme resistant since they possess
the peptidoglycan-specific O-acetyltransferase.'!tI
The presence of S aureus in the nose elicits a subclinical
immune response, as shown in a study where
seroconversion occurred after carriage was established.'''
S aureus produces protein A that binds the Fc region of
iillI11unoglobulins, thereby inactivating tllem." It is clear
that S aureus has a wide arsenal of strategies to evade the
host immune response. Further studies are needed to
http://infection.thelancet.com Vol 5 December 2005
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identifY all the components of the immWle response
towards S aureus in the nose.
How does 5 aureus adhere to, and propagate in, the
anterior nares?
The vestibulum nasi is limited laterally by the interior of
the wing of a nostril and medially by a mucous fold (limen
nasi) . behind which the nasal cavity with mucosal lining
begins (figure 5)." TIle epithelial inner wall of a nostril is
fully keratinised and includes apocrine sweat glands.
sebaceous glands. and hair follicles of the vibrissae:" Most
studies on determinants of S aureus nasal carriage focus
on mucosal and mucin binding.''''''' Considering the
anatomy of the vestibulum nasi. this focus should be
changed.
Bibel and colleagues" demonstrated the importance of
keratinised epithelial cells in binding S aureus. In addition
to the nose. S aureus can also multiply independently in
the area of the perineum.'7 Both the vestibulum nasi and
the perineum contain large apocrine sweat glands. which
is an important clue in studying determinants of S aureus
nasal carriage. but has not been studied thoroughly.'"
Since S aureus binding to mucosa or mucin probably has a
transient nature. we propose that: (1) intermittent carriers
are actually "mucosal carriers" and (2) persistent carriers
use a special niche. such as an apocrine gland. where
S aureus cells can multiply to high numbers.
S aureus adherence may also be non-specifically
mediated via physicochemical forces. including
hydrophobic interactions.' Alternatively. adherence may
be more specifically accomplished through binding of
certain bacterial cell surface moieties (adhesins) to defined
structural receptors in the membranes of the host cells."
S aureus has a greater affinity for nasal epithelial cells
sampled from carriers than from non-carriers:" and the
bacterium adheres better to nasal epithelial cells from
patients with eczema than to cells from patients without
eczema."
Recent experiments have shown that clumping factor B
(ClfB) and the S aureus surface protein G (SasG) bind to
nasal epithelial cells .....·' clm specifically binds human
cytokeratin type 10 and SasG to an unknown ligand of
desquamated nasal epithelial cells." Also. cell wall teichoic
acid is essential for S aureus nasal carriage!'lOU Microbial
surface components recognising adhesive matrix
molecules (MSCRAMMs) can bind to fibronectin.
fibrinogen. and collagen related polysaccharides."
MSCRAMMs probably have a role in the binding of
staphylococci to sites where the mucosal lining is
breached. exposing these matrix molecules.'" Differences
in the expression of genes coding for these factors.
depending on the ecological niche. and other putative
adhesins and receptors may provide clues to the true
determinants of S aureus nasal carriage or non-carriage.
Bacterial interference has been postulated to be a major
determinant of the S aureus carrier state. or rather. noncarrier state. When an ecological niche is already occupied
htt p://infect ion.thelancet .com VolS December 2005

Figure 5: Anatomy of the nostril
Adapted from reference 92.

by certain bacteria. other bacteria do not seem to have the
means to replace this resident bacterial population.'o, The
resident flora must be reduced or eliminated before other
bacteria can successfully "interfere" with the resident
bacterial population.'''' Cross-inhibition of the expression
of various virulence factors by the accessory gene regulator
(agr) and staphylococcal accessory regulator (sar) may be
one mechanism by which one strain excludes others from
colonising sites including the anterior nares. W ! although a
large S aureus population genetic analysis failed to
confirm this suggestion."" Still. bacterial interference can
be seen as a determinant of S aureus nasal carriage.
although it does not appear to be the ultimate
determinant."
Bacterial interference by active colonisation using a nonpathogenic S aureus strain (S02A) was successful in
nurseries during outbreaks of S aureus infections in the
1960s and for treatment of patients with recurrent
furunculosis .""·1fI1 The early practice of artificial
inoculation with S aureus S02A was abandoned after
alleged complications"" and the advent of newer
antistaphylococcal antibiotics in the early 1970s.
Bacterial population dynamics
To understand S aureus nasal carriage and the relation
with subsequent disease. we need to define the population
structure of S aureus. Several techniques have been used
to describe the natural population structure of S aureus.
including multilocus enzyme electrophoresis.,o7 pulsedfield gel electrophoresis."'" multilocus sequence typing
(MLST).'" "" and amplified fragment length polymorphism
(AFLP)."() These studies have revealed that S aureus is
highly clonal. by contrast with other pathogenic species
such as Streptococcus pneumoniae.'" Most recent studies
have assessed the population structure of S aureus using
MLST.'9.109 This molecular typing method characterises
bacterial isolates on the basis of the sequence of internal
fragments of seven housekeeping genes that represent the
stable "core" of the bacterial genome. These MLST studies
have placed most S aureus isolates (colonising as well as
invasive isolates of meticillin-sensitive S aureus [MSSAJ
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and MRSA) in five major clusters-clonal complex (CC) 8,
CC30, CC5, CC22, and CC45."I'J·"Ull MRSA isolates were
found in several major clonal complexes, indicating that
meticillin resistance has developed in most distinct
phylogenetic sub-populations of S aureus.,,0,1l4m The
pandemic penicillin-resistant S aureus clone in the 1950s,
now known as CC30, is currently re-emerging as a
pandemic MRSA clone. ' ''''''7
Most population structure studies of S aureus were
biased by the use of mostly clinical isolates and collections
of nosocomial MRSA.II~, I I ' Recently, the population
structure of S aureus isolated from the nose of people
living in the community was analysed by AFLP .110 AFLP is
a whole genome typing method, documenting the
contribution of "accessory genetic elements" as well as
genome-core polymorphisms. This study revealed the
existence of three major (I. II, III) and two minor (IVa and
IVb) genetic clusters of S aureus (figure 6). AFLP clusters
II and III-identical to MLST CC30 and CC45,
respectively-account for almost half (47%) of all carriage
isolates, suggesting that these two clonal complexes have
evolved to be very successful in colonising human
beings, 1111 Melles and co-workers"o identified the same
major clusters as the MLST studies (Oxford database, UK;
http://www.mlst.net). Apparently, these clonal clusters
have spread successfully worldwide. 110
There is controversy as to whether all S aureus strains
have equal disease invoking potential or whether invasive
disease is associated with particularly virulent genotypes.
Feil and co-workers!'" fOlmd no significant differences in
the disuibution of genotypes between strains isolated
from carriers and those from patients with invasive
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Figur. 6: Principal component analysis of 1056 5 aureus strains reveals genetic dusters of hypervirulent
dones 1l1J ,ll'
The diff.rent boxes, plotted here in a three· dimensional space and coloured according to their source, represent
each Sallrells strain analysed in the study. The five circles indicate the three major (I. II, and III) and two minor (IVa
and IVb) different phylogenetic clusters identified by AFLP, Although strains from each of the genetic dusters are
essentially able to cause invasive disease, some clusters contain proportionally more invasive isolates,

756

470

disease. There was, therefore, no evidence for the
existence of hyper-virulent S aureus clones. By contrast,
subclusters of strains with differential degrees of
pathogenicity were observed in the study by Melles and
colleagues,"U who identified subclusters with an overrepresentation of bacteraemia isolates. Furthermore,
expansion of multidrug-resistant clones or clones
associated with skin disease (impetigo) were observed,
Some clones have been shown to be more virulent than
others; however, given the appropriate clinical conditions
each and every strain of S aureus can become a lifethreatening pathogen. Another study found that invasive
S aure:us strains belonging to a clonal complex are
associated with a higher in-hospital mortality rate,
indicating co-evolution of S aureus virulence and spread
among human beings." 9 This study also concluded that
(major) CC45 was significantly under· represented among
invasive strains (odds ratio [OR] 0·2, 0.04-0.6), which
corroborated earlier findings.IIO,1I9 Furthermore, Peacock
and colleagues! '" provided evidence of considerable
horizontal transfer of virulence-associated genes in a
clonal background. In summary, S aureus will remain an
important clinical challenge and, apparently, some strains
will present challenges that are more vigorous than others.
It remains to be seen whether the possibility of identifying
the more pathogenic clones of S aureus in the laboratory
can be translated into a reliable diagnostic tool with
clinical relevance in the future.

Risks of Saureus nasal carriage
Community-acquired infections
Most-studies regarding the risks of acquiring S aureus
infections in the community concern skin and soft tissue
infections. Several, mostly older, studies investigated the
relation between S aureus nasal carriage and skin
infections, '" including furunculosis,1Zl,!lJ impetigo,'"
sycosis barbae,!lI,m,,,; and stye.116 On average, 80% (range
42-100%) of those with skin lesions were S aureus nasal
carriers, and 65% (range 29-88%) had the same phage
type in the nose and lesion.
In one large prospective population-based study among
elderly people there was no relation between persistent
S aureus nasal carriage and all-cause mortality, a surrogate
end-point for serious staphylococcal disease. 7' Earlier
retrospective cohort or case-control studies have
demonstrated increasing age, male sex, alcoholism, lung
disease, cancer, diabetes mellitus, end stage renal failure,
and dialysis to be risk factors for community-acquired
S aureus infections necessitating hospital admission.l17-119
These factors have also been identified earlier as
determinants of S aureus nasal carriage in case-control or
cross-sectional studies.'
The spectrum of commtmity S aureus disease is rapidly
changing with the advent and spread of community-onset
MRSA strains. 7·,,'IC,, 1l0,1l' Overall MRSA carriage rates in the
community are stilllow,W,ll! but seem to be rising rapidly
in certain parts of the world. uO,m In the only prospective
http://infection,thelancet,com Vol5 December 2005
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study done so far on nasal carriage of community-onset
MRSA and risk of infections in soldiers, Eliis and coworkers'" found a relative risk on· 1 (95% CI 1· 5-6·5) for
nasal MRSA carriers to acquire a MRSA infection (eg,
cellulitis, abscesses) in the commtmity. In a retrospective
study concerning community-onset MRSA skin infections
among professional football players, Kazakova and
colleagues 7\ did not find any MRSA in nasal swabs or
environmental cultures, although 42% were nasal carriers
of MSSA strains. Apart from these highly selected
populations, it remains questionable whether the results
from these studies can be extrapolated to the general
population.'" We need more community-based studies to
better understand the ecology, pathophysiology, and
epidemiology of S aureus nasal carriage and infections in
the community and to develop and target preventive
measures.
Nosocomial infections
S aureus (MSSA as well as MRSA) ranks as the second
most common cause of hospital-acquired (nosocomial)
bloodstream infections. About 20% of patients
undergoing surgery acquire at least one nosocomial
infection. leading to increased morbidity. mortality,
hospital stay. and costs.l!·~"'J Hospital treatment usually
requires that first line barriers for pathogens--of which
the skin is an important one--are intentionally breached.
resulting in an increased risk of infection. Most of these
nosocomial S aureus infections are caused by the patient's
own S aureus cells, which were already present on the skin
or mucosal membranes before hospital admission in at
least 800/0 of the casesY It could well be that more
infections are of endogenous origin, since 10% of the
nasal S aureus carriers have more than one genotype or
phage type in their nose. S,""
5 aureus nasal carriage has been identified as a risk
factor for the development of nosocomial infections in
general hospital populations.''' surgical patients
(general.',(,,9 orthopaedic.''' thoracic surgery,'" and
children'''), patients on haemodialysis or continuous
peritoneal dialysis,w,,.,14,,J4(, patients with liver cirrhosis and
after liver transplantation.'8,147-'" HIV-infected patients.'"''''
and patients admitted to intensive care units.'·.... ,\] In a
recent study there was a threefold increased risk for nonsurgical patients who were S aureus nasal carriers to
acquire a nosocomial S aureus bacteraernia versus noncarriers.' Also nasal carriers among surgical patients have
a higher risk (OR 4·0) for nosocomial S aureus
bacteraemia compared with controls.';'
Second to coagulase-negative staphylococci,S aureus is
the most prevalent organism causing intravascular deviceassociated bacteraemia.','37,'" Pujol and colleagues"'"
looked at bacteraemia in an intensive care unit. Most of
the 5 aureus bacteraemias had an intravascular device as a
source. In this study. carriers of S aureus had a relative risk
of 12·4 for the development of S aureus bacteraemia. "" In
a study by Wertheim and co-workers,' the source of
http://infection,thelancet.com Vol5 December 2005
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bacteraemia was device related in more than 50% of the
cases. Interestingly, the mortality rate from S aureus
bacteraemia is higher in non-carriers compared with
carriers.' Since bacteraemia is usually endogenous in
carriers. partial immunity may have an important role
here. This finding needs confirmation and the underlying
medlanism resolved.
In HIV-positive patients, increased rates of S aureus
bacteraemia and deep soft tissue infections have been
observed. which frequently recur. Even higher infection
rates are fotmd in patients with AIDS compared with
HIV-positive asymptomatic patients. Nguyen and
colleagues" found that nasal carriage is an important risk
factor in this patient population (OR 5 ·1). Other risk
factors for infection in this study were presence of a
vascular catheter (OR 4·9), low CD4 cell count
«100 cells/f.l.L; OR 3·5), and neutropenia. The risk for
developing an S aureus infection was approximately 10%
for every 6 months in patients who were nasal carriers of
S aureus and had CD4 cell counts ofless than 100 cells/ f.l.L.
It should be noted that S aureus nasal carriage was more
common in patients who were not receiving cotrimoxazole prophylaxis for prevention of Pneumocystis
jiroveci pneumonia.
In haemodialysis patients. S aureus is the most
frequently found pathogen in infections at the vascular
access site and in bacteraemia. The infection rate is higher
in carriers on haemodialysis, with relative risks varying
from 1· 8 to 4· 7.',,",14\,146';" S aureus isolates are usually
identical to the one previously isolated from the patient's
nose."" In a study by Nielsen and colleagues,1\', the relative
risk for S aureus bacteraemia was 26·2 (6·1-113) when
S aureus was colonising the insertion site, and
3·3 (0·74-15·1), in the case of only S aureus nasal
carriage. However, multiple studies have demonstrated
that long-term eradication of S aureus nasal carriage by
(repeated) application of mupirocin effectively prevents
S aureus infections among patients who are receiving
dialysis. thereby decreasing complications and costS.1I7-'60
Additional application of a local antibiotic ointment to exit
sites is also important in preventing infections.'M
In patients on continuous peritoneal dialysis, S aureus is
the leading cause of continuous peritoneal dialysis-related
infections, often leading to catheter loss. S aureus nasal
carriage has been found to be a major risk factor for
infections in patients on continuous peritoneal dialysis,
mainly associated with exit site and tunnel
infections. ;1.10,"2-"'" Intervention studies consistently
demonstrated a substantial reduction in the incidence of
exit site infections, but not a consistent reduction in the
incidence of continuous peritoneal dialysis-related
peritonitis.\4,'66-"o Two studies did not find a correlation
between S aureus nasal carriage and the development of
5 aureus exit site infections.''',17l In a recent study it was
demonstrated that only continuous peritoneal dialysis
patients who are persistent S aureus nasal carriers are at
increased risk of acquiring continuous peritoneal dialysis-

471

757

I

Review

carriage sites. Health-care workers can be important
sources of transmission of S aureus and cross-infection.'"

Search strategy and selection criteria
We searched Pubmed with the following search terms:
"Staphylococcus aureus", "colonisation", "carriage", "nose",
"nasal", "vestibulum nasi", "mucosa", "nasal", "nosocomial",
"epidemiology", "determinants", "risk factor", "treatment", and
"infection". The following limits were used: English language,
abstract, and human studies. We identified additional articles
by searching the reference lists of existing articles.

Conclusions

Many studies have been published on S aureus nasal
carriage--a Pubmed search with the terms
"Staphylococcus aureus" and "nasal" gives 1383 hits.
Based on these studies and the results of contradicting
twin studies""'" a simple Mendelian trait probably does
not explain the different S aureus nasal carrier states. ".41<
The repeated exposure to S aureus in the (household)
related S aureus infections. n Intermittent nasal carriers of environment is considered to be an important
S aureus have the same risk of S aureus infection as non- determinant of S aureus nasal carriage, probably more
carriers .... Targeting interventions to prevent continuous important than the genetic background of individuals.
peritoneal dialysis-related infections is thus possible, In general, a multifactorial genesis underlies S aureus
thereby eliminating unnecessary prophylactic and nasal carriage.
therapeutic antibiotic use and resistance development. l7J
We now need to identifY which factors of S aureus and
The nasal strain and the infectious strain are clonally the nasal niche are of importance in adherence. Recent inrelated in most patients on continuous peritoneal dialysis vitro and in-vivo studies in rats have begun to elucidate
with S aureus infection. I•. B •56
these factors, which is an important step forward .....""
Studies in the 1950s and 1960s show that with Furthermore, we may need to change the focus from
increasing numbers of staphylococcal bacteria in the nose, mucosal adherence to adherence to more prevalent
as in persistent carriers, S aureus skin carriage rates epitopes present in the anterior nares. The real
increase proportionally. in parallel with a rise in risk of importance of these factors needs to be confirmed in a
S aureus surgical site infections.'·u.l74.m The more recent human colonisation model. Only then may we find new,
observation that patients carrying S aureus in their nose as effective ways of decolonising the nares and other body
well as perineal (or rectal) skin are at a higher risk for sites.-So far there is limited evidence that decolonisation of
subsequent S aureus infections when compared with only the anterior nares to prevent staphylococcal disease is only
perineal or nasal carriers can probably also be explained by effective in dialysis and surgical patients. Recent clinical
a higher S aureus load.'" Presumably people who carry trials in non-surgical and orthopaedic patients did not
S aureus in their nose contaminate their hands, then show any positive effect.''''·,·, Focusing only on at-risk
transferring the organism to other sites on their bodies.'"' patients-eg, persistent carriers-may improve the
The number of staphylococcal cells needed to cause outcome of an intervention. Also the decolonisation of
infection decreases dramatically at the site of a suture, extra-nasal sites needs to be improved."
compared with healthy skin.""
So far, there has been concem only for the increased risk
Although S aureus nasal carriage is unanimously of S aureus nasal carriers for acquiring S aureus infections.
accepted as one of the most important risk factors for However, studies have shown that non-carriers who
nosocomial and surgical site infections today and studies acquire exogenous S aureus bacteraemia have a fourfold
using historical controls have reported substantial increased mortality rate compared with S aureus nasal
reductions of surgical site infections among patients carriers.7 Thus, the immunological mechanisms of
receiving mupirocin. 1JI•. m -'7') randomised controlled trials S aureus nasal carriage need to be resolved. In nonuniformly failed to confirm these results.,·,so.'81 Perl and carriers, preventing the acquisition of S aureus strains
colleagues') could only demonstrate a significant effect deserves more attention.
(48% risk reduction, p=0· 02) on the rate of nosocomial Conflicts of interest
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Methicillin-Resistant Staphylococcus au reus:
An Evolutionary, Epidemiologic,
and Therapeutic Odyssey
Stan Deresinski
Division of Infectious Disease and Geographic Medicine. Department of Medicine. Stanford University. Stanford. and Santa Clara Valley
Medical Center. San Jose. California

Methicillin-resistant Staphylococcus au reus, first identified just over 4 decades ago, has undergone rapid evolutionary changes and epidemiologic expansion. It has spread beyond the confines of health care facilities,
emerging anew in the community, where it is rapidly becoming a dominant pathogen. This has led to an
important change in the choice of antibiotics in the management of community-acquired infections and has
also led to the development of novel antimicrobials.

HISTORICAL BACKGROUND
AND EPIDEMIOLOGY
It was only 1 year after an Oxfordshire constable, Albert
Alexander, became the first recipient of penicillin, that
Rammelkamp reported the identification of isolates of
Staphylococcus aureus resistant to this miracle drug [1].
Infections caused by penicillin-resistant S. aureus were
initially limited to hospitalized patients and were only
later detected in the community, where they eventually
became common [2]. In an historical reprise, the identification of methicillin-resistant S. aureus (MRSA) was
reported within 1 year after the 1960 introduction of
this semisynthetic penicillin, and once again, an organism that was initially present only in hospitals later
became prevalent in the community [2, 3]. The spread
of MRSA from the hospital to the community was a
predictable event. The emergence in the past decade of
novel strains of MRSA in the community that are genetically distinct from MRSA strains originating in the
hospital was perhaps less anticipated.
MRSA is currently the most commonly identified
antibiotic-resistant pathogen in US hospitals [4, 5]. Al-
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though 25.9% of S. aureus strains isolated from outpatients were methicillin resistant [5], most of these
strains were recovered from individuals who were likely
to have acquired them in the health care environment
[6, 7J. Their association with health care may, however,
have been indirect; household contacts of individuals
with hospital-acquired MRSA (HA-MRSA) are at significantly increased risk for MRSA colonization [8]. In
a recent and dramatic evolutionary development, however, infection with novel community-acquired strains
of MRSA (CA-MRSA) in previously healthy individuals
without either direct or indirect association with health
care facilities has emerged as a new and important public health problem [9-11].
In-some community settings, CA-MRSA have become the prevalent form of S. aureus isolated from
cutaneous infections, especially among children. At a
Houston pediatric hospital, 74% of community-acquired S. aureus strains isolated since 2001 have been
resistant to methicillin [12]. Clusters and outbreaks in
adolescents and adults have been reported to occur in
Native Americans [13], homeless youth [14], men who
have sex with men [9], jail inmates [10], military recruits [15], children in child care centers [16], and
competitive athletes [17]. Although most infections
have involved skin and skin structures, potentially lethal
invasive infections have also occurred. The report in
1999 of the deaths of 4 previously healthy children in
Minnesota and North Dakota who did not have pre-

vious contact with health care facilities unequivocally illustrated
the potential dangers presented by CA-MRSA [18).
Reversing and completing an epidemiologic cycle, CA-MRSA
are now being introduced from their site of origin in the community into the hospital [19,20). At some hospitals, CA-MRSA
are displacing classic hospital-associated strains of S. aureus,
which is consisitent with the hypothesis that the former may
be more fit [21).

MOLECULAR EPIDEMIOLOGY OF METHICILLIN
RESISTANCE
The mechanism of resistance to methicillin was uncovered in
1981 with the the identification of reduced-affinity penicillinbinding proteins in MRSA [22). The altered protein, PBP2a
(PBP2' in the United Kingdom), retains effective transpeptidase
activity while having reduced affinity for penicillin and other
available /3-lactam antibiotics. PBP2a exhibit both a reduced
rate-constant for acylation by /3-lactams and elevated dissociation constants [23). These 2 factors, acting together, prevent
acylation of PBP2a and thus result in /3-lactam resistance [23).
PBP2a is encoded by the mecA gene (for a glossary of genetic
terms, see Appendix) [24). The mobile mecA gene complex is
comprised of mecA together with its regulator genes, mecI and
mecR, and resides within a genomic island, the staphylococcal
cassette chromosome mec (SCCmec) that constitutes 1%-2%
of the -2.9 million-bp S. aureus chromosome [24-26) (figure
1). SCCmec also contains the insertion sequence, IS431 mec, as
well as recombinases necessary for site-specific integration and
excision. Some SCCmec types also contain various additional
genetic elements, such as Tn554 (which encodes resistance to
macrolides, clindamycin, and streptogramin B) and pTl81
(which encodes resistance to tetracyclines) [2).
The expression of PBP2a is induced by the binding of /3lactam antibiotics to a cytoplasmic membrane sensor-transducer receptor encoded by the mecRl gene, triggering a signal
leading to the proteolytic release of the mecI repressor from
the operator region of the mecA gene [27, 28). Phenotypic
resistance to methicillin is variably expressed, and population
analysis demonstrates that each MRSA strain has a characteristic growth profile at each concentration of methicillin examined [29). In contrast to this heterogeneously expressed resistance to methicillin, homogeneous resistance requires the
interaction of additional factors, such as the femA-F genes that
are involved in peptidoglycan synthesis [30).

MOLECULAR EVOLUTIONARY HISTORY
Although PFGE is commonly used in hospitals to determine
the relatedness of isolates for epidemiologic purposes, this
method is insufficiently discriminatory for evolutionary studies
[31). The overall genetic background of S. aureus isolates is
unambiguously determined through multiJocus sequence typ-
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Figure 1. Diagram showing the staphylococcal cassette chromosome
mec type IV (SCCmec type IV) (adapted from [24)). SCCmec type IV lacks
antibiotic resistance elements directed at non-/3-lactam antibiotics that
are present in SCCmec types characteristic of hospital-acquired methicillin-resistant Staphylococcus aureus. ccrA2and ccrB2designate cassette
chromosome recombinases. viS 1272designates IS431mec insertion sequences. mecA encodes PBP2a. orfX indicates an open reading frame.
t:.mecRl is a signal transducer gene whose activation by /3-lactam antibiotics inactivates the mecl repressor gene product. allowing expression
of mecA.

ing by determination of the sequence of portions of 7 housekeeping genes [25). The mobile SCCmec elements, on the other
hand, are classified by analysis of their cassette chromosome
recombinase (cer) and mecA gene complexes [32). SCCmec
types also differ with regard to their acquisition of resistance
determinants acquired as the result of integration of plasmids
and transposons [32). At least 5 SCCmec types (types I-V),
varying in size from -20 kb to 68 kb, have been identified [33)
(table 1). The smallest of these-SCCmec types I, IV, and Vcontain only recombinase genes and the structural and regulatory genes for resistance to methicillin and lack the transposable elements and genes encoding resistance to non-/3-lactam antibiotics carried by types II and III [33, 35). SCCmec
types I-IV contain alleles of cerA and cerE, whereas type V,
which has to date been identified in a small number of Australian CA-MRSA isolates, contains a novel cerdesignated ccrC
[33). Two possible additional SCCmec types have recently been
identified among Australian CA-MRSA strains [36).
Genetic evolutionary analyses have demonstrated that the
mecA gene has been transferred into methicillin-susceptible S.
aureus (MSSA) on *20 occasions, having emerged in *5 phylogenetically d~stinct lineages (as well as reemerging within indvidual lineages) [25, 31, 37J. It has been suggested that the
emergence of PBP2a initially resulted from a recombination
event involving the genes encoding an existing PBP and an
inducible /3-lactamase [38). The donor strains that became the
source of PBP2a are likely to have been coagulase-negative
staphylococci, with Staphylococcus sciuri identified as a prime
candidate [39). A recent study of 44 methicillin-resistant Staphylococcus epidermidis isolates from the blood of patients with
prosthetic valve endocarditis from 1973 to 1983 found that 2%
carried SCCmec type I, 34% carried type II, 28% carried type
III, and 36% carried type IV [40). The introduction of mecA
from the putative donor species into MSSA strains that are
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Table 1.

SCCmec
type

II
III

Characteristics of staphylococcal cassette chromosome mac ISCCmec) types I-V.

SCCmec
size. kb

34
53

PUB110 (aadO)b. Tn554 (ermA!"

67

PUB110 (aadO)b. PT181 (tetK)d

Infrequent

Hospital

Infrequent

Hospital

Infrequent

21-24

Community

Frequent

V

28

Community

Unknown

NOTE.

Data is adapted from 140J and 11551. PVL. Panton-Valentine leukocidin; S. aureus. Staphylococcus aureus.

40%-90% of S. aureus
b Encodes resistance
C Encodes resistance
d Encodes resistance

5. aureus strains that carry SCCmec types I-III also carry the PVL gene; with some exceptions.
strains that carry SCCmec type IV carry the PVL gene.
to tobramycin and kanamycin.
to macrolide-lincosamide-streptogramin antibiotics.
to tetracycline.

already successfully adapted to hospital environments and to
the community have, in turn, created successful epidemic HAMRSA and CA-MRSA clones [31, 35, 41, 42].
Evidence indicates that the ancestral MRSA genotype, ST250MRSA, is a strain originating in Denmark and possessing
SCCmec type I, most extant isolates of which were obtained in
the 1960s [37]. (By convention, strains are named by their
sequence type [ST] and the presence or absence of methicillin
resistance. Thus, this strain is a methicillin-resistant S. aureus
of a sequence type designated as 250). ST250-MRSA arose as
the consequence of the acquisition of the mec gene by the
methicillin-susceptible strain ST250-MSSA, which had itself
arisen from ST8-MSSA by a chromosomal point mutation [37).
ST250-MRSA is no longer a major cause of epidemic MRSA
infections, but ST247-MRSA (the "Iberian clone"), which
evolved from ST250-MRSA by a single point mutation, remains
an important hospital pathogen in Europe and has been reported to have caused an outbreak in a New York City hospital
[43]. As indicated above, there have since been multiple introductions of mec into S. aureus [31]. The emergence of CAMRSA strains, in particular, has repeatedly occurred as a result
of the introduction of SCCrnec type IV into a variety of genetic
MSSA backgrounds [41). In the United States, one of the resultant clones, ST8-MSSA (USA 300) has proven increasingly
successful [44].

EPIDEMIOLOGIC SUCCESS AND VIRULENCE
OF CA-MRSA
CA-MRSA strains differ in a number of important ways from
the 6 major pandemic clones of MRSA that account for nearly
70% of epidemic HA-MRSA strains [45]. These differences are
found in the composition of the gene cassette coding for methicillin resistance, in the carriage of plasmids encoding resistance

em
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a In general. <5% of
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Origin of
S. aureus isolatates
carrying the specified
SCCmec type

Other
antibiotic-resistant
elements (gene) on SCCmec

Presence of
Panton-Valentine
leukocidin in
S. aureus isolates
carrying the specified
SCCmec type"

to antibiotics of other classes (as well as resistance to heavy
metals), and in their associated virulence factors.
The earliest strain of MRSA in which SCCmec type IV has
been identified was isolated in 1981 [32]. Despite this apparently recent emergence, an analysis of a large number of MRS A
isolates detected SCCrnec type IV in twice as many clones as
any of the other types, suggesting its greater promiscuity and
successful persistence [26]. This may be the result of greater
efficiency of transfer and/or a lesser fitness cost to the recipient
clone, possibly because of its smaller size and lack of the" excess
baggage" included in other SCCmectypes [26,35,41]. Although
HA-MRSA has been reported to replicate more slowly than
MSSA [46], a CA-MRSA clinical isolate harboring SCCmectype
IV has been demonstrated to replicate more rapidly than HAMRSA isolates with other SCCmec types [41, 42J. In contrast,
transformation of an SCCrnec type I element into S. aureus
strains yielded highly oxacillin-resistant transformants with a
reduced growth rate [47]. This relatively greater fitness ofCAMRSA strains carrying SCCrnec type IV may account for its
remarkable success in displacing other MRSA strains in some
hospitals after its introduction from the community [21].

MOLECULAR BASIS OF VIRULENCE
OFCA-MRSA
Sequencing of the genome of CA-MRSA strain MW2, which
caused fatal sepsis in a 16-month-old girl from North Dakota
[18], identified 19 putative virulence genes not found in 5
simultaneously examined HA-MRSA strains [42]. These included genes for several superantigens, such as enterotoxins B
and C, as well as the amphipathic leukotoxin, the PantonValentine leukocidin (PVL). PVL, first described in 1932 [48),
is a bicomponent synergohymenotropic (synergistic membrane-tropic) toxin that was present in <5% of unselected S.
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aureus isolates but is present in the majority of CA-MRSA
isolates studied [49, 50]. CA-MRSA isolates from Australia, on
the other hand, infrequently carry the genes encoding PVL [36].
PVL is encoded by contiguously located cotranscribed
genes, lukS-PVand lukF-PV, inserted near the att site [50].
These genes are transmitted by a temperate phage designated
0PVL [51, 52]. Their gene products, 33 kDa and 34 kDa in
size, respectively, assemble as hetero-oligomers and synergistically exert cytolytic pore-forming activity specifically directed at the cell membranes of polymorphonucelar neutrophils and monocytes and/or macrophages [49, 50J. Injection
of PVL into the skin of rabbits causes dermal necrosis [53),
suggesting that it may playa role in the severity of skin and
skin-structure infections in humans. In addition, an association between PVL-containing strains of MRSA and virulent
necrotizing pneumonia has been reported [54].

RESISTANCE TO ANTIBIOTICS OTHER THAN
/3-LACTAMS
In contrast to the multidrug resistance usually seen in HAMRSA strains, antibiotic resistance in CA-MRSA strains is often
limited to iJ-lactams. The small size of SCCmec type IV may
preclude its carriage of additional genetic material, in contrast
to the characteristic presence of additional genetic material in
SCCmec type II and SCCmec type III [25, 26]. This does not,
however, preclude chromosomally encoded resistance or the
presence of resistance plasmids in strains carrying any of the
mec types. For instance, some CA-MRSA strains isolated in
western Australia contain a 41A-kb plasmid encoding resistance
to tetracycline and trimethoprim, as well as resistance to mupirocin and cadmium [55, 56). Fluoroquinolone resistance is
frequent in CA-MRSA carrying SCCmec type IV isolated from
homeless youth in San Francisco [57). Nonetheless, in contrast
to HA-MRSA strains, most CA-MRSA isolates remain susceptible to tetracyclines, clindamycin, and trimethoprim-sulfamethoxazole (TMP-SMZ) [11).

AVAILABLE ANTIBIOTICS FOR THE
TREATMENT OF MRSA INFECTION
Vancomycin. Compared with iJ-lactam therapy, vancomycin
therapy has been associated with slower clinical response and
longer duration of MSSA bacteremia, and it has been associated with more frequent complications in patients with endocarditis [58, 59). Failure of vancomycin therapy may be
observed in the treatment of patients with bacteremia due to
strains of MRSA that have MICs of vancomycin well within
the range considered susceptible [60]. Heterogeneous vancomycin resistance, which is not readily detected by routine
clinical laboratory methodology, is also associated with failure
of vancomycin therapy [61, 62]. The appearance of vanco-

mycin-intermediate S. aureus and, more recently, vancomycin-resistant S. aureus is of further concern [63].
Quinupristinldalfopristin. This combination is active in
vitro against MSSA and MRSA [64). It is bactericidal against
S. aureus, although in the presence of constitutive expression
of macrolide-lincosamide-streptogramin resistance, it is only
bacteriostatic [65J. In a randomized trial, patients with nosocomial MRSA pneumonia who received quinupristin/dalfopristin had a clinical response rate of 19.4%, compared with
40% in vancomycin recipients [66).
Linezolid. Linezolid and vancomycin yielded comparable
results in hospitalized patients with MRSA infections at a variety
of anatomic sites in a randomized, open-label trial [67), as well
as in the treatment of skin and skin-structure infections caused
by gram-positive organisms [68). A retrospective subset analysis
of 2 prospective randomized clinical trials found evidence suggesting that Iinezolid was superior to vancomycin in the treatment of hospital-acquired pneumonia due to MRSA [69, 70).
Daptomycin. Daptomycin is a novellipopeptide antibiotic
with bactericidal activity against S. aureus that binds, in a calcium-dependent manner, to the bacterial cell membrane, disrupting membrane potential [71]. Daptomycin has received
approval from the US Food and Drug Administration for the
treatment of complicated skin and skin-structure infections due
to susceptible gram-positive pathogens [72]. Daptomycin therapy failed in a trial involving patients with community-acquired
pneumonia; daptomycin not only has limited penetration into
pulmonary epithelial lining fluid, but its activity is inhibited
by pulmonary surfactant [72, 73).
Tetracyclines. In vitro susceptibility results involving tetracycline derivatives must be interpreted with caution, because
S. aureus isolates that are tetracycline-resistant but that have
relatively low MICs of doxycycline and/or minocycline may, in
fact, harbor inducible efflux genes [74, 75). Minocycline has
been shown to have bactericidal activity similar to that of vancomycin against a single strain of MRSA in an animal model
of endocarditis [76). Of 14 patients with MRSA infection who
were treated with doxycycline or minocycline, either alone or
in combination with rifampin, 3 (21 %) experienced treatment
failure [77].
TMP-SMZ. TMP-SMZ was less active than vancomycin in
a rabbit model of MRSA endocarditis and less rapidly bactericidal than nafcillin in a rabbit model of MSSA meningitis
[78,79). A randomized trial of treatment of S. aureus infections,
47% of which were due to MRSA, concluded that treatment
with TMP-SMZ was inferior to treatment with vancomycin
[80]. An extensive literature review, however, concluded that
TMP-SMZ "may be effective for the treatment of infections
due to low bacterial burdens of susceptible strains of S. aureus"
[81, pg. 340).
Fluoroquinolones. Although most CA-MRSA strains are
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reported to be fluoroquinolone susceptible, this is not true in
some locales [36, 57J. Fluoroquinolone resistance emerged very
rapidly in HA-MRSA in the years after widespread utilization
of agents of this class; at one institution, fluoroquinolone resistance increased from 7% before 1988 to 83% in 1990 [82J.
In vitro passage of both fluoroquinolone-susceptible MSSA and
MRSA in the presence of either ciprofloxacin or levofloxacin
is associated with the frequent selection of clones resistant to
these antibiotics [83 J. Furthermore, fluoroquinolones select
MRSA from among heterogeneously methicillin-resistant populations in vitro [84], and fluoroquinolone use is associated
with an increased risk of nosocomial acquisition of MRSA (but
not of MSSA) [85J. The fluoroquinolones with C8 substitutions, such as gatifloxacin and moxifloxacin, appear to be more
potent against S. aureus than are older drugs of this class, and
they may be less likely to select resistant mutants, an effect that
may be strengthened by the addition of rifampin [86-88J.
Clindamycin. Clindamycin has been used successfully in
the treatment of invasive CA-MRSA infections in children [89,
90J. Inducible resistance to c1indamycin, however, is not detected by routine susceptibility testing, but requires the use of
other methods (e.g., a double-disk diffusion test) [90-93J . Flattening of the zone in the area between the disks to resemble
the letter "D" indicates the presence of inducible resistance
(figure 2 and table 2).
Rifampin. Rifampin selects resistant mutants from among
both MSSA and MRSA strains at a frequency of 10- 6 to 10- 8,
but this may be prevented by using rifampin in combination
with a second active drug [94J.

Topical agents. MRSA strains that are resistant to mupirocin, mutants of which can be selected in vitro at frequencies
of 10- 7 to 10- 8 , are reported with increasing frequency [95J.
MRSA isolates with elevated MICs oftriclosan have been identified [96, 97].

OVERVIEW OF CHOICE OF SYSTEMIC
ANTIBIOTIC THERAPY
For some infections that require parenteral therapy and are due
to MRSA strains that are multidrug resistant, the treatment
choices may be restricted to vancomycin, daptomycin, linezolid,
and quinupristinldalfopristin therapy. The potential superiority
of linezolid therapy over vancomycin therapy in treating nosocomial pneumonia due to MRSA has been noted [69, 70J.
Daptomycin is ineffective in the treatment of pneumonia (Cubist Pharmaceuticals, data on file). The bacteriostatic activity of
linezolid may prove to limit its effectiveness in circumstances
in which bactericidal activity is required [67J.
Choices for treatment of infections due to CA-MRSA may
include, in a<;kijtion to the drugs mentioned above, TMP-SMZ,
tetracyclines, c1indamycin, and fluoroquinolones. The widespread use of fluoroquinolones for treating these infections
may, if history repeats itself, lead to the rapid emergence of
resistance to this class of antibiotics. Tetracycline therapy, contraindicated in children and in those who are pregnant, may
prove to be effective, but further clinical data are required.
TMP-SMZ appears to be effective in treating infections of limited extent and severity. Linezolid is an effective agent for which

Figure 2.
Image shows the results of a double-disk diffusion test for inducible. erm-mediated resistance to clindamycin. The demonstration of
flattening of the clindamycin zone between the disks is indicative of inducible resistance to clindamycin [34J.
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use has been limited by its cost. Antibiotic therapy is not always
required: a retrospective analysis has found resolution of CAMRSA infection in children with subcutaneous abscesses <5
cm in diameter who underwent incision and drainage in the
absence of administration of an antibiotic to which the pathogen was susceptible [98 J.

INVESTIGATIONAL AGENTS WITH ACTIVITY
AGAINST MRSA

Semisynthetic glycopeptides. Oritavancin is a semisynthetic
glycopeptide derivative that is active against some vancomycinresistant, gram-positive bacteria [99, 100]. A randomized trial
of oritavancin in the treatment of skin and skin-structure infections demonstrated results comparable to those observed
with a vancomycin-based regimen [10 1]. Its mean terminal
plasma half-life (± SD) of 151 ± 39 h allowed it to be given
in a total of 3 daily doses [10 1, 102].
Dalbavancin has a terminal plasma half-life of 9-12 days
[ 103]. A total of 2 doses given 1 week apart in the treatment
of skin and skin-structure infections resulted in a 94% cure
rate, compared with a 76.2% cure rate in those patients randomized to receive standard-of-care [103]. A third drug of this
class, telavancin, with a terminal plasma half-life of7 h in young
volunteers and 11 h in elderly subjects, was effective in a neutropenic mouse thigh model and is also in clinical trials [104107].
Glycylcyclines. The minocycline derivative tigecycline has
bacteriostatic activity against both MSSA and MSRA, including
tetracycline-resistant strains [99, 108, 109J. In a randomized
dose-comparison study, clinical cure rates were 67% and 74%
in patients with skin and skin-structure infections who received
25 mg and 50 mg daily, respectively [110].
Novel {3-lactams. A series of {3-lactamase-stable cephalosporins with high affinity for PBP2a are in clinical development
[Ill]. The PBP2a affinity of BMS-247243 is 100-fold greater
than that of methicillin or cefotaxime, and the drug is bactericidal against MRSA at twice the rate of vancomycin [112].
Other drugs of this class in development include the zwitterionic cephem RWJ-54428 [113], CB-I81963 [114], BAL5788
[115], a prod rug of BAL9141 [116, 117], and S-3578 [II8J.
ME1036 (formerly CP5609) is a C2-modified carbapenem with
high affinity for PBP2a and with an MIC.o of2.0 ,ug/mL against
MRSA [119]. SM-I97436, SM-23272I, and SM-232724 are
novel methylcarbapenems that are also active in vitro against
MRSA [120].
Fluoroquinolones. DW286, a naphthyridone, is among
several fluoroquinolones in development that have in vitro activity against MRSA [121]. Active against MRSA strains that
are resistant to other fluoroquinolones, it selects fluoroquinolone-resistant mutants at a lower frequency than do older
agents (as may another fluoroquinolone, ABT-492) [122, 123].

Oligosaccharides. Evernimicin is a complex sugar derivative with a novel mode of action [124, 125]. A related compound, avilamycin, has been used in animal feed, raising the
specter of rapid emergence of resistance to this class of drugs
[126].
Miscellaneous antimicrobials. The rifamycin rifalazil retains activity against some isolates that are resistant to rifampin
[127]. Epiroprim is a dihydrofolate reductase inhibitor with
activity against some trimethoprim-resistant strains of S. aureus; its combination with dapsone results in in vitro activity
against S. aureus that is greater than that of TMP-SMZ [128J.
Iclaprim is another dihydrofolate reductase inhibitor with activity against MRSA [129].
Other examples of modifications of existing molecules with
antistaphylococcal activity include the oxazolidinones ranbezolid [130, 131] and eperezolid [129, 132], as well as N-acylated
ornithine analogues of daptomycin [133]. Among drugs with
novel targets are the peptide deformylase-inhibitors NVP-PDF
713 [134, 135] and BB-83698 [136].
A number of naturally occurring cationic proteins have in
vitro activity against S. aureus [137], and some have been demonstrated to have activity in animal models of infection [138].
Lysostaphin is active in vitro against S. aureus [139] and was
effective in a rabbit model of MRSA endocarditis [140]. Its use
in a patient with S. aureus infection and neutropenia was first
reported in 1974 [141]. Specific bacteriophage has been demonstrated to be effective in protecting mice against lethal S.
aureus infection [142, 143].
Targeting virulence factors. RNAIII-inhibiting peptide inhibits S. aureus pathogenesis by disrupting quorum-sensing
mechanisms [144]. The accessory gene regulator (agr) is an
important regulator of virulence that is, at least in part, related
to quorum sensing [145]; a truncated thiolactone peptide has
been found to be a potent inhibitor for all 4 agr-specificity
groups of S. aureus [146].
S. aureus immune globulin intravenous (human) (Altastaph;
NABI Biopharmaceuticals) is a hyperimmune, polyclonal, intravenous immunoglobulin product derived from the plasma
of human donors who have previously been vaccinated with
S. aureus polysaccharide conjugate vaccine (StaphVAX; NABI
Biopharmaceuticals), a bivalent conjugate capsular polysaccharide covalently bound to recombinant exoprotein A, which has
been demonstrated to provide temporary protection against the
occurrence of S. aureus bacteremia in patients receiving hemodialysis [147, 148]. Patients with S. aureus bacteremia and
persisting fever are currently being enrolled in a phase 1111 trial
[149]. Also in progress is a phase II prevention trial involving
infants with low birth weights [150].
Tefibazumab (Aurexis; Inhibitex) is a humanized monoclonal
antibody directed at the microbial surface components recognizing adhesive matrix molecule (MSCRAMM) clumping
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Table 2.

Macrolide-lincosamide-streptogramin resistance in methicillin-resistant Staphy-

lococcus aureus.

Mechanism of resistance
Efflux
Ribosomal methylation
NOTE.

Drug resistance

Gene
determinant

Erythromycin

Clindamycin

msrA
erm

Resistant
Resistant

Susceptible
Susceptible or resistant (inducible);'
resistant (constitutive)

Data are adapted from 134).

Resistant strains have inducible resistance. Determination of resistancerequires specific testing (e.g., use
of a double-disk diffusion test).
a

factor A [151] that is currently being evaluated in a phase II
trial in patients with S. aureus bacteremia [152J. INH-A21 (Veronate; Inhibitex) is a donor-selected human polyclonal immunoglobulin preparation that is also enriched in antibody to
staphylococcal MSCRAMM proteins and that is undergoing
clinical trial evaluation for the prevention ofinfection in infants
with very low birth weights [153]. Another cell surface component, teichoic acid, is the target of BYSX-AllO, an IgGI
chimeric monoclonal antibody that is in clinical trials for the
prevention of staphylococcal infections in infants with low birth
weights [154].
Aurograb (NeuTec Pharma) is a single-chain antibody fragment lacking the immunoglobulin Fc domain targeted at
EMRSA-15, a 61-kDa ABC transporter expressed by epidemic
strains of MRSA that is in clinical therapeutic trials in the
United Kingdom [ISS, 156].
Pooled intravenous immune globulin preparations neutralize
a number of staphylococcal superantigen toxins and, as a consequence, are commonly used in the therapy of toxic shock
syndrome [157]. The identification of a conserved epitope on
staphylococcal enterotoxins that appears to be critical to their
activity raises the possibility of another approach to superantigen neutralization [158]. PVL can also be neutralized in vitro
by commercial intravenous immunoglobulin preparations
[ 159].
The story of antibiotic resistance and virulence in S. aureus
is, as has been stated by others, one of "depressing evolutionary progression" [37, pg. 92]. The emergence of CAMRSA, the rapid introduction of SCCmec type IV into multiple genetic backgrounds, and the epidemiological success of
the resultant strains indicate that this problem will continue
its inexorable march [37, 160, 161J. Mathematical modeling
demonstrates difficulty in the epidemiologic control of MRSA
in the face of its increased prevalence in the community and
the increasingly daunting tasks for hospital infection-control
programs [162 J. An effective vaccine will be the only effective
long-term solution.
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APPENDIX
Cassette chromosome recombinase (eer) A gene necessary for the mobility of SCC that enables its site-specific integration into and precise excision from the S. aureus
chromosome.
Genomic island Genomic islands (often abbreviated as
GIS or GEls) are horizontally acquired chromosomal regions
of DNA carrying several genes encoding traits associated with
increased adaptability or fitness under specific conditions. They
are termed pathogenicity, fitness, symbiosis, metabolic, or resistance islands, depending on the functions encoded [163].
Housekeeping gene A gene involved in basic functions
required for cell viability and constitutively expressed in most
cells. Housekeeping genes evolve much more slowly than do
tissue specific genes that encode proteins necessary only in
selected types of cells.
Insertion sequence A DNA sequence involved in the mobilization of genetic information to and from vectors such as
plasmids.
mee gene complex Gene complex composed of mecA and
its regulator genes, mecJ and mecR.
mecA The gene encoding PBP2a, responsible for resistance
to methicillin and other {3-lactam antibiotics.
mecI The meeA repressor gene.
mecRl A signal transducer gene that encodes a transmembrane receptor that responds to covalent binding of a {3lactam antibiotic and its extracellular sensor domain. Binding
initiates events that lead to inactivation of the mecI gene repressor product by a protease, allowing expression of mecA.
Staphylococcal chromosome cassette (SCC)
see (or
SCCmec) is a mobile, 52-kb DNA cassette containing the gene
that encodes resistance to methicillin (mecA), as well as those

568 • eID 2005:40 (IS February) • Deresinski

483

genes (ccrA and cerB in most cases)
encode the integration
and excision necessary for its recombination in the staphylococcal chromosome, in addition to insertion sequences.
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to Iw standard,. TJw additional yield of culturing the throat is

only;

Throat Swabs Are Necessary
to Reliably Detect Carriers
of Staphylococcus aureus

it

wnsidc'red to bt' negligibh:. bix,mM.' it adds di.~comfort fiJr the

patient aml (mt to the health care wstem without significantly
in..:rea,ed ~l'l1sitivity. This belief is based on the obsen,.uion that
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as well. How<!ver, colonization of the throat but no! of
the fwn::; rnay- be more (ommon than is currently
,Kkn,)wledged,
Pub!.icaliolls from the 194/)s reported throat colonization
rates of 4<1'(...··63% [:~l. A feC(mt study confirmed the observ.ltion
that the throat may be sdectively colonized and escape current

throat carriers of S.
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Th(' anterior nlln's arc the most important screening :lite of
colonil,.ltiol1 with StllpllylowCCll$ l1ureus. We screened 2966
individuals fOT S. mm:lls carriage with swabs of both nares

and throat. A total of 37.]O/() of persons were nasal carriers,
.Hld ) 2.81l/o were .solely throat earners. Screcning of throat
swabs significantly incl'eases the sensitivity of detection
among carriers by 25.7%.

routine scrt'cning programs 1JOJ,
Unr~'mgnizl:d carriers rna~' spf(~ad !vlRSA and rl:llder infectioll-control programs futile. Therefore. we questioned lhe
practice of sGcening of the anterior nares ;llone ilnd ('valuated
til(' additional benefit of screening hoth thl: !li!rcs ilnd the thm:lt
in 4 different ~t\ldy populations.

P'ltients a.nd methods.

Ill';' anterior nares Me; considCf<'d to bt:' the primary coloni-
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,wd j~ associilted with dfl irKrcascd risk of infectious comp!i·
e;,lli(ll1:> .lner surgery in patients with t'nd·slilge renal f,li1me an.i
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,,( inv,.\sive nl.1sncornial inl-C(lions are of endogenous origin in
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hO:;l'ilal~ and in the community ha~ triggered many s(rt'cning
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Lull' identification of cHriers is ,1 (Tucial Mt'p in MRSr\ pre·
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We collt'cted data from 4. difIt'rent
groups of individmls. The fir,t group induded pati.;>nts ,md
health (are worker, who were s(f(·{~n ....d afwr exposure to an
tv1 RSA carrier during tiw )'eMS 2000-.::n05. Slnc:e 1997, thi,
procedure h.l!, Iwen part of the ho~pit<11' s policy (or preven!inf)
of the 5pr~'ad of MRSI\. The ,("cond group consisted of lwalth

or..' Io\'(,lrkers \',!ho p<lrticip<lted in a trad(' f:1ir fnr medical and
hospital equipment (the Intermltionale Fachllw~se fur Arzttlnd Spitalbedorf colwentiol1 at an exhihition cenler in Zurich.

Switzerland) Of) 26-·29 October 2004 and who voltml~'ercd to
participate in a pr,:va/cllce surV{'Y (\( S. aI/fellS carriage iUllong
th(' Swiss population. The third group included healthr bk.od
donors who\vere screened I()f $, aureus in the year 2005. Gr(lup
4 consists of a large sample of nasal and (I1m.11
W(:f('

group I.
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This group comists of patients and health can.' workers, a, III
jvlRSA carriers '"ere an,llyzed separately to avoid any potenli,1I bias, beGlU",' i1 is unknown wh.,tller IvlRSA has the S<lH1C
pattern as IHethicilJin-5us«'ptil)lt:' S. aureus
i tv!.S):'\ L Screening was perfon1wd bv inft:ction··control nurses
Of phy,ic.ian5 aftt'T appropriate \r;)ining. The study was ,lp·
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Ih.lt Wde

2~)'7
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C,:'ft,! '/iC,·rh,;(:,:, ~\';'~' ...vhor~': ~,,\\,ab~~ tf<)f"', fhf:~ r!,~;rG!''; dr~\,j

"ecund swab. :,wab~ were sent to the laboratofr in a lTan.<.pnrt

.'J.
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:180
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P('(~3()nS

(}Vfrr;;il'

,Jg.H plate, or" m,lft r,,(cnily.;\ (('f,}xilin disk,

individual~,

wert' screened till'S. aI/rem «lrriage, \vith ~eparal'"
result" i()J' Bose and throllt carriage, A fourth group (group 4)
musisted of 2075 individuals tilr whom data from n;m:s and
!hroat swahs were pooled in Ih(; laboratory, Tn\" av('rilgt~ ag<:
was 50 :.t: 21 Y"'<lrs, and 50.4% of the suhjec!s \WI'{' female. In
groups I--J, a total of 1480 individual, H'>.9'Ni) tested positive
!~)f S. II/lftilS (t,lhk I ). A total tlf J7.1 (~{\ of the study populatiNl
(in groups 1..· 3} h,ld nasa! cMriage of S. wrrellS, with OJ' without

positive l11ro.lt mltul'e result ... A total of JRO p<.'r~om, (12,0';';'

til(' study ill1pulation and 23.7'!{, of tit,: S. aI/rem (arn;:f5)
Wt~1"7 colnnih'd in the !l1m,1! alone. 'rhus, s.cre"nmg of the throal
<;ignilk,Ultly IJ1dT;!;;<.'..l th.;- sensitivity by 25.7 i l'H. '1 hl' ,mt('ri()!'
narcs W';-fC the ,ile most frt'qtk'ntly (olonizcd with S. (wrefls.
with rlw exc'l'ption of the group ofbiood dOl'H)J':;; am0I1!1 blood
d'Jl1<lrs. the throat swah cultures viddcd S. Mllrt'us mort' fre·
IJf

tn,tn cultures of swab 'p(;cimcns

in '.K(ordMKC with guiddines i.ssu('d by tlv: (linical and tab
nr,tlory St;wdards Jnslitllf(' rfOnlH.:dy NeeLS). JI l't'l>ults were
equt\'()Cal or if MIl.SA W;h SliSPI.'(H~d, additional tcs!~ WCl'<' per·-

gwup) wa5 52.I')(i., which i~ ~imiL1r to that observed with the

f,mnt'd, as (oHows: the preWI1C,' of ;H.lreaSt~ was del,:rmin('d

combined results I~.. r

ming Rapi,b.· ."I;ipll i hi(I\j('riwx)' the i'vlibA .. Saef'fl (llenka
,,<;,jk,~n) 1,las w'l.·d tn d,?!('(! pcniciHio···binliing pl\}!ein 2;\ .•me!

1·5.

pc.n

carriage ({).74(~·i, of aU individuals 5crct~nt'd). In 23 MRSA car·

II/as ll';ed to d('1C~:! the mecA ;md 1i~mA g(~nt's; al,;,), .1

':()Inprc-hensivc <HHihiogr;nn

"Hi>

performcd in

aCCOrdalKC

with

tht' (Jini,";!! and I..lhHalory Standards InstItute guiddint:s.

U:csuits. i\ «lui of :>()4 J persolls Wt'!\C .inc·luded in Ol.ll' study.
gnlllp' (gr<)Ur'~; [".' I. whidl illcluded a tolal nt 2966

'litre'\,

quently

from lhe nares. Th;-

rate of S. mm:tls (arri"g~ in group 4 (i.e., the pook'd n!suits

A :,nll;,\,,! analrsis
rh:~r~,

lIMC;;

W;\S

sep;lrate results

and throat swab cultures i.n groups

pcrformt'd for 37 subjects with }"·fHSA

\l7t'rC

Ilvail;lblt.' for cu!tUfX>S of throat and

nasal ~wab .. pcdrm:ns. The additiomll yield o( throat ct1lturc~
wa.~

wrn!,al'abk with the results described for 1".1S5;\: 5 of 23

(22.'q, (If all i'vlRSA caniers versus 25.7<;'() of all MSSA carri('[sl.

1

"1

j
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21_····

t hl~
h,:1VL' c'V.'lhi ..itt'd i he inlponan('c of t'l

13 rge.\!

ro~H in

S.

S1 utly to

iUli"t'i15 elf··

r IJ1~(' The .lddifi(lfWI thrlM! ;,INab ,:utlttr(", fnfr(';)<.('d til,' yield
irl)1l1 .':"\' (C\l]tlJ1'C, (If !1'H'(';' ;.wab, onlyl tn ,1111lo:;t :;!J'!\) (cui·
t un.'s

,)/" flares and [I1[(1.1t :;wab~ combilH'cl'l, an

ilhTCa'ie

of :;,,1]'

,jrivity hy 2;'.;"h" Rc:;ult'i t()f group 4 tthc pooled specimen
gt'nul' )--·-separatc cultures 1)( ("wab spetimclls from nares ilnd
1 he throat W('I'(' no! pcrh.lrmcd---··\,OITo!mratnj the n:~;;ults h11'
gr\lups l ....,),with a l'n;·vai.:n(c ,;( S. I1HtCUS Guri<1!!t' of 49.'1q·iJ

The <lddilioll of
the :.intl~ri(lr 11,:1.i\:5
~cH'{'ning

by 1""/",,. Overall, };. J ()';, ,)f :>ubjccts had na,a! car ..

riai;t: of S. ,1111'1:11>, hur 12.S% of the individuaL, h:td tl1m,lt
carri,lge ilJolle, MId these subjects would have e~Clpl:d tradi
tional sl'r('.;ning methods. Therd~m:.', any \cf.:-cning f,,)' S. all
1'(·us--.. . ·in pnrticular, screening for MRSA-should include borh
cultnres of sw.lhs samples from the anterior narcs and the

throat. Pooling the

~:llnpk~

and 52.1 (~,;" rcspl'clivdy. Ther.:fore, pooling <ulturt, ft:su!ts for
~w'lb, ii'om nar,'s :lI1d 111(' Il1m:11 mil)' he an appropriate method
( ... npttmi7C rh,,' yidd (If S. (.lIlft'If.~.. positive wbile "'ilying the
,."xp('n~es of .ldditiorul cultures.
'Tilda)', S. 11111'1'11.' sacl'lling i.., mainly perliJfl!led to identify
~1 R;';i\ carri.:!'s. Unidentiiicd thro,}! farrier~ may sprt'.llJ ;vIESA.
t'xpl.lining, in pMt, whv nlMW decol.oniz.lttnn ,>,hemes ;m.?
pronc to Ciilnre. Thront (;]lTi:\gc cI'cn triggered a farge lJUtbrGlk

Acknowledgments

of \IR5:\ infection, whi,:h wa~ [n!u.'d b.l\.k

ft)nthcts<

h)

a ilt'afth ('l!'t~

peDSCS

a~soci;\ted

can m<liniilln the additional ex

w'ith throat screening while maintaining

s{'n~itivitl'.

f'ilUmdfll support.

Tll" Swi",.' N,;tiottlll Sdmce Fimmlali'.'l1 :.l.CtltJBO..

11).1179).

['otetltilll C/lllflicts of i"/('r('$1, On~ year after completion o( 11l(~ ;w<k
.\1". 3uq'(~d ;t f",,;t;,'n at F. 1"101'1'",;\111\..·1.< Rod,e. All •.>thl:'( author,,: n')

"'<lrKer who WdS ,oldy cololli/.ed in the thro.1I. Hnutinc nasal
\Cfl','ning f.likt! tn identil)· this (ani.c)' [It i. Admi,~ion ',·n.'cn'

ing (If ,declt'd patients or of all palieI1h th~lt aims to cl\l1tl,)1
~d H,,/\ inknion is perfnrnwd in many hnspiLlls, but 'Int'cning
t<)Cuses l,n the' narc" alnng in most institutinnA !9:. 11ow('v(;'[,
thrnat '>Viall 'I'C('im(TI' hane hCl'n obtailwd mntindv in The
:--':l·ther!and, for dc,';ldes ,IS part (If tilt: sllcccs,;fllJ scardl'and,
,festr,)}, polin'. which j, 'Hltlinc,j in their natinfl.1! guidelines
(bt~l

L Kin,,! man', I. Y,1n HdhnI1 A.

(\l!lfirm the

rc.~sult.'i

of prCVi(Jth studics that the

anterior nilfC~ are till' single most colonized site with S. arm'lIs.
The fat,' of carridge W;I$ higher in the throat than in thc' f),ln.'S
only ,unong h!(IOd donor', (gn,up j). The tinding may be reLlt('d
h) tf\(; (a '. : [ that onlv I lrainni. highly m!)tiv;H(~d investigator

uhtainvd .111 of t hl'\(' swah S!1l'Cillll'l1S. l.Iml'aiw:d investigators
IT;;I)' lind il ddfi(ult tnS(rCell the posterior wall (If [he throat
while avoiding p;ltknt di;.,·ornf(lrl. ,\It(Tl1atlvdy. duoall:arri;lge
[naY imk"'d bc more i'Ol11mllf1 among hCillthy individual.s til ,HI
:nllong individual..; who drc ::,p(J~t'd to the h"illrh (are "f.-tern,
hut 'Udl a hypo!he~i:; rcql!i!('~ (ollfinmlfi(m bv nther inn:"!i,,
)iiltn!'s in di/l,:r('nt. nnn· .. health carc populatinfh,

111<1\1

(,lkctJ

int.)

.1C«'ltnt.

In t'.!<.:t, the

rale' of n,lsa! ",lrrial't' (with datn fwm throat culturcs cxciud(:d I
Ill;)V

11,~

<Hid

~~ftf)d:'Hed

!.Iin Ivlinnbi,,1 l{p\, 1997; lO:';05 .. ?tj
", i q'\\<Y i'D. S!tt[tnr1'h\J:.':u..4 dU;'(~1f, int~~di('1n!i, N Fngll !\kd 1995;3.)(t'
S2(),,· .12.
:.\. \'\"iHi:utls KL H(Onhhy (~rrri~'igt;~ (:If StfJphvtO('tJ(dl'i> {:ntrl~US: ih pn~v~lk'n<t"
and jfHP(\rt~Hi..:e. B~h't('!'io} Fh"l 196J~ 2756,-.;L
4. B;'!".~tli S, \VnW"bcrf! L. r'Hl"i [1, ,~( a1. C~uria"e (If Stapi!yl,)ft'cCus
M'HOn~~ injrXtion drug !.h(~fS: lo\v{'T prt:,y,:dc-o(e in an injection heroin

lrtilint<:nancc program than in an ora! methadone pmgram. Infect Con ..
S.
6.

.,

x.
9.

I:' J.

c:;;phrin this discn'paney. First, in other

'illdic,. throat clrriage W.l' 110t
IN,!'

H. ;J.l:;;)! (;Hriai:c (.f St,)!'};r-

risk~.

lJ\'lT:\Il, the ~H<.:v'llc!l(c of clrriagc was -50'1'", whid) is higher

th,m th" l.lle n'p<l!'kd in most other "Hldit~s (25% ..·.E,'!'i!.,

5t'\,\:r,1I lilCtors

\'(,rhrnl~1

IO(~H'(U,\' iUlf(·Uf.~ t.:.'pTd(~rniolul:rr\ un<.kdr~.n-g rn("(hani"lnl~,

ali',''''

(httr'://ww,\'.wip. n1).

t)ur
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Cutaneous Leishnlaniasis during
vI : Exuberant Lesions and
Preg.nanc
....
Potential Fetal Complications

,lied '\'lith advt:r,<,,' f.:tal oukonws [6:. In thi:' C;1!'e of ki~hman·
infection with the vi&cc:rotropk f,)nn h;b been de,criht'd
during pregnancy, rewltinp; in vertk:;! tran,;mis~jon ,]nd (cIa!
Jus, wht'n t realmen! [liltl),,' occur, [71, After occdsioHnl ,,[hlT
v,{t.iOfl\ of atqJk,ll CL during prt'gn<1!1cy, we n:-lm,;pectivdy

Olmiel J. Morg,m.' luiz H. Gllimaraes.' Paulo

n.l. Machado;

Argcmiro O'Oliveira Jr.} ROCfue P. Almeida.' Ednaldo L lallo.'
Daniela R. Faria,' Wagner L Tafuri.' Waldercl O. Outra,' and
Edgar M. Carvalho'
:,I!'Vf:",cn of in:Bffli!t!(:Jfa! MCt11Uno anj !nfectimJf; D!sea::;e;), VVei!! ivh::dicu!
Col!f:~!Jt~

Hr:~;pitni

of C(:tm~;l Un!''/f'(~itv, Ne..v York, anfi
de Ip'!HOohqlc dt)
UtJJ'iCI $i:~lri(l P!ot Ed~F1fii :)antG':;, (Jl1;jjors;dad(~ Fnrierar da BahIa

r~:,:1!'/ackiL ;:'!l',:d ·'r.:pp~lr;i1Ir!€pto I<:~?

L;e

l

::11s, E~~~:(; j":OHll)ntH,

r... 1ud::;i!(j~.;ia<

t}nrvH::<!,;~dl~ rr;~dl?!,)i d~; f\.4int!:,

(Ha..:-II

Cutant'ous leishmaniasis atlects millions of people worldwille. After observations of atypinll lesions in pregmmt

women at the health c('nters oj' Corte de Pcdra, Brazil, 9
years of records were reviewed, ltnd 26 pregnant pntients
were identified. A retrospe('tive elise-control Mudy revellied
that lesions in pregnant women ,vert' much larger than those
in noupn'gnant patients in an age- and sex-matched group
"mean area, 6.08 em' vs. 1.46 ow;; P "'" .0(8), Imd many lesiolls h~j(l an exophytic nature. Despite foregoing treatment
until after (.ldiveI'Y, response to pentavllient antimony therapy \\'al> favorable (rUle of cure with I wurse of trcutment,
85%). High fOlks of pn~tenn bil,ths (to.5'!';.) ilnd sti!lbi.rths
(10.5%) Wt're reported, Cutaneous lcishmalli'lsis during preg"
nilncy produces distinct lesions and "HI}' have adverse fetal
dfefts.
\\'orklwid,'. ki:-.hm.!ni'l\is ;lfit""!s > J2 million p<?ople in 88 COlln ..
Irks, with

,1 )'t';lrlV

Hlcidencc fl1';:

,'as.:s (ll, The majority
(CU, which i~ mo~1 com,

millJOl1

(If (,he;; arc dl\,IHt'OU:' iei;;brna!lia.~is
Inon in ,ldc.k\(.t'rlts ,mil j','Uflg adult.;. jJ-,)!1l rur.ll area, "f ex ..
t [,'fIlC
!l,l[l(\'

l'overT\' I:' ] ... ,) popui:ltloll with a hit:!! fertility Lite. Pr<?~·
j, ,lz;s()ci;ltcd with ImplY,Vell1Cl1t (,f 11)('SI inlhrrllnatot"y

di\(',!.\,'.,

1 ..\ 1 dill! ,HI

in.: l\:a,.;(~d ous(t'ptibilit\, to lT1JflY inktli,)1J$

il1duding '\'/,IiIlr1d
I '} I and f.j,:cria I1WIIO(}'IOX,cItt's
;\ lOfcuvcr, dUrin), pn:gl1<H1cy, mar1\' infections .1f~ <l5sod ..

,l}!,(:llb.

,}:~cup':':~;:

L: Ja"u,!,",
n!~:l( r'l:~ c,>

i;'J'

L.";' /\rnf ::UGT cl~'ic:;nflw;l!l'i J;urqYfH;i! ~.: .h~'-: .infl}

"\'~~~Pf:l~tI«(I:':'; D' (1;)," tl!

.1

Mu~~j.'w, Dru~~!(!! (it lffh""\1f1f/1;~: j\.'11;t1!(,1r(~ .:.l~;d

!q'"z!, '.'. \,h.d:'-J~d:F,. 'l'f'C H r\'~"ik';l C.I~jC;l"·;:1 ("ffne;! t;nh',::;;
'L'd

~'i'(

h u;)r;

irK;:I! 1dw<:(I.JH;i;~n·i:· !':rrf

Clinit:llllnfeclious Oisaases

2001;45:418 .. ·82

r(rk l ..,\,~~, t~4,'f NF'I\.-

revic\wd all Cl5CS of CL and mtl«()(lljlmeou~ !ei~~Hnania;,i~
r;"IL) ,een at a rdcr<?l1o? remer, identifying gravid pati>i'nts \a
standard s(rt~,'ning question). We feport dinic.,! asrwcb. of Ih",;;e
(:.151.'8, including lesion size and impact Of) pregnancy nuh:ull1t.
In addaioll, it f('trospl.'cLive case-control5tudy compilting lesion
sin' and response to (hcr,IP), \\,~lS perii)nllt:d_
Methm/s. The swdy ,vas p(~J'f()rmcd ;1! ttlt: Corte (I( Pedr>!
Hefcrcnct' Ccoter f(}f Ti::f:urncmiHY Lej,hm.miasis in B;lhia, Hra·
I.il, WlllCh has been in operation for >20 )'t';HS [2 i. Ye ..lriy, >1,00
patients .m.' tf(,;.ltcd {()l' CL and l'v!.L at thh (enkr,
W(: manuaHy' rt'view<?d charts {(Ir ,Ill patient; with (;1 or .\!J
who wen' 5et~n at the rderral ('cnter during the period 199;'···
2005. sel('Cling patients \>\'h" were pregnant and h~d !>ign;; of
leishmaniasis. elSe, were ddined bY' inclusion nikri.! of J .lc(
init£' diagnosis of CL OJ' ;\11, as the combination of a compalibk

ksinn and (Il biopsy r<:'suits ,howing ama~tagl)l('s Of ClHllpat
ihle hi~topathologt( finding.';, (2) ['ositin: (ulture n'$uh~ from
.1 lesion aSptraH' <;pccimcn, (If L,) positive l.<'i~hmanjn k;;, rc
~\llt>;. Exclusion rritrri.l were incornplete do(umenLltJOH oj
pregnan.:y or of IH)$lpanuITI follow-up. COlllrnJ SUbji:ct;\

W('fi'

agc"mJtdwd (within:' years of age) and st'x-r\l,Udkd; lhe :;
consecutive patJenb with definite leishrnania~is who were ('va!·
t;:lted after each (;1$<' patient were dlOsen a,; (,(Hllm! ~lIhkdS.
Prob,lbk CI. or f>H, wali defined as a cornpatiblc iC1'i'lIl with
. iack of defmitive test results.
AI the initial vi,it. patiern weight, bior\ size ;md Incalion,
alld lh" numb.:r of lesions were recorded, and past medical
history wa., (~VahMtt'd in a ~fandard manner by I !lm~e. Ali
women tIl' dlildbearing age were evaluated for pregn:l!KY, Lell>h·
rn.lnin H~sting W:1S pertimm:d ,It (he initial visit. The inilial
le,lon ,i7:(, wa~ the "i7.e oi tl'll' k,i(111 fl~corded ,1t the initial \'i~iL
T!w m.lximum I""illn ,;i/e \V;1;; the Sill' of the
mented ksiofL All patients found ttl be prc!!nant wen? fnlh.)\\!t'l!
up clinicallv wit bout m';Jlrrh'nt ((J!' ddjlliti\'{~ ki~hl1!ani;1;;i5 f i.t'.,
pcm:lV;lknt antirm)!lr c,mlp<)u1'l(b) until aft<~r delivery.
This study wa~; approved by tht~ Committe(: p( l:.thics o(Tl·",·
Ftdc-r;tl University of Bahia (Salvador, Brazill and the instillt
lion.li r,~vkw hO;l[d of \t\i<~ill Medical College of Comell Un;·
Vl'f~il}'

(Ne'W York, NY l. Laboratory studi(:s w,;·re perfnrnwd in

the univer"itv laboratory u$ing stand:lf(j (omnwrd.l! tc'cb,

niqt](;", lfi.,lnpathnlogk t'xamin,ltion \\'.)5 ped(mn(·d in [he

r:; • em
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p,J~

Mnined h

2

rc,l!.kr~

!ll.ll..F :md \VJ ..T.l. \dw '
h ,lick' for d('f'lTHll dod
cl'idt'rm,ll dlilJlgc:S, the natur{~ of the inJlarmnalory inJi!tra!e,
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Table 1. Clinical and laboratory findings for 26 pregnant patients with probable
and definite leishmaniasis, compared with findings for 36 nonpregnant control
subjects with definite cutaneous leishmaniasis.
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Figure 1.

Ivlild1v

Appcmrance of cutaneous Inishmanil1$i$ GlJrinq pregnancy. A Tvpicai, w(~!i,dern<lrr~ated ulcer with raised bordllfS on a palient'" leg B.
lesion ()'l a patient's back. ~,tb sSivt~. V')(j61iJti'l8 \esln(ls on it patient's buttock re) and thigh (0}. l1ulers represent Cr;ntil1leter ~\.

f1]i~!>[ L VWII;COUS

n ellu:d

;1

f'f'('term birth

(if'

stillbirth did not differ from tho5e

in patients Whd fxpcri(' IK('d norm al ddh'\ 'ries l\lith rt~S!)el:( to
dillieal (hi.lra(ll:'ri~ti,.'i or (rimester of omet of infe( tion .
J3iopw 5pl'cill1t:I1S fmln pregnant individuals had an inflam'
In.lIor), exudate thaI

\\iilS

more intense than lhat tvpically found

in Ct, with a predominance of ncutrophils, \\:h idl is not typ o
icallY' obserl'ed. Cu ltUf(" t(·"ulls w{~rc positive for /,eislwul/Iia
:;pt·~j('s in 7 nf I! pmlcnts eXiHuincd. Fiv<~ spt'cinwns \\'{'re no
longer viahle . '1\"'-0

spe( imcn .~

\\Tre typed a, Lels/wwllia bra··

;:il il'!l!.i.; by multilo(us enzyme electrophoresis.

Eighteen pati,~ nts with definite kisilrnaniasis ,vCfe compared

UQR, 0.1'9-3.78 Llnl!: P := .008. by M.aun·\Vhitncv U test ) ,)f)d

median maxim;lllesi.on ,11"C<1 (14,46 nn ' [IQR. 5.50-54.95 em' l
em' !JQR. 0.79 - 3.78 emil; P< .O(Jl, by J\ti<mn ·\VhitrtE,!·

V~;. L46

U lest ). wefe significantly furger among pregnant \'talUm than
among (oulJol suhjects.
Discussion. This study dem()ll5trate~ the influence of preg ·
1t.11K)' on the clinical manifestations of (:1. in a region with L.
bmzilieHsis tran:;mission. Patients who presented ""~Ih CL whil<:
pr("gnant had Illllch larger lesious than did nonpregnant womt~ n
(median initial lesion are,l, 6.08 em l V5·. 1.46 ern"). desp ite show ·

\. . ith 36 all"'" and sex··rniltched control ~uhied;;. ;-':0 diffrfe uce
lVilS j(lI.Jl'ld betwecn pregnant patients and nonpregnant control
,ubi c,;ts wi.tll rq;;lJ'd to thl' med ian Si7(' Of tlK' krshmanin dc ·
Lly·ed·lypi? hypersensitivity !est r('su l! Und\lliltion, 1.77 CH)"' fint(Ttju ,lrlile ranf'l' 1I(1!{ ). 1.11 <~.:;:) ,:Ill ' j \'s. 1.77 (01 ' IIQR,
n ..'lo···~'.'11i (Hl'!). rnt'dian du ratiol1 of If,ions prior to tilt' tirsl
vi,it (1.25 months !JQR, UJ·2.0 In<)]1111."1 \is,I.G month rIQR,

ing no diftercrlCl' in disease duration. Lesion ~ize was abo larger
Mll<Hlg (lur patients than among patients set'Jl in a historiC,l!
cohort from rhe sa.m e region who did not receive rreatm.:'nl
(nledinll lesion area, <I ('m' ; IQR, 3- 5 cm 1) [9 ]. In contrast HI
the typical presentation of a wd.1"dernarGlfed uker with rai,ed
hord('r~, ksiollS were frequ.:ntly of .1 cauliflower a[)pearanct'.
which rahed' concern for other diseases, such as dlfOl11mnr··
cosis, y,IWS, or neoplasms. Although not previously reported,

1.(1· ::,0 Illollth."j L m(~di il n Iltunbt'r oi lesions (1.0 l<~si()ns IIQ R.

HlOt"c"cxlIherant CL involving other species, including l.eis!: ·

1.() .. )'O

k5ions) \'., . 1.0 k'~i()11 IIQR, J.{}····2.0 irsions)), and me

diM) Ilumb(~r of tn'<llrnent (() ursc~ (].o course [IQR, 1.0··2.0

cour,cs]

VS. l,()

course IIQR. 1.0·..·2.0

COUfS('S!).

illiti,ll i<' sinJl a rc;! (6.01> cm' [f QR, 1,I(S··· j 2.Dl

,lx\j ,

em

Both tllt'dian

ern ' l \".

1.46 (nT'

mania major. ha~ been obscrv('d during preg.n ancy in Northern
Afrie) (H. l.o11zir, personal communication).
In a C57BLi6 nwuse l.. major model. larger C1, lesions 0 1.>
.::urrcd during pregnancy. which correlated with decrt~ased Thl
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Figure 2.
p\):;t~rv;lJm

Sponlanf)(Jlis irnpwvl"nent o! cutaneOlJS le!.:;hrnani;;sis postpartHm . Raised. atypical lesions seen during pregnancy
prim to trl).'ltnlent iB ilnd E.l. ilnd after 1 (;(J(JfSil of pent3val!>,nt antimony trea tment (e and n.

iA and [}), 1- 2 months

cytokinc production I to]. 'The human cell-mediated immune

immune response, including HIV ~er()positivity, wh.ich could

re:;porhe i~ altered during pregnancy [ 11], with an O\'ercom·
peflsatioll immediately ,tfh:r del ivery. BeGll1sc the ma.in his topathologic.al diff<'ITnce in lesions in pregnant women with Iyp·
ical ksiorls \\'<\.<, inneased. neutrophilic inti.ltration and fibrinoid
11('(f'(l<,is, differcnt ial Jlt'utrophil signaling. (ll' actiwlliol1 llIay
pl.ly .; ~p,'cifi c role in ,kvci{){,lllenl of al~viud lesioll$.
<:;t;lIldar,! trcaiment of CL caused b~' /.. i>r,uiiictfsi, is 20 dJ}'s
of' intr,lvcnolls pentavalent MHinllHlY componnd. which is po·lcmiaJJv abortogenic. l:kc<lllse of this (OI1(:Cl'n, tmly 2 patient!.
r,xci\'cd antirnoI'J)' during prcgllillKy (the 2 patit'nu, <lOpped
lH'.Jtrl1Cn t alkl' they realized llh')l were pregnant). or note, th ese
patients experit' l1ccd full - tum deliveries of health,' infants. al·
though th eir Ic~ions wert' no! cured until after delivery_ Ikc,msc
spontancous cu re has been r<~p(}r('(:1 to occur after ddi",,,ry I'll,
th,' III ('!'i ( of different treatments cannot be cvaluatt'd. !'\o pa-

modify disease presentation. In addition, our study W,t') retrospccti\'(: :Ind,-thcref'iJre, had no formalized protom[ f()r trea tment or datit (ollc(till·n.
CL during pregnancy is characterized by larger k'" ions with
a highlr at),pical, <'x.o phytic appe.lrancc, No therapy is known

cure dise,lse during prc·gnancy. although postpartum cnre

to

IU5 been found to bt: complete. <::1. during pregnancy has ,1
nO!;lbly diffef't'nt clinical prescntation and may inCrCil$C the nsk
of fetal (omplkatio!ls. It is important for physicians who are
CHing fm patients in regions whe re disea,<: ;$ endemi( to f'tTognize this presentation_
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Methicillin-Resistant Staphylococcus aureus (MRSA)
Nares Colonization at Hospital Admission and Its
Effect on Subsequent MRSA Infection
Kepler A. Davis,' Justin J. Stewart,2 Helen K. Crouch/ Christopher E. Florez,3 and Duane R. Hospenthal'
'Infectious Disease Service. 'Department of Medicine. and 'Infection Control Service. Brooke Army Medical Center.
Ft. Sam Houston. Texas

Background. Asymptomatic colonization with methicillin-resistant Staphylococcus aureus (MRSA) has been
described as a risk factor for subsequent MRSA infection. MRSA is an important nosocomial pathogen but has
currently been reported in patients without typical risk factors for nosocomial acquisition. This study was designed
to evaluate the impact of asymptomatic nares MRSA colonization on the development of subsequent MRSA
infection. The incidence of MRSA infection was examined in patients with and patients without MRSA or methicillin-susceptible S. aureus (MSSA) colonization at admission to the hospital and in those who developed colonization during hospitalization.
Methods.
Patients admitted to 5 representative hospital units were prospectively evaluated. Nares samples
were obtained for culture at admission and during hospitalization. Laboratory culture results were monitored to
identify all MRSA infections that occurred during the study period and 1 year thereafter.
Results. Of the 758 patients who had cultures of nares samples performed at admission, 3.4% were colonized
with MRSA, and 21 % were colonized with MSSA. A total of 19% of patients with MRSA colonization at admission
and 25% who acquired MRSA colonization during hospitalization developed infection with MRSA, compared with
1.5% and 2.0% of patients colonized with MSSA (P< .01) and uncolonized (P< .01), respectively, at admission.
MRSA colonization at admission increased the risk of subsequent MRSA infection, compared with MSSA colonization (relative risk [RRj, 13; 95% confidence interval [Clj, 2.7-64) or no staphylococcal colonization (RR, 9.5;
95% CI, 3.6-25) at admission. Acquisition of MRSA colonization also increased the risk for subsequent MRSA
infection, compared with no acquisition (RR, 12; 95% CI, 4.0-38).
Conclusion.
MRSA colonization of nares, either present at admission to the hospital or acquired during
hospitalization, increases the risk for MRSA infection. Identifying MRSA colonization at admission could target
a high-risk population that may benefit from interventions to decrease the risk for subsequent MRSA infection.
Methicillin-resistant Staphylococcus aureus (MRSA) has
become a progressively more important human pathogen since its initial description in 1961 [1] and the
first documented outbreak of infection in 1968 [2j. The
most recent data from the National Nosocomial Infections Surveillance System of the Centers for Disease Con-
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trol and Prevention showed in August 2003 that MRSA
on average accounts for 57% of S. aureus isolates causing
nosocomial infection in intensive care units (ICUs) [3j.
This is higher than the reported prevalence of 35%50% for 1995-1999 [4j. Risk factors for MRSA colonization have been well described [5j. Rates of colonization or infection with MRSA vary by geographic
location, type of health care facility, and the specific
population being studied. In acute-care settings, the
prevalence of MRSA colonization varies depending on
patient location within the facility. The reported prevalence of MRSA infection or colonization in the ICU
has been 4%-8% [6, 7j. The prevalence of MRSA colonization in the general inpatient setting has been reported to be 0.18%-7.2% [8-10], with a prevalence of
nosocomial acquisition of up to 1.7% [11, 12j. Community-acquired colonization has recently been de-

scribed as an important reservoir of MRSA, with a reported
prevalence of 1.3%-2% [13, 14].
Whether MRSA is more virulent than methicillin-susceptible
S. aureus (MSSA) is a controversial issue. There have been those
whose findings support increased virulence of MRSA, compared with MSSA [15-17], those who demonstrate no difference in virulence [18-20], and still others whose conclusions
are equivocal [21]. Those who argue that MRSA is more virulent than MSSA have demonstrated higher mortality associated with MRSA bacteremia in analyses that controlled for other
factors [15-17J. Other investigators have demonstrated that
inappropriate antimicrobial therapy, comorbid conditions, and
advanced patient age-rather than methicillin resistance-account for increased mortality associated with MRSA bacteremia
[ 18-20]. However, there are studies in which MRSA infection
or colonization were demonstrated as leading to increased risk
of subsequent MRSA infection during the same hospitalization
[22,23] and up to 18 months after hospital discharge [24]. The
reported rate of subsequent MRSA infection after identification
of MRSA colonization is -30% [24-26]. This increased risk of
infection with MRSA has led some to recommend screening all
patients [12,24] or those at highest risk [27, 28] for colonization
at admission to the hospital. This study was designed to measure
the prevalence of MRSA colonization at admission to our institution (Brooke Army Medical Center; Ft. Sam Houston, TX)
and to determine its impact on subsequent MRSA infection.

METHODS
Data were obtained from a prospective observational study of
subjects who were admitted to 5 systematically chosen representative inpatient hospital units. The study was approved by
the Brooke Army Medical Center institutional review board.
All patients admitted between I June 2002 and 31 August 2002
were eligible for inclusion. The observed hospital units included
a general medical/surgical ward, a medical ICU, a surgical ICU,
a trauma ICU, and a monitored step-down unit, the patients
of which, taken together, represent our typical inpatient population. The study hospital is a tertiary care military medical
training center located in San Antonio, Texas, that had 203
available inpatient beds during the study period. This facility
serves a patient population of active-duty and retired military
personnel and their dependents. Individuals in this population
receive the majority of their medical care from the military
health care system in San Antonio. Additionally, the facility is
a level 1 trauma center that treats a limited number of civilian
trauma patients who would otherwise not be eligible for care
within the system.
Nares cultures were performed within 48 h after admission
to an observed hospital unit. Cultures were also performed
when patients were transferred to other study units, weekly
during prolonged hospital stays, and at hospital discharge. One

sterile culture swab (BBL Culture Swab; Becton Dickinson) was
used to sample both nares. The swab sample was streaked onto
5% sheep blood agar (BBL Stacker plates; Becton Dickinson)
and colistin-nalidixic acid (CNA) agar (Columbia CNA agar
with 5% sheep blood Stacker plates; Becton Dickinson) and
incubated for 18-24 h at 37°C in 5% CO 2, If no growth was
detected, plates were incubated for another 24 h. Colonies with
i3-hemolytic activity and properties consistent with those of
staphylococci were screened for catalase activity (3% H 20 2 ),
and if they tested positive, they were then screened with a rapid
slide agglutination test for coagulase and protein A (Staphaurex;
Remel). Coagulase-positive organisms were confirmed with a
tube coagulase test (BBL coagulase plasmas; Becton Dickinson)
and were inoculated onto oxacillin screen agar (BBL stacker
plates). Susceptibility testing of MRSA isolates was conducted
by Vitek system GPS-105 cards (bioMerieux).
Information recorded for study patients included age, sex,
length of hospital stay, and number of nares cultures completed.
If S. aureus was detected in the admission culture, the patient
was identified as having been initially colonized with either
MRSA or MSSA. If the admission culture was negative for S.
aureus but results of a subsequent nares culture during the
course of hospitalization were positive, the patient was identified as having acquired MRSA or MSSA colonization. Patients
without S. aureus identified in any nares culture during hospitalization were identified as having not been colonized with
S. aureus.
All patients included in the study were followed to determine
whether they developed clinical infection with MRSA. Patients
were followed during the 3-month study period and for 1 year
thereafter, through 31 August 2003. MRSA infection was defined as recovery of the organism from either normally sterile
sites (blood samples or urine specimens without a Foley catheter in place) or nonsterile sites concomitant with a diagnosis
of infection by the primary physician caring for the patient.
Nonsterile sites included indwelling vascular catheters, skin and
soft tissue, and sputum. All patients included in the study also
had their names compared with those from the list of patients
previously known to have infection or colonization with MRSA
in our hospital.
The precision of relative risks for MRSA infection was determined by the method for calculating 95% Cis described by
Altman [29]. Statistical significance (i.e., the P value) was calculated for the difference in rates of MRSA infection by Fisher's
exact test [30]. The hypothesis that MRSA infection was dependent on age was evaluated with the independent-sample
Student's t test. The hypothesis that MRSA infection was dependent on length of stay was evaluated with the Mann-Whitney
rank sum test. Difference in descriptive statistics among evaluated patients and excluded patients was completed with the
Mann-Whitney rank sum test.
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Tabie 1. Demographic and clinical characteristics of 758 admitted patients for whom
cultures of nares were performed to assess methicillin-resistant Staphylococcus aureus
(MRSA) colonization status.
Sex. no. of patients with
MRSNtotal no. in unit (%)
Medical/surgical
Intensive care
Medical
Surgical
Trauma
Step-down
Total

Length of stay. days

Male

Female

Age. mean
years (range)

Mean

Median (range)

157/347 (45)

190/347 (55)

49 (17-87)

3.9

2 (1-40)

53/96 (55)

43/96 (45)

65 (18-101)

6.6

3 (1-96)

50/67 (75)

17/67 (25)

46 (8-84)

14

54/74 (73)

20/74 (27)

59 (18-101)

10

88/174 (51)

86/174 (49)

67 (20-93)

5.2

3 (1-67)

402/758 (53)

356/758 (47)

56 (8-101)

6.1

3 (1-96)

Study unit

RESULTS
During the study period, 758 of 990 patients admitted to the
observed units had nares cultures performed within 48 h after
admission to the hospital. The mean age was higher for patients
admitted to the medical ICU, the trauma ICU, and the monitored step-down unit (table 1; P< .01). Among patients admitted to the surgical and trauma ICUs, the mean and median
length of stay was longer (P < .01) and there were proportionally
more men (P< .03). Cultures were performed an average of
1.7 times (range, 1-6 times) for each patient during hospitalization. There were no significant differences with respect to
sex (P = .223) or length of stay (P = .163) for patients who
did not have a culture completed within 48 h of admission,
and thus these are not included in the evaluation. Patients who
were not included in the evaluation were less frequently admitted to a medical-surgical ward (22% vs. 45%; P< .01) and
were more frequently admitted to the telemetry unit (47% vs.
23%) than were patients who were included. They were older
(mean age, 60 years; P< .01) than those who were included in
the study.
Of the 758 study patients, 163 were initially colonized with S.
aureus. Twenty-six patients (3.4%; 95% CI, 2.1-4.7) were colonized with MRSA, and 137 (21 %; 95% CI, 18-24) were colonized
with MSSA (table 2). The incidence of subsequent MRSA infection for those initially colonized with MRSA was close to 10
times the incidence for patients colonized with MSSA or not
colonized with S. aureus at admission (P< .01 for both) (table
3). The relative risk (RR) for developing MRSA infection was
much higher for those colonized with MRSA at admission, compared with those colonized with MSSA (RR, 13; 95% CI, 2.764) or those not colonized with S. aureus (RR, 9.5; 95% CI, 3.625) at admission. Patients who subsequently developed MRSA
infection were older (mean age, 69 years; range, 29-91 years;
P = .015) and were admitted for a longer period (mean length
of stay, 16 days; range, 1-67 days; P< .01). They also tended to
be admitted to a monitored unit (P = .lO). Table 4 describes the

8 (1-85)
7 (1-63)

infections that occurred in these patients, including the time of
onset and whether they occurred during the same or a future
hospitalization.
In addition to presenting with colonization at admission,
there were patients who acquired colonization during the study
period. There were 394 patients who had "" 1 nares culture
completed during hospitalization, of whom 25 had a change
in their nares colonization status. Twelve (3.0%) of these patients acquired MRSA, 3 of whom were initially colonized with
MSSA. Five patients (2.0%) were in the medical-surgical ward,
none were in the medical ICU, 1 (2.4%) was in the surgical
ICU, 4 (8.9%) were in the trauma ICU, and 2 (4.3%) were in
the monitored step-down unit. Of these patients, 250/0 later
developed MRSA infection. The relative risk for developing
MRSA infection for patients who acquired MRSA colonization
was also higher, compared with those who were not colonized
with S. aureus (RR, 12; 95% CI, 4.0-38; P< .01).
There was 1 patient who developed infection with MRSA who
was known to have previous infection with MRSA. This patient

Table 2. Staphylococcus aureus colonization
in patients for whom nares were cultured at
admission.
S. aureus colonization status.

no. of patients/total no.
screened in unit (%)
Study unit
Medical/surgical
Intensive care
Medical
Surgical
Trauma
Step-down
Overall
NOTE.
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MSSA

7/347 (2.0)

57/300 (19)

7/96 (7.3)

18/90 (20)

2/67 (3.0)

16/57 (28)

3/74 (4.1)

13/68 (19)

7/174 (4.0)

33/152 (22)

26/758 (3.4)"

137/667 (21)b

MSSA. methicillin-susceptible S. aureus.

• 95% CI. 2.1-4.7
b 95% CI. 18-24.

778 • CID 2004:39 (15 September) • Davis et aL

MRSA

Table 3. Subsequent methicillin-resistant Staphylococcus aureus (MRSA) infection, by S.
aureus colonization status at admission.
MRSA colonization at
admission, no. (%)
of patients
Study unit

Total

Medical/surgical

7

MRSA infection

MSSA colonization at
admission, no. (%)
of patients
Total

1 (14)

57

MRSA infection
0(0)

No colonization at
admission, no. ('Yo)
of patients
Total

MRSA infection

283

2 (0.7)

Intensive care
Medical

7

2 (29)

18

1 (5.6)

71

1 (1.4)

Surgical

2

0(0)

16

0(0)

50

3 (60)

Trauma

3

0(0)

13

0(0)

57

2 (3.5)

Step-down

7

2 (29)

33

1 (3.0)

134

4 (3.0)

Overall

26

5 (19)a

137

2 (1.5)b

595

12 (2.0)c

NOTE.

MSSA. methicillin-susceptible S. aureus.

95% CI, 3.9--34.
b P< .01 (incidence not large enough to calculate 95% CI).
c 95% CI, 0.9--3.1; P< .01.
a

was not colonized with MRSA at admission to the medicalsurgical ward, but repeated screening later identified colonization before infection. There were 6 other patients in the study
group who had previously been identified with MRSA infection.
Four of these 6 patients were colonized with MRSA at admis-

sion, 1 acquired colonization during hospitalization, and 1 was
never identified with MRSA colonization during the study period. This patient had 2 cultures with negative results during
the hospital stay that followed the admission culture for which
negative results were obtained.

Table 4.

Methicillin-resistant Staphylococcus aureus (MRSA) infection, according to
S. aureus colonization characteristics at admission.

Colonizing isolate,
by patient no.

Time from
S. aureus
colonization
to MRSA
infection, days

Infection type

Hospitalization
in which MRSA
a
infection occurred

MRSA
1

Toe amputation site abscess

6

2

Bacteremia

7

Concurrent

3

Central catheter infection

9

Concurrent

Concurrent

4

Right axillary abscess

24

Future

5

Right BKA site abscess

60

Future

MSSA
6

Bacteremia

7

LLE soft tissue abscess

82

Future

268

Future

None
Concurrent

8

Bacteremia

9

Osteomyelitis

22

Concurrent

10

Bacteremia

23

Concurrent

8

Future

9

11

Abdominal wound abscess

12

Pneumonia

31

Future

13

Pneumonia

42

Future
Future

14

RLE BKA site abscess

77

15

LLE BKA site abscess

87

Future

16

Osteomyelitis

336

Future

NOTE. BKA, below the knee amputation; LLE, left lower extremity; MSSA, methicillin-susceptible
Staphvlococcus aureus; RLE, right lower extremity.
a

Data limited to 1 year after the hospital stay dunng which MRSA colonization was initially identified.
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Table 5. Antibiotic susceptibility patterns of methicillin-resistant Staphylococcus aureus (MRSA) isolates.
Antibiotic to
which MRSA
was susceptible

MRSA type, % susceptible
Colonizing isolates
(n =

56)

Ampicillin

0

Cefazolin

4
9

Clprofloxacin
Clindamycin
Erythromycin
Rifampin
Tetracycline
TMP-SMZ
Vancomycin

27
4

100
96
96
100

Infecting isolates
(n

= 30)
0
0
13
7
3
90
93
97
100

NOTE. All isolates tested positive for iJ-lactamase production. TMP-SMZ,
trimethoprim-sulfamethoxazole.

The susceptibility patterns for MRSA isolates obtained from
nares cultures and for those causing clinical infection were similar
(table 5). Nares isolates from patients initially colonized with
MRSA were more susceptible to tested antibiotics than were
isolates from those who acquired colonization. The isolates that
caused infection in patients who were initially colonized with
MRSA had the exact same susceptibility patterns as the colonizing isolates from these patients. Isolates that caused infection
in patients who were not colonized with S. aureus or in those
who acquired MRSA colonization before infection tended to
be more resistant to the tested antibiotics, which is consistent
with patterns of hospital-acquired MRSA. The isolates of 1 of
the 3 patients who acquired colonization and were later infection with MRSA also had the same susceptibility patterns. The
other 2 patients had isolates that varied by either clindamycin
or ciprofloxacin susceptibility only.

DISCUSSION
The prevalence of initial MRSA colonization in this study was
3.4%, with 3.0% of patients subsequently acquiring MRSA colonization. In this study, patients colonized with MRSA were at
much higher risk of subsequent MRSA infection than were
those colonized with MSSA or those not colonized with S.
aureus. There was a lO-fold increase in the rate of infection
between these groups, with a significant difference in relative
risk. Antibiogram data for these isolates suggest that the colonizing isolates were the same isolates that subsequently caused
infection in these patients.
Recent reports have demonstrated a similar increased risk of
subsequent MRSA infection for MRSA-colonized patients. Huang
and Platt [24] reported on subsequent MRSA infection in 209
adult patients newly identified with MRSA infection or colonization. They retrospectively identified these patients from
infection-control records and found that 29% developed MRSA
780 •
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infections over the next 18 months. One-half of the infections
occurred after discharge from the hospital. Mest et al. [31)
rep9rted on a smaller group of patients, compared with our
study, who were in the surgical ICU. They screened all patients
preoperatively for MRSA colonization of nares and found that
4% were colonized with MRSA. Twenty-six percent of these
patients developed MRSA infection, compared with 1.3% of
those who were not colonized. They hypothesized that preoperative MRSA colonization of nares significantly increased
the risk for subsequent postoperative MRSA infection. Roghmann et aJ. [23] retrospectively studied the risk associated with
MRSA colonization of ulcers and the subsequent development
of MRSA infection in a cohort of patients with chronic sacral
decubitus and diabetic foot ulcers. They found that 30% of
ulcers were colonized with MRSA. Seventeen percent of patients
with MRSA-colonized ulcers developed subsequent MRSA bacteremia, compared with only 1% of the patients without colonization. Roghmann et al. [23] reasoned that MRSA colonization
of chronic ulcers increases the risk for MRSA bacteremia.
Other studies evaluated cohorts of MRSA-colonized patients.
Coello et al. [22] observed a group of 479 patients colonized
with MRSA. Of these patients, 11 % developed MRSA infection
during the course of hospitalization, but Coello et al. [22] did
not compare this risk with that for noncolonized patients. They
demonstrated that ICU patients had an increased risk of subsequent MRSA infection, compared with medical patients, which
was similar to our results that showed that MRSA infections
tended to occur in patients admitted to monitored units (table
3). Garrouste-Orgeas et a1. [25J also reported on a cohort of
MRSA-colonized patients who were treated in the ICU. In their
study, Garrouste-Orgeas et al. [25] observed patients during
hospitalization but not after discharge, and they identified
MRSA colonization in 10% of medical-surgical ICU patients,
with 27% developing MRSA infection, compared with <1 % of
noncolonized patients who developed MRSA infection during
hospitalization.
The limitations of our study include the relatively small number of MRSA infections that were identified. The conclusions
based on this data are statistically significant; however, a larger
data set would strengthen these conclusions. A small data set
may introduce sampling bias, because of the small numbers of
infections found. There were also a number of patients who
were not included in the study because they were not screened
within 48 h after admission or not screened at all. The demographic data of this population did not differ significantly
from those of patients in the study group, but the former were
more frequently admitted to the medical surgical or telemetry
units. It is possible that the failure to include this population
could have introduced sampling error, which could affect the
overall conclusions, Additional review, however, demonstrated
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that this group did not have a significant number of MRSA
infections that would have changed the study outcomes.
This study supports the results of previously published reports
and further demonstrates the natural course of MRSA colonization of nares. Most of the previous studies identified MRSA
colonization for inpatients and the associated risk for subsequent
infection during the same hospitalization. As demonstrated by
Huang and Platt [24], one- half of these infections occurred after
hospital discharge. These studies typically retrospectively identified patients who had MRSA colonization at some point during
the hospitalization-not necessarily at admission, as our study
did--or observed a cohort of MRSA-colonized or -infected patients without comparing them with noncolonized patients. By
sampling a group of consecutively admitted patients and observing them for> I year, we were able to define the incidence
of subsequent infection in a prospective manner.
We have demonstrated that MRSA colonization of nares,
both at admission and hospital-acquired, increases the risk for
subsequent MRSA infection. Our data suggest that further investigation of patients at risk for MRSA infection is warranted
on the basis of the presence of MRSA colonization. It may be
possible to focus infection-control measures on a high-risk group
of MRSA-colonized patients to decrease the incidence of subsequent MRSA infection. This study has demonstrated that an
leu patient population would be best suited for this because it
had the highest risk for MRSA colonization of nares and the
highest incidence of subsequent MRSA infection.
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Predicting the Staphylococcus aureus Nasal Carrier
State: Derivation and Validation of a "Culture Rule"
Jan L. Nouwen,I.2.3 Alewijn Ott,I.3 Marjolein F. O. Kluytmans-Vandenbergh,' Holime A. M. Boelens,l Albert Hofman,3
Alex van Belkum.' and Henri A. Verbrugh l
Departments of 'Medical Microbiology and Infectious Diseases and 'Medicine, Infectious Diseases Section, and 'Department of Epidemiology
and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands

Background. To study determinants and risks of Staphylococc-us aureus nasal carriage, adequate differentiation
between the different S, aureus carrier states is obligatory. We set out to develop a "culture rule" capable of
differentiating between persistent and intermittent or noncarriers that uses a minimum of nasal swab cultures.
Methods.
In 51 healthy volunteers (derivation cohort), 12 quantitative nasal cultures were performed to
establish S. aureus nasal carriage states. Persons with 11 or 12 cultures positive for S. aureus were classified as
persistent carriers, and those with negative results of all cultures were classified as non carriers. All other persons
were classified as intermittent carriers. By means of logistic regression and receiver operating characteristic (ROC)
curves, a culture rule was derived. This culture rule was subsequently validated in 106 participants of an ongoing
study in 3882 elderly persons, again with the use of 12 quantitative nasal cultures.
Results. In both cohorts, the positive predictive value of 2 consecutive positive culture results for persistent
carriage was 79%. The model best differentiating between persistent and intermittent or noncarriers used the
number of positive culture results combined with the amount of S. aureus in these cultures. By using the outcome
of 2 cultures, the areas under the ROC curves were 0.981 (95% confidence interval [CI], 0.949-1.0) for the
derivation cohort and 0.936 (95% CI, 0.881-0.990) for the validation cohort.
Conclusions. Combining qualitative and quantitative results of 2 nasal swab cultures accurately predicted the
persistent S. aureus carriage state with a reliability of 93.6%. Thus, this culture rule can be used in studies of
determinants and risks of S. aureus nasal carriage.
Staphylococcus aureus nasal carriage is a major risk factor for both community-acquired and nosocomial infections [1-7], and the anterior nares are the primary
reservoir of S. aureus in humans [8-10]. Three S. aureus
nasal carriage patterns can be discerned: persistent carriage, intermittent carriage, and noncarriage [11-22].
However, no consensus has been reached on how to
exactly identify these different states, but most studies
use findings from 10-12 weekly nasal swab cultures
[23].
The number of colony-forming units (CFUs) of S.
aureus isolated from the anterior nares are higher in
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persistent than in intermittent carriers [24, 25], resulting in more extensive dispersal of staphylococci in
the environment [25] and in an increased risk of S.
au reus infection [26-28J. Bacterial variability (i.e., the
number of S. aureus genotypes isolated in repeated cultures from one individual) is lower for persistent than
for intermittent carriers [15, 22, 29], indicating that the
underlying mechanisms determining persistent and intermittent carriage differs. Adequate differentiation between persistent and intermittent carriage is thus relevant for epidemiological studies.
At present, a large study of S. aureus nasal carriage in
a population aged ;;:.60 years is being conducted at Erasmus Medical Center (Rotterdam, The Netherlands). The
main objectives are to study determinants and risks of
S. aureus nasal carriage. This is part of the Rotterdam
Study, a population-based prospective study of chronic
diseases in the elderly population. The Rotterdam Study
started in 1990 with 7983 persons and has just finished
its third phase, in which >4000 persons have been included. In this large survey, an efficient and reliable way

to assess S. au reus nasal carriage was obligatory. It would be
impossible to perform 10-12 weekly nasal swab cultures in all
participants. Thus, we developed a "culture rule" to discriminate reliably between persistent carriage and non carriage or
intermittent carriage, with a minimum of nasal swab cultures.
Our main questions were as follows: (I) how many quantitative nasal swab cultures are needed to accurately predict
persistent carriage in a cohort of healthy adult volunteers, and
(2) does the derived culture rule correctly predict persistent
carriage in the elderly cohort of the ongoing Rotterdam Study?

PATIENTS AND METHODS
Patient Cohorts and Microbiological Investigations

Derivation cohort. In 1988, a cohort of healthy volunteers
(staff members of the departments of medical microbiology
and infectious diseases and virology at Erasmus Medical Center)
was formed to investigate bacterial and human factors associated with S. aureus nasal carriage [23]. During the period of
September 1995 through March 1996, a total of 51 volunteers
agreed to participate in this study. Nasal swab cultures were
performed weekly for 12 weeks. All nasal swab samples were
obtained for culture by one study physician (M.F.Q.K.-V.), according to the protocol below.
Validation cohort. On the basis of the results of the derivation cohort, 2 quantitative nasal swab cultures of samples
obtained at I-week intervals were performed in 3882 participants of the Rotterdam Study. While this study was ongoing,
106 participants entering the study during the period of October 1997 through April 1998 agreed to be included in the
validation cohort. Persons with 2 positive or 2 negative nasal
swab culture results were oversampled to estimate the predictive
value of these cultures for persistent carriage and noncarriage,
or for intermittent carriage. One trained research assistant visited the participants at home and performed 10 additional nasal
swab cultures at I-week intervals, according to protocol.
The study was approved by the Medical Ethics Review Committee of the Erasmus Medical Center, University Medical Center,
Rotterdam. Informed consent was obtained from all participants.
Definitions

S. aureus nasal carriage state was assessed by means of the results
of nasal swab cultures 3-12, as follows: persistent carrier, 9 or
10 of 10 cultures were positive for S. aureus; noncarrier, no
positive culture results; and intermittent carrier, all intermediate
numbers of positive culture results.
Microbiological Procedures

Nasal swab cultures were performed according to a standard
operating procedure, as described elsewhere [23]. Nasal swabs
specimens were obtained with sterile cotton-wool swabs (Transwab; Medical Wire and Equipment). Both the left and right an-

terior nares were swabbed by rubbing the swab 4 times around
the inside of each nostril while applying an even pressure and
rotating the swab without interruption. The swabs were immediately placed in Stuart transport medium and kept at 4°C
until inoculation (within 24 h).
Swabs were then cultured quantitatively on phenol-red mannitol salt agar (PHMA) and in phenol red mannitol salt broth
(PHMB). The flasks with transport media containing the nasal
swab were vortexed for 15 s. The swab was then pressed firmly
against the wall of the flask with a sterile pincette and cultured
in 8 mL of PHMB. Subsequently, 500 /A-L of the remaining
bacterial suspension was inoculated evenly onto a large PHMA
culture plate (diameter, 14 cm). Another PHMA culture plate
(diameter, 8.5 cm) was divided into 3 sectors, which were inoculated with 10 /A-L of the original bacterial suspension, 10 /A-L
of a 1: 10 diluted bacterial suspension, and 1 /A-L of the 1: 10
diluted bacterial suspension, respectively. The PHMB was incubated at 37°C for 7 days; the PHMA culture plates were
incubated at 37°C for 48 h and at room temperature for 5 days.
Both were interpreted after 7 days of incubation. If, after 7
days, no S. aureus had grown on the PHMA but the PHMB
demonstrated a yellow color, a PHMA culture plate (diameter,
8.5 cm) was inoculated with 10 /A-L of PHMB and incubated
as before. Culture results were recorded as 0 (no S. aureus), 1
(S. aureus only on the PHMB culture plate), 2 (2-9 CFU), 3
(10-99 CFU), 4 (100-999 CFU), or 5 (;:;,:1000 CFU).
Identification of S. aureus was based on colony morphology
on the PHMA culture. Suspected colonies were cultured overnight on Columbia blood agar plates (Becton-Dickinson). A
catalase test and a latex agglutination test (Staphaurex Plus;
Murex) were then performed. All S. aureus isolates were stored
at -70°C in glycerol-containing liquid media.
Statistical Analysis

Percentages and continuous data were compared using Fisher's
exact test and the Mann -Whitney test, respectively. Logistic
regression was performed, and receiver operating characteristic
(ROC) curves were constructed for different tests and combinations of tests (number of positive cultures, IOlog-transformed CFUs [IOlog {CFU + I} 1and the geometric mean CFUs
of;:;,:2 cultures [e.g., {3j/2]) to study their ability to discriminate
between persistent carriage and noncarriage or intermittent carriage [30]. Culture results of the derivation cohort were added
as independent covariates to a logistic regression model with
our "gold standard" diagnosis of persistent carriage or not (derived from 10 consecutive cultures) as binary outcome variate.
The right side-of the regression equation was [/30 +/31 X number of positive cultures + /32 X geometric mean of CFUs]. Fitting
the model gave us /30 to /32. Then we calculated the odds of
persistent carriage for all persons of the validation cohort by
adding their respective culture outcomes in the formula: odds

=
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[e({30 +,61 x number of positive cultures + (32 X geometric mean
of CFVs) J. Subsequently, the probability of persistent carriage
was obtained by [odds/(I + odds)J. We choose the midpoint
between 0 and 1 as the cut point. Areas under the ROC curves
(AVC) and the corresponding SE were estimated by a nonparametric method (2-sample Wilcoxon test) [31,32]. Differences between AVCs of the different test combinations were
compared by the method of Hanley and McNeil [33J.

Table 1. Classification ofthe Staphylococcus aureus nasal carrier state based on results of the first 2 cultures. compared with
results of cultures 3-12. for derivation and validation cohorts.
Results of cultures 1 and 2
Both
negative

Cohort

Both
positive

Total

Derivation cohort
Noncarrier
Intermittent carrier

RESULTS
Fifty-one persons were included in the derivation cohort (19
men [37%J and 32 women [63%]), with a mean age 29 years
(range, 20-52 years). Twenty (39%) participants were classified
as non carriers, 16 (31 %) were classified as intermittent carriers,
and 15 (29%) were classified as persistent carriers (derivation
cohort; table 1). Positive predictive values for persistent carriage, derived from regression models that included the results
of cultures 1 and 2, ranged from 0.79 in a model containing
the qualitative outcome only, to 0.88 in a model including both
qualitative and quantitative results (figure lA). The use of the
results of only 1 culture (either 1 or 2) produced a positive
predictive value of only 0.69.
The validation cohort consisted of a subset of 106 participants of the Rotterdam Study cohort (44 men [42%J and 62
women [58%]), with a mean age 73 years (range, 62-89 years).
For the present study, persons with 1 positive and 1 negative
culture result were less informative. Two positive culture results
could either indicate persistent or intermittent carriage. Possibly, the number of CFVs of S. aureus cultured could differentiate between persistent and intermittent carriage. Persons
with 2 negative culture results could help to assess the predictive
value for true noncarriage. Therefore, after initial random inclusion of participants, we decided to oversample persons with
2 positive or 2 negative screening culture results. Fifty-seven
participants (54%) were classified as noncarriers, 17 (16%) were
classified as intermittent carriers, and 32 (30%) were classified
as persistent carriers (validation cohort; table 1). In 1 participant, both screening culture results were negative, and the
results of cultures 3-12 were all positive. The most probable
explanation for this would be either sample handling mistakes
or a laboratory error. Because exclusion of this person did not
significantly alter the data, and because mistakes happen in real
life, it was decided not to exclude this person's data from analysis. The positive predictive value derived from regression models that included the results of cultures 1 and 2 was 0.79 in a
model containing the qualitative outcome only, as well as in a
model including also the quantitative results (figure lB). The
use of the results of only 1 culture (either 1 or 2) produced a
positive predictive value of 0.74.
The numbers of CFVs of S. aureus were significantly higher
in the validation than in the derivation cohort (figure 2). The

1 Positive
and 1 negative

19

1

7

5

Persistent carrier
Total

26

6

20

4

16

15

15

19

51

Validation cohort
Noncarrier

53

4

Intermittent carrier

7

2

Persistent carrier

1

Total

61

6

57

8

17

31

32

39

106

NOTE. Data are no, of subjects, S. aureus carrier status is based on results
of cultures 3-12, For the validation cohort. persons for whom the results of
both culture 1 and 2 were positive or negative were oversampled (see Patients
and Methods), Therefore. the distribution of the different carrier states does
not represent the population prevalence,

median geometric mean in intermittent and persistent carriers
were 1.4 (range, 0.3-3.3) and 3.6 (range, l.9-3.9) in the validation
versus 1.0 (range, 0.3-2.0) and l.8 (range, 0.9-3.2) in the derivation cohort (P .001 and P< .OO!), respectively. Persistent
carriers had significantly higher numbers of CFVs of S. aureus
in their positive nasal swab cultures than did intermittent carriers
(figure 2): 1.8 CFVs (range, 0.9-3.2 CFUs) versus 0.98 CFVs
(range, 0.30-2.0 CFVs; P = .001) in the derivation cohort and
3.6 CFVs (range, 1.9-3.9 CFVs) versus 1.4 CFVs (range, 0.303.3 CFUs; P< .00l) in the validation cohort (figure 2).
In the derivation cohort, logistic regression showed that the
model best differentiating between persistent carriage and noncarriage or intermittent carriage used qualitative culture results
in combination with quantitative data. The model that used
the results of 2 cultures performed significantly better than a
model that used the results of only 1 culture. Adding the results
of a third or fourth culture did not significantly improve the
model. Results from the ROC analysis showed that all tests
used had good performance (all AVCs were >0.9), with the
combined model being slightly-but not significantly-better
than the qualitative result of 2 nasal swab cultures (figure lA).
In the validation cohort, 2 qualitative culture results (positive
or negative) discriminated similarly between persistent carriage
and noncarriage or intermittent carriage as the combined qualitative and quantitative results. All logistic regression models
were significantly improved by adding data on a third culture.
However, in the ROC analysis, the differences between the
models were small. Adding data on a third (but not a fourth)
culture only significantly improved the model when both qualitative and quantitative culture results were used (figure IB).
The AVCs that used the combination of qualitative culture

=
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Figure 1. A, Receiver operating characteristic (ROC) curve illustrating the predictive value of different tests for the persistent Staphylococcus
aureus nasal carrier state in the derivation cohort. * Area under the ROC (AUG) of 2 versus 1 cultures (P < ,05), B, ROC curve illustrating the predictive
value of different tests for the persistent S. aureus nasal carrier state in the validation cohort. *AUC of 3 versus 2 cultures in the combined test
(P< ,05). PVt, positive predictive value; PV-, negative predictive value.
results and the geometric mean CFUs of 2 cultures were 0.981
(95% CI, 0.949-1) for the derivation cohort and 0.936 (95%
CI, 0.881-0.990) for the validation cohort, respectively (figure
1). The logistic regression equation that uses the combination
of qualitative culture results and the geometric mean of CFUs
from 2 cultures could be written as follows: probability of persistent S. aureus nasal carriage = e({:W +{31 X number of positive cultures + (32 X geometric mean of CFUs)/ 1 + e({30 + {31 X
number of positive cultures + (32 X geometric mean of CFUs).
In the derivation cohort, the respective values of {30, {31, and
{32 were -20.171, 9.341, and 1.661. In the validation cohort
these values were -4.572, 2.563, and 0.274, respectively.
When a cutoff of 0.50 was used, above which probability
persons were classified as persistent carriers, it followed from
the logistic regression equation from the derivation cohort that
a per'son was a persistent carrier only if both cultures were
positive with a geometric mean of ;;'0.9 (-8 CFUs per culture).
This culture rule, when applied to the validation cohort, had
a positive predictive value of 0.78, a negative predictive value
of 0.96, and an AUC of the corresponding ROC curve of 0.936
(95% CI, 0.881-0.990).

DISCUSSION
We examined the diagnostic value of2 weekly quantitative nasal
swab cultures to predict the S. au reus nasal carriage state and
developed a culture rule to enable adequate differentiation between persistent carriage and intermittent carriage among those
individuals with 2 positive screening culture results.
We used logistic regression and ROC analysis to derive a culture rule under ideal laboratory circumstances in a cohort of
healthy adult volunteers. Strictly speaking, the derivation cohort
actually was more of an exploratory data set to help select the
variables in the model, but not the actual predictions. The culture
rule was subsequently validated under real-life conditions in a
subset of elderly participants of the Rotterdam Study.
In the derivation cohort, the best test combined qualitative
culture results (number of positive culture results) with quantitative data (geometric mean number of CFUs of S. aureus in
nasal swab cultures). In the validation cohort, however, the
simple qualitative culture result when data on 2 cultures were
used performed as well as the more complicated culture rule.
The culture rule performed slightly less well in the validation
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Figure 2. Geometric mean (1°log) number of colony-forming units (CFUs)
of Staphylococcus aureus in positive cultures in intermittent versus persistent carriers from both cohorts. Boxes, median, quartile, and extreme values;
*persistent versus intermittent carriers in derivation cohort (P = .001); t,
persistent versus intermittent carriers in validation cohort (p < .001); ~,
intermittent carriers, derivation versus validation cohort (P = .001); §, persistent carriers. derivation versus validation cohort (P < .001).

cohort (AVC, 0.981 in the derivation and 0.936 in the validation cohort, respectively). In the ideal laboratory situation,
one trained physician performed all nasal swab cultures in a
cohort of healthy individuals. In the real-life situation of largescale epidemiologic surveys, misclassification of the carrier state
could have occurred for a variety of logistic reasons, such as
differing nasal culturing techniques of study physicians, samplehandling mistakes, and laboratory errors. In theory, many of
these "errors" are preventable but can never be totally eradicated. The fact that in the validation cohort the first 2 cultures
were obtained at the Rotterdam Study research center by various study physicians, whereas cultures 3-12 in the validation
cohort were performed by one trained person, certainly affected
culture results: when cultures 3 and 4 of the validation cohort
were used, instead of cultures 1 and 2, the AVC was increased
from 0.936 to 0.996.
Misclassification of the carrier state could also have occurred
because of factors associated with individual participants of the
Rotterdam Study. Culture results will potentially have been influenced by the use of medication (recent courses of antibiotic
therapy), institutionalization (recent hospital admissions), and
underlying diseases, as well as other unknown determinants.
We confirm earlier data that showed that the number ofCFUs
of S. aureus in the anterior nares was higher in persistent carriers

than in intermittent carriers [24, 25]. We also found a striking
difference in the amount of S. aureus in the nose of persistent
carriers between young, healthy volunteers and healthy, elderly
participants. No previous data are available regarding age and
the number of CFVs of S. aureus in the noses of persistent
carriers. From the Rotterdam Study (3851 persons), the high
numbers of CFUs (median geometric mean, 2.8) in elderly persistent carriers are confirmed (data not shown), but the underlying mechanisms of this finding remain to be elucidated. The
differences in the number of CFVs in persistent carriers in both
cohorts will have affected the performance of the derived culture
rule in the validation cohort. When applying this culture rule to
other patient populations, it will need to be validated in the
specific population first, when possible.
Combining qualitative results with quantitative data is, in
our opinion, conceptually the best choice. Incorporating quantitative data makes it possible to refine associations between
potential determinants and S. aureus nasal carriage because not
only carriers are compared with noncarriers, but carriers with
low CFUs can also be compared with carriers with high CFVs
in their anterior nares. Incorporating quantitative data will also
make it possible to refine associations between carriage state
and morbidity and mortality. However, in large-scale epidemiologic studies, simplicity will often prevail because of logistic reasons and resources. It is therefore reassuring that, in the
validation cohort, the simple qualitative culture results performed as well as the more complicated culture rule.
Thus, 2 nasal swab culture of samples obtained at a I-week
interval can indeed provide sufficient information to adequately
predict the S. aureus nasal carriage state. The use of only 1
nasal swab culture to predict the carriage state, as is often done,
cannot be recommended on the basis of our data because it
will lead to misclassification of the carriage state. On the other
hand, the addition of a third or fourth quantitative nasal swab
culture only minimally improved test performance. Of importance, no persons whose first 2 culture results were positive
were found to be non carriers. The finding of 2 negative screening culture results in 1 person with subsequent positive culture
results is difficult to explain but may be attributable to sample
handling mistakes or laboratory error. These results were included in the evaluation, however. One negative screening culture result virtually excludes persistent carriage. Predicting the
noncarrier state from 2 nasal swab cultures is more difficult
because ;;:;7 nasal swab cultures would be needed to distinguish
intermittent carriers from noncarriers.
At present, data on determinants of persistent S. aureus nasal
carriage in elderly patients in the Rotterdam Study are being
analyzed by means of this culture rule. This is the first study to
validate the potential of a limited number of nasal swab cultures
in predicting the S. aureus carrier state. Because the incidence of
S. aureus infections has increased substantially, and because of
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the dramatic worldwide increase in antibiotic resistance (methicillin and, recently, even vancomycin resistance) in S. aureus,
prevention is now more important than ever. Apart from its role
in the Rotterdam Study, we hope that the presented culture rule
will prove to be a helpful tool in identifying determinants of S.
aureus nasal carriage and infections, as well as in identifying highrisk patient populations and the implementation of new methods
in the prevention of S. au reus infections.
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Community-Associated Methicillin-Resistant Staphylococcus
aureus: The Way to the Wound Is through the Nose
Clarence BuddV Creech 11,1 Thomas R. Talbot/.3 and William Schaffne~
'Division of Pediatric Infectious Diseases, Department of Pediatrics, 'Division of Infectious Diseases, Department of Medicine, and 'Department of Preventive
Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee

(See the article bV Kuehnert et al.. on pages 172-9.)

The US microbiologist Theobald Smith is
credited with the view that "disease is an
accident occurring in the development of
the parasitic state" [1, p. 2], This perspective can certainly be applied to the
staphylococcus, an organism replete with
strategies to establish harmony with its
host in the form of nasal colonization. In
this issue of the Journal of Infectious Diseases, Kuehnert et al, [2] provide the first
large population-based assessment of nasal colonization with Staphylococcus aureus
and, more importantly, with methicillinresistant S, aureus (MRSA). As the frequency of community-associated MRSA
infections continues to increase, investigation into the dynamics of nasal colonization will be valuable in the creation of
plausible strategies for controlling this
emerging pathogen,
It is well established that, at any given
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time, -30% of all persons are colonized
with S. aureus, with the anterior nares
serving as its critical niche [3], Although
colonization typically precedes infection,
relatively few colonized individuals develop staphylococcal infections. There
are, undoubtedly, a variety of host-organism interactions that playa role in this
symbiosis; yet, much of what is known
has been derived from the study of persons with clinical disease, not those in
the asymptomatic carrier state.
Using the sample provided by the 20012002 National Health and Nutrition Examination Survey (NHANES), Kuehnert
et aJ. assessed S, aureus nasal carriage in
all participants ;;.1 year old. Nearly 10,000
participants were enrolled; 2964 (32.4%)
were colonized with S. aureus, of whom
only 75 (0.8% of the total) harbored
MRSA, These findings translate into
weighted estimates of 89.4 and 2.3 million persons being colonized with S. aureus and MRSA, respectively, in the
United States in 2001-2002. Thus, although the proportion of the US population colonized with MRSA was low,
the absolute number of MRSA-colonized
persons was already quite large in 20012002. Risk factors for MRSA colonization
were age ;;;.60 years and being female;
however, when the analysis was limited
to community-associated MRSA (as determined by the presence of the staph-

ylococcal cassette chromosome mec IV
gene), younger children and non-Hispanic black persons were found to be at
increased risk.
Kuehnert et al, also sought to understand the microbiological and molecular
epidemiologic character of the colonization isolates from their study population.
Their antibiotic-susceptibility data suggest
what other investigators have reported for
community-associated MRSA-namely, favorable resistance profiles for such agents
as trimethoprimlsulfamethoxazole, rifampin, gentamicin, and vancomycin, as
well as the variable presence of an inducible resistance phenotype for clindamycin. This information becomes increasingly germane to practitioners whose
empirical choices of therapy for community-associated staphylococcal infections have moved away from the {:Hactams. In addition, results of the analysis
of the toxin repertoire were substantially
different from what would be expected
from simple extrapolation of data from
invasive isolates; for example, although it
appears that the genes for the cytolytic toxin Panton-Valentine leukocidin are
found in the majority of clinical isolates
of community-associated MRSA [4], its
presence was less common (8.0% of MRSA)
among the carriage strains in Kuehnert
et aJ.'s population-based study, a finding
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corroborated by subsequent local investigations [5, 6J.
The carriage estimates produced by
Kuehnert et al. must be interpreted in their
historical context. Their results from investigation of a large, national population
are quite consistent with the results oflocal
investigations completed at the same time.
In 2001, colonization studies from geographically diverse institutions found a
similar frequency of MRSA nasal carriage. Studies from Chicago, IL; Nashville, TN; Charlottesville, VA; and San
Francisco, CA, suggested that a small but
noteworthy reservoir of MRSA carriage
existed in these areas, at prevalence rates
ranging from 0.6% to 2.8% [7-12J. Because these data very closely match Kuehnert et al.'s results from the NHANES
population, it would seem that they were
not simply local phenomena; rather, it
would seem that geographically specific
colonization data are important harbingers that signal trends in staphylococcal
epidemiologic patterns.
All of these studies were conducted before the widespread emergence of community-associated MRSA infection, which,
in some areas, now accounts for up to
75% of all community-associated staphylococcal infections in children [13 J. In
addition, the increased frequency of community-associated MRSA infection has
been associated with reports of increased
morbidity and mortality-specifically, a
longer duration of fever, prolonged hospitalization, a higher incidence of pulmonary complications along with bone
and joint infections, and the reemergence of a severe staphylococcal sepsis
syndrome [14-16J. In 2004, to assess
whether a change in the MRSA nasal colonization rate accompanied the increase
in disease frequency, our group studied
500 healthy children [5J. Using the same
methods that we had used in 2001, we
found that 46 (9.2%) of the 500 children
were colonized with MRSA. This percentage represented a >lO-fold increase
in the MRSA nasal colonization rate in
the same community from 2001 to 2004

[5, lOJ. Similarly, Pan et al. studied >300
homeless youths in the San Francisco
area in 2004 and found that 6.2% of the
enrolled subjects were colonized in the
nares with MRSA [17J. Last, Alfaro et al.
recently reported that -22% of children
admitted to Driscoll Children's Hospital
in Corpus Christi, TX, in 2005 were colonized with MRSA [lSJ. The timesalong with MRSA colonization ratesare, indeed, changing.
The question remains: To what extent
does colonization with S. aureus (and with
MRSA, in particular) confer increased risk
to the host? If we are to understand the
implications of Theobald Smith's assertion that disease is accidental, then we
must understand just how "accident
prone" the circulating strains of community-associated MRSA are. A recent
study of US soldiers by Ellis et al. helps
to clarify this issue [6J. Of 812 soldiers
who were enrolled at the start of basic training, 24 (3%) were colonized
with community-associated MRSA. Nine
(3S%) of the 24 soldiers developed softtissue infections during the 2-month
study period. This rate was significantly
higher than that (i.e., 28%) observed
among the 229 participants colonized
with methicillin-susceptible S. aureus, of
whom only S (3%) developed clinical
staphylococcal infections (relative risk, lO.7
[95% confidence interval, 4.6-25.2]). In a
similar vein, Pan et al. [17] have suggested that, among community-associated MRSA, there are distinct populations that are successful colonizers,
successful pathogens, or both. What factors govern these distinctions remain
largely unknown.
These studies highlight the changing
epidemiologic profile of MRSA in the
community and suggest that community-associated MRSA may have acquired
2 properties that are of particular concern: first, it has the ability to colonize
effectively, even in the absence of antimicrobial pressure-and potentially via
mechanisms that allow them to outcompete other staphylococcal strains in the
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nares; second, it possesses a variety of
virulence factors necessary to cause an
array of disease, from simple, uncomplicated furunculosis to deep abscesses,
osteomyelitis, necrotizing pneumonia, and
sepsis [13-16, 19J. This combination of
factors demonstrates the profound adaptability of the staphylococcus.
In light of the increasing frequency of
community-associated MRSA infection,
new antimicrobials are needed, particularly given the emergence of glycopeptideresistant strains. Yet, new antimicrobials
will remain fingers in the proverbial dike
until a more-definitive solution can be
found. Can staphylococcal colonization be
prevented? If not, can we develop a strategy to prevent invasion and establishment
of infection? For the better part of a century, scientists have considered the composition and application of a staphylococcal vaccine, refined over time via an
improved understanding of the virulence
factors specific to staphylococci. Now,
stimulated by the successes that Haemophilus injluenzae type b (Hib) vaccine
and pneumococcus conjugate vaccine
have had in both eliminating the carriage
state (a particular success for the conjugate Hib vaccine) and preventing infection, several major pharmaceutical
manufacturers have turned their attention to the creation of a staphylococcal
vaccine. The appropriate components of
such a vaccine (such as capsular polysaccharides, surface-exposed proteins, and/
or extracellular toxins) remain an area of
active research, but early successes confirm that the vaccine-based approach is
a viable undertaking. For example, the
persistent reduction of S. aureus bacteremia 40 weeks after vaccination of patients with end-stage renal disease who
are undergoing dialysis highlights the
potential of a vaccine-based approach to
the prevention of staphylococcal disease
[20J. Whether such a vaccine should be
used universally-or whether it should
be targeted to those with risk factors for
disease or administered in persons undergoing certain medical procedures that

confer a high risk of staphylococcal wound
infections-remains to be determined.
Studies of the ecological patterns of S.
aureus colonization in the us population,
such as the study conducted by Kuehnert
et aI., will continue to be important as we
attempt to understand the evolution of
antimicrobial resistance, the risk factors
that predict the carriage state, and the molecular characteristics of circulating strains.
Ultimately, it is hoped that such studies
will provide a measure of the impact that
staphylococcal vaccination has on colonization in the population.
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Predicting the Staphylococcus aureus Nasal Carrier
State: Derivation and Validation of a ((Culture Rule"
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and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands

Background. To study determinants and risks of Staphylococcus aureus nasal carriage, adequate differentiation
between the different S. aureus carrier states is obligatory. We set out to develop a "culture rule" capable of
differentiating between persistent and intermittent or noncarriers that uses a minimum of nasal swab cultures.
Methods.
In 51 healthy volunteers (derivation cohort), 12 quantitative nasal cultures were performed to
establish S. aureus nasal carriage states. Persons with 11 or 12 cultures positive for S. aureus were classified as
persistent carriers, and those with negative results of all cultures were classified as noncarriers. All other persons
were classified as intermittent carriers. By means of logistic regression and receiver operating characteristic (ROC)
curves, a culture rule was derived. This culture rule was subsequently validated in 106 participants of an ongoing
study in 3882 elderly persons, again with the use of 12 quantitative nasal cultures.
Results. In both cohorts, the positive predictive value of 2 consecutive positive culture results for persistent
carriage was 79%. The model best differentiating between persistent and intermittent or noncarriers used the
number of positive culture results combined with the amount of S. aureus in these cultures. By using the outcome
of 2 cultures, the areas under the ROC curves were 0.981 (95% confidence interval [CI], 0.949-1.0) for the
derivation cohort and 0.936 (95% CI, 0.881-0.990) for the validation cohort.
Conclusions. Combining qualitative and quantitative results of 2 nasal swab cultures accurately predicted the
persistent S. aureus carriage state with a reliability of 93.6%. Thus, this culture rule can be used in studies of
determinants and risks of S. aureus nasal carriage.
Staphylococcus aureus nasal carriage is a major risk factor for both community-acquired and nosocomial infections [1-7], and the anterior nares are the primary
reservoir of S. aureus in humans [8-10 J. Three S. aureus
nasal carriage patterns can be discerned: persistent carriage, intermittent carriage, and noncarriage [11-22].
However, no consensus has been reached on how to
exactly identify these different states, but most studies
use findings from 10-12 weekly nasal swab cultures
[23J.
The number of colony-forming units (CFUs) of S.
aureus isolated from the anterior nares are higher in
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persistent than in intermittent carriers [24, 25J, resulting in more extensive dispersal of staphylococci in
the environment [25J and in an increased risk of S.
aureus infection [26-28J. Bacterial variability (i.e., the
number of S. aureus genotypes isolated in repeated cultures from one individual) is lower for persistent than
for intermittent carriers [15, 22, 29 J, indicating that the
underlying mechanisms determining persistent and intermittent carriage differs. Adequate differentiation between.persistent and intermittent carriage is thus relevant for epidemiological studies.
At present, a large study of S, aureus nasal carriage in
a population aged ;;:;.60 years is being conducted at Erasmus Medical Center (Rotterdam, The Netherlands). The
main objectives are to study determinants and risks of
S, aureus nasal carriage. This is part of the Rotterdam
Study, a population-based prospective study of chronic
diseases in the elderly population. The Rotterdam Study
started in 1990 with 7983 persons and has just finished
its third phase, in which >4000 persons have been included. In this large survey, an efficient and reliable way

to assess S. aureus nasal carriage was obligatory. It would be
impossible to perform 10-12 weekly nasal swab cultures in all
participants. Thus, we developed a "culture rule" to discriminate reliably between persistent carriage and noncarriage or
intermittent carriage, with a minimum of nasal swab cultures.
Our main questions were as follows: (1) how many quantitative nasal swab cultures are needed to accurately predict
persistent carriage in a cohort of healthy adult volunteers, and
(2) does the derived culture rule correctly predict persistent
carriage in the elderly cohort of the ongoing Rotterdam Study?

PATIENTS AND METHODS
Patient Cohorts and Microbiological Investigations

Derivation cohort. In 1988, a cohort of healthy volunteers
(staff members of the departments of medical microbiology
and infectious diseases and virology at Erasmus Medical Center)
was formed to investigate bacterial and human factors associated with S. aureus nasal carriage [231. During the period of
September 1995 through March 1996, a total of 51 volunteers
agreed to participate in this study. Nasal swab cultures were
performed weekly for 12 weeks. All nasal swab samples were
obtained for culture by one study physician (M.F.Q.K.-V.), according to the protocol below.
Validation cohort. On the basis of the results of the derivation cohort, 2 quantitative nasal swab cultures of samples
obtained at I-week intervals were performed in 3882 participants of the Rotterdam Study. While this study was ongoing,
106 participants entering the study during the period of October 1997 through April 1998 agreed to be included in the
validation cohort. Persons with 2 positive or 2 negative nasal
swab culture results were oversampled to estimate the predictive
value of these cultures for persistent carriage and noncarriage,
or for intermittent carriage. One trained research assistant visited the participants at home and performed 10 additional nasal
swab cultures at I-week intervals, according to protocol.
The study was approved by the Medical Ethics Review Committee of the Erasmus Medical Center, University Medical Center,
Rotterdam. Informed consent was obtained from all participants.
Definitions

S. aureus nasal carriage state was assessed by means of the results
of nasal swab cultures 3-12, as follows: persistent carrier, 9 or
10 of 10 cultures were positive for S. aureus; noncarrier, no
positive culture results; and intermittent carrier, all intermediate
numbers of positive culture results.
Microbiological Procedures

Nasal swab cultures were performed according to a standard
operating procedure, as described elsewhere [231. Nasal swabs
specimens were obtained with sterile cotton-wool swabs (Transwab; Medical Wire and Equipment). Both the left and right an-

terior nares were swabbed by rubbing the swab 4 times around
the inside of each nostril while applying an even pressure and
rotating the swab without interruption. The swabs were immediately placed in Stuart transport medium and kept at 4°C
until inoculation (within 24 h).
Swabs were then cultured quantitatively on phenol-red mannitol salt agar (PHMA) and in phenol red mannitol salt broth
(PHMB). The flasks with transport media containing the nasal
swab were vortexed for IS s. The swab was then pressed firmly
against the wall of the flask with a sterile pincette and cultured
in 8 mL of PHMB. Subsequently, 500 J.'L of the remaining
bacterial suspension was inoculated evenly onto a large PHMA
culture plate (diameter, 14 em). Another PHMA culture plate
(diameter, 8.5 em) was divided into 3 sectors, which were inoculated with 10 J.'L of the original bacterial suspension, 10 J.'L
of a I: 10 diluted bacterial suspension, and I J.'L of the I: 10
diluted bacterial suspension, respectively. The PHMB was incubated at 37°C for 7 days; the PHMA culture plates were
incubated at 37°C for 48 h and at room temperature for 5 days.
Both were interpreted after 7 days of incubation. If, after 7
days, no S. aureus had grown on the PHMA but the PHMB
demonstrated a yellow color, a PHMA culture plate (diameter,
8.5 em) was inoculated with 10 J.'L of PHMB and incubated
as before. Culture results were recorded as 0 (no S. aureus), I
(S. aureus only on the PHMB culture plate), 2 (2-9 CFU), 3
(10-99 CFU), 4 (100-999 CFU), or 5 (;::.1000 CFU).
Identification of S. aureus was based on colony morphology
on the PHMA culture. Suspected colonies were cultured overnight on Columbia blood agar plates (Becton-Dickinson). A
catalase test lind a latex agglutination test (Staphaurex Plus;
Murex) were then performed. All S. aureus isolates were stored
at -70°C in glycerol-containing liquid media.
Statistical Analysis

Percentages and continuous data were compared using Fisher's
exact test and the Mann-Whitney test, respectively. Logistic
regression was performed, and receiver operating characteristic
(ROC) curves were constructed for different tests and combinations of tests (number of positive cultures, IOI0g-transformed CFUs ['Olog {CFU + Il J and the geometric mean CFUs
of;::.2 cultures [e.g., {3 1/21) to study their ability to discriminate
between persistent carriage and noncarriage or intermittent carriage [301. Culture results of the derivation cohort were added
as independent covariates to a logistic regression model with
our "gold standard" diagnosis of persistent carriage or not (derived from 10 consecutive cultures) as binary outcome variate.
The right side of the regression equation was [{:lO+{:ll X number of positive cultures + {:l2 X geometric mean of CFUs I. Fitting
the model gave us {30 to {32. Then we calculated the odds of
persistent carriage for all persons of the validation cohort by
adding their respective culture outcomes in the formula: odds =
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[e(/30+/31 x number of positive cultures +/32 X geometric mean
of CFUs)]. Subsequently, the probability of persistent carriage
was obtained by [odds/(l + odds)]. We choose the midpoint
between 0 and 1 as the cut point. Areas under the ROC curves
(AUC) and the corresponding SE were estimated by a nonparametric method (2-sample Wilcoxon test) [31,32]. Differences between AUCs of the different test combinations were
compared by the method of Hanley and McNeil [33].

Table 1. Classification of the Staphylococcus aureus nasal carrier state based on results of the first 2 cultures. compared with
results of cultures 3-12. for derivation and validation cohorts.
Results of cultures 1 and 2
Both
negative

Cohort

Noncarrier

RESULTS

808 •

em

Both
positive

Total

Derivation cohort
Intermittent carrier

Fifty-one persons were included in the derivation cohort (19
men [37%] and 32 women [63%]), with a mean age 29 years
(range, 20-52 years). Twenty (39%) participants were classified
as non carriers, 16 (31 %) were classified as intermittent carriers,
and 15 (29%) were classified as persistent carriers (derivation
cohort; table 1). Positive predictive values for persistent carriage, derived from regression models that included the results
of cultures 1 and 2, ranged from 0.79 in a model containing
the qualitative outcome only, to 0.88 in a model including both
qualitative and quantitative results (figure lA). The use of the
results of only 1 culture (either 1 or 2) produced a positive
predictive value of only 0.69.
The validation cohort consisted of a subset of 106 participants of the Rotterdam Study cohort (44 men [42%] and 62
women [58%]), with a mean age 73 years (range, 62-89 years).
For the present study, persons with 1 positive and 1 negative
culture result were less informative. Two positive culture results
could either indicate persistent or intermittent carriage. Possibly, the number of CFUs of S. aureus cultured could differentiate between persistent and intermittent carriage. Persons
with 2 negative culture results could help to assess the predictive
value for true non carriage. Therefore, after initial random inclusion of participants, we decided to oversample persons with
2 positive or 2 negative screening culture results. Fifty-seven
participants (54%) were classified as noncarriers, 17 (16%) were
classified as intermittent carriers, and 32 (30%) were classified
as persistent carriers (validation cohort; table 1). In 1 participant, both screening culture results were negative, and the
results of cultures 3-12 were all positive. The most probable
explanation for this would be either sample handling mistakes
or a laboratory error. Because exclusion of this person did not
significantly alter the data, and because mistakes happen in real
life, it was decided not to exclude this person's data from analysis. The positive predictive value derived from regression models that included the results of cultures 1 and 2 was 0.79 in a
model containing the qualitative outcome only, as well as in a
model including also the quantitative results (figure lB). The
use of the results of only 1 culture (either 1 or 2) produced a
positive predictive value of 0.74.
The numbers of CFUs of S. au reus were significantly higher
in the validation than in the derivation cohort (figure 2). The

1 Positive
and 1 negative

1

7

5

4

16
15

26

6

15
19

53

4

7

2

Persistent carrier
Total

20

19

51

Validation cohort
Noncarrier
Intermittent carrier
Persistent carrier
Total

61

6

57

8

17

31

32

39

106

NOTE. Data are no. of subjects. S. aureus carrier status is based on results
of cultures 3-12. For the validation cohort. persons for whom the results of
both culture 1 and 2 were positive or negative were oversampled (see Patients
and Methods). Therefore. the distribution of the different carrier states does
not represent the population prevalence.

median geometric mean in intermittent and persistent carriers
were 1.4 (range, 0.3-3.3) and 3.6 (range, 1.9-3.9) in the validation
versus 1.0 (range, 0.3-2.0) and 1.8 (range, 0.9-3.2) in the derivation cohort (P
.001 and P< .001), respectively. Persistent
carriers had significantly higher numbers of CFUs of S. aureus
in their positive nasal swab cultures than did intermittent carriers
(figure 2): 1.8 CFUs (range, 0.9-3.2 CFUs) versus 0.98 CFUs
(range, 0.30-2.0 CFUs; P .001) in the derivation cohort and
3.6 CFUs (range, 1.9-3.9 CFUs) versus 1.4 CFUs (range, 0.303.3 CFUs; P< .001) in the validation cohort (figure 2).
In the derivation cohort, logistic regression showed that the
model best differentiating between persistent carriage and noncarriage or intermittent carriage used qualitative culture results
in combination with quantitative data. The model that used
the results of 2 cultures performed significantly better than a
model that used the results of only 1 culture. Adding the results
of a third or fourth culture did not significantly improve the
model. Results from the ROC analysis showed that all tests
used had good performance (all AUes were >0.9), with the
combined model being slightly-but not significantly-better
than the qualitative result of 2 nasal swab cultures (figure lA).
In the validation cohort, 2 qualitative culture results (positive
or negative) discriminated similarly between persistent carriage
and noncarriage or intermittent carriage as the combined qualitative and quantitative results. All logistic regression models
were significantly improved by adding data on a third culture.
However, in the ROC analysis, the differences between the
models were small. Adding data on a third (but not a fourth)
culture only significantly improved the model when both qualitative and quantitative culture results were used (figure 1B).
The AUes that used the combination of qualitative culture
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Figure 1. A, Receiver operating characteristic (ROC) curve illustrating the predictive value of different tests for the persistent Staphylococcus
aureus nasal carrier state in the derivation cohort. *Area under the ROC (AUC) of 2 versus 1 cultures (P< .05). B, ROC curve illustrating the predictive
value of different tests for the persistent S. aureus nasal carrier state in the validation cohort. * AUC of 3 versus 2 cultures in the combined test
(P< .05). PVt. positive predictive value; PV-. negative predictive value.
results and the geometric mean CFUs of 2 cultures were 0.981
(95% CI, 0.949-1) for the derivation cohort and 0.936 (95%
CI, 0.881-0.990) for the validation cohort, respectively (figure
1). The logistic regression equation that uses the combination
of qualitative culture results and the geometric mean of CFUs
from 2 cultures could be written as follows: probability of persistent S. aureus nasal carriage = e({30 + {31 X number of positive cultures + {32 X geometric mean of CFUs)11 + e({30 + (31 X
number of positive cultures + {32 X geometric mean of CFUs).
In the derivation cohort, the respective values of {30, {31, and
{32 were -20.171, 9.341, and 1.661. In the validation cohort
these values were -4.572, 2.563, and 0.274, respectively.
When a cutoff of 0.50 was used, above which probability
persons were classified as persistent carriers, it followed from
the logistic regression equation from the derivation cohort that
a person was a persistent carrier only if both cultures were
positive with a geometric mean of ;;;'0.9 (-8 CFUs per culture).
This culture rule, when applied to the validation cohort, had
a positive predictive value of 0.78, a negative predictive value
of 0.96, and an AUC of the corresponding ROC curve of 0.936
(95% CI, 0.881-0.990).

DISCUSSION
We examined the diagnostic value of2 weekly quantitative nasal
swab cultures to predict the S. aureus nasal carriage state and
developed a culture rule to enable adequate differentiation between persistent carriage and intermittent carriage among those
individuals with 2 positive screening culture results.
We used logistic regression and ROC analysis to derive a culture rule under ideal laboratory circumstances in a cohort of
healthy adult volunteers. Strictly speaking, the derivation cohort
actually was more of an exploratory data set to help select the
variables in the model, but not the actual predictions. The culture
rule was subsequently validated under real-life conditions in a
subset of elderly participants of the Rotterdam Study.
In the derivation cohort, the best test combined qualitative
culture results (number of positive culture results) with quantitative data (geometric mean number of CFUs of S. aureus in
nasal swab cultures). In the validation cohort, however, the
simple qualitative culture result when data on 2 cultures were
used performed as well as the more complicated culture rule.
The culture rule performed slightly less well in the validation
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Figure 2. Geometric mean ('olog) number of colony-forming units (CFUs)
of Staphylococcus aureus in positive cultures in intermittent versus persistent carriers from both cohorts, Boxes, median, quartile, and extreme values;
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intermittent carriers, derivation versus validation cohort (P == ,001); §, persistent carriers, derivation versus validation cohort (P < ,001 J,

cohort (AVC, 0.981 in the derivation and 0.936 in the validation cohort, respectively). In the ideal laboratory situation,
one trained physician performed all nasal swab cultures in a
cohort of healthy individuals. In the real-life situation of largescale epidemiologic surveys, misclassification of the carrier state
could have occurred for a variety of logistic reasons, such as
differing nasal culturing techniques of study physicians, samplehandling mistakes, and laboratory errors. In theory, many of
these "errors" are preventable but can never be totally eradicated. The fact that in the validation cohort the first 2 cultures
were obtained at the Rotterdam Study research center by various study physicians, whereas cultures 3-12 in the validation
cohort were performed by one trained person, certainly affected
culture results: when cultures 3 and 4 of the validation cohort
were used, instead of cultures 1 and 2, the AVC was increased
from 0.936 to 0.996.
Misclassification of the carrier state could also have occurred
because of factors associated with individual participants of the
Rotterdam Study. Culture results will potentially have been influenced by the use of medication (recent courses of antibiotic
therapy), institutionalization (recent hospital admissions), and
underlying diseases, as well as other unknown determinants.
We confirm earlier data that showed that the number ofCFUs
of S. aureus in the anterior nares was higher in persistent carriers

than in intermittent carriers [24, 25). We also found a striking
difference in the amount of S, aureus in the nose of persistent
carriers between young, healthy volunteers and healthy, elderly
participants. No previous data are available regarding age and
the number of CFUs of S. au reus in the noses of persistent
carriers. From the Rotterdam Study (3851 persons), the high
numbers of CFUs (median geometric mean, 2.8) in elderly persistent carriers are confirmed (data not shown), but the underlying mechanisms of this finding remain to be elucidated. The
differences in the number of CFVs in persistent carriers in both
cohorts will have affected the performance of the derived culture
rule in the validation cohort. When applying this culture rule to
other patient populations, it will need to be validated in the
specific population first, when possible.
Combining qualitative results with quantitative data is, in
our opinion, conceptually the best choice. Incorporating quantitative data makes it possible to refine associations between
potential determinants and S. aureus nasal carriage because not
only carriers are compared with noncarriers, but carriers with
low CFUs can also be compared with carriers with high CFUs
in their anterior nares. Incorporating quantitative data will also
make it possible to refine associations between carriage state
and morbidity and mortality. However, in large-scale epidemiologic studies, simplicity will often prevail because of logistic reasons and resources. It is therefore reassuring that, in the
validation cohort, the simple qualitative culture results performed as well as the more complicated culture rule.
Thus, 2 nasal swab culture of samples obtained at a I-week
interval can indeed provide sufficient information to adequately
predict the S. aureus nasal carriage state. The use of only 1
nasal swab culture to predict the carriage state, as is often done,
cannot be recommended on the basis of our data because it
will lead to misclassification of the carriage state. On the other
hand, the addition of a third or fourth quantitative nasal swab
culture only minimally improved test performance. Of importance, no persons whose first 2 culture results were positive
were found to be non carriers. The finding of 2 negative screening culture results in 1 person with subsequent positive culture
results is difficult to explain but may be attributable to sample
handling mistakes or laboratory error. These results were included in the evaluation, however. One negative screening culture result virtually excludes persistent carriage. Predicting the
non carrier state from 2 nasal swab cultures is more difficult
because ~7 nasal swab cultures would be needed to distinguish
intermittent carriers from non carriers,
At present, data on determinants of persistent S. aureus nasal
carriage in elderly patients in the Rotterdam Study are being
analyzed by means of this culture rule. This is the first study to
validate the potential of a limited number of nasal swab cultures
in predicting the S. aureus carrier state. Because the incidence of
S. aureus infections has increased substantially, and because of

810 • eID 2004:39 (15 September) • Nouwen et al.

518

the dramatic worldwide increase in antibiotic resistance (methicillin and, recently, even vancomycin resistance) in S. aureus,
prevention is now more important than ever. Apart from its role
in the Rotterdam Study, we hope that the presented culture rule
will prove to be a helpful tool in identifying determinants of S.
aureus nasal carriage and infections, as well as in identifying highrisk patient populations and the implementation of new methods
in the prevention of S. aureus infections.
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IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK

JUDY NIELD,

)

Case No. CV-09-3869-PI

)

Plaintiffs,

)
)
vs.
)
)
POCATELLO HEALTH SERVICES, INC. )
a Nevada Corporation d/b/a POCATELLO)
CARE AND REHABILITATION
)
CENTER and JOHN DOES I-X, acting as )
)
agents and employees of POCATELLO
)
HEALTH SERVICES, INC. d/b/a
POCATELLO CARE AND
)
REHABILITATION CENTER,
)
)
Defendants.
)

MEMORANDUM IN SUPPORT OF
PLAINTIFF'S MOTION TO STRIKE
THE AFFIDAVIT OF DR. COFFMAN

)

COMES NOW Plaintiff, by and through the undersigned counsel, and submits this
Memorandum in Support of Plaintiffs Motion to Strike the Affidavit of Dr. Coffinan.

I. INTRODUCTION
In support of Defendant's motion for summary judgment, Defendant offered the Affidavit

of Dr. Coffinan. As will be asserted in greater detail in the remainder ofthis Memorandum, ~~ 12,
14,22,23,24,25,26, and 27 of Dr. Coffinan's affidavit must be stricken or, in the alternative, not
considered by the Court in determining Defendant's motion for summary judgment.
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II. STANDARD OF REVIEW
IRCP 56(e) provides, in pertinent part, as follows:
Supporting and opposing affidavits shall be made on personal knowledge, shall set
forth such facts as would be admissible in evidence, and shall show affirmatively
that the affiant is competent to testifY to the matters stated therein.

The question of admissibility of affidavits under Rule 56(e) is a threshold question to be
analyzed before reviewing motions for summary judgment, and a court must look at the affidavit to
determine ifit alleges facts, which if true, would render the testimony admissible. Foster v. Traul,
145 Idaho 24, 28, 175 P.3d 186, 190 (2007).
Expert testimony offered in a medical malpractice case, "like any other case, is governed by
the rules of evidence regarding the opinion testimony oflay witnesses and experts under Idaho Rules

of Evidence 701 and 702." IRE 702 provides: "If scientific, technical, or other specialized
knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a
witness qualified as an expert by knowledge, skill, experience, training, or education, may testifY
thereto in the form of an opinion or otherwise.
However, expert testimony that is based on speculation, is not admissible under Rule 702.
Speculation, as it relates to expert testimony is defined as "the-art of theorizing about a matter as to
which evidence is not sufficient for certain knowledge." Karlson v. Harris, 140 Idaho 561, 564, 97
P.3d 428,432 (2004).
An expert opinion that is speculative or unsubstantiated by facts in the record is
inadmissible because it would not assist the trier of fact to understand the
evidence or determine a fact that is at issue. Expert opinion that merely
suggests possibilities would only invite conjecture and may be properly excluded."

Id. [Emphasis added][Internal citations omitted]. See also Jones v. Crawforth, 147 Idaho 11,205

MEMORANDUM IN SUPPORT OF PLAINTIFF'S MOTION IN STRIKE THE AFFIDAVIT OF DR. COFFMAN - PAGE 2

521

P .3d 660 (2009)( expert opinions are only admissible if they assist the trier of fact in understanding
the evidence or determining an issue of fact); Weeks v. E. Idaho Health Servs., 143 Idaho 834, 838,
153 P.3d 1180,1184 (2007)(expertopinion that is speculative, conc1usoryorunsubstantiated by facts
in the record does not assist the jury and is inadmissible).

III. AGRGUMENT
1. Paragraph 12 is conclusory and lacks foundation.
Paragraph 12 of Dr. Coffinan's affidavit, specifically, the portions stated on page 4, Dr.
Coffinan does not identifY how he is trained or has experience in how a technician "does not culture
every micro-organism from a wound or fluid culture" and makes this conclusion that in every case,
a technician does not perform a complete culture. This assertion is speculation, especially due to the
fact that Dr. Coffinan does not endeavor to contact the technician or obtain facts to support his
unsubstantiated conclusion.

2. Paragraph 14 is inadmissible speculation.
Dr. Coffinan again asserts supposition in concluding, in the last sentence ofParagraph 14 that
carries over from page 4, to page 5, in his statement that "it appears" that Dr. Zimmerman's
reference in his discharge summary of Judy Nield, to a negative MRSA screen refers to the culture
taken, "and not an actual MRSA screening based on the lack of any MRSA screen report." Dr.
Coffinan goes on to speculate, "it is fair to assume that a MRS A screen was not performed." Again,
Dr. Coffinan speculates, and does not endeavor to produce any facts to ascertain whether a screen
and culture were done.
Dr. Coffinan goes on to conclude: "If Ms. Nield was not screened for MRSA, it is not
possible to determine if she was MRSA colonized at the time she was admitted to Pocatello Care and
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Rehab on August 25, 2007." This is again supposition and conclusory speculation. Dr. Coffman's
speculation is evident by his use of "If' indicative of his conclusory speculations.

3. Paragraph 22 is inadmissible speculation.
Dr. Coffman again speculates as to whether Judy Nield was MRSA or pseudomonas
colonized at the time of her admission at PCRC. Dr. Coffinan's speculation is again based on his
unfounded conclusion that the technicians did not properly screen or culture Judy's wounds.

4. Paragraph 23 is based on speculative "possibility."
Dr. Coffinan, again, concludes, based on his speculation, whether each of Ms. Nield's
wounds were cultured, leading to his conclusion, the wound culture "does not rule out the possibility
Ms. Nield was colonized or infected with MRSA or pseudomonas." Dr. Coffman goes on to
speculate, "[i]t is possible Ms. Nield had MRS A and/or pseudomonas in one or more, but not all of
her wounds ... it is possible the swab was taken from one of the wounds in which she did not have
MRSA and/or pseudomonas." The inadmissible nature of these statements is self-evident by Dr.
Coffinan's continuous use of "possible", which he uses several times. Again, this is speculative and
conclusory, entirely void of any facts.

5. Paragraph 24 is also based on speculation.
Dr. Coffinan speculates that "[i]t is possible... the culture did not grow out and identify
[MRSA or pseudomonas] resulting in a false negative." This conclusion is based on no facts.
Again, Dr. Coffinan does not endeavor to ascertain any facts to support this or his final conclusion,
"It is very possible MRSA and/or pseudomonas were present in the wound that was cultured ...but

were not dominant microorganisms and were not grown out."

This is again inadmissible

speculation.
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6. Paragraph 26 is inadmissible speculation.
Dr. Coffinan concludes, without any factual bases, that Judy was potentially exposed to
MRSA or pseudomonas when she had visitors. Lacking in this conclusory statement is any evidence
the visitors were MRSA or pseudomonas colonized or infected.
7. Paragraph 27 is inadmissible speculation.
Dr. Coffinan again asserts it is not possible to determine whether Judy's pseudomonas
infection on November 9, 2007 was related to her right hip infection. Again, Dr. Coffinan's
admission that "it appears" Judy's infection was resolved by antibiotics and that "it appears" Judy
had two different strains of pseudomonas are nothing but speculation.
Finally, Dr. Coffinan's affidavit must be tempered by his admission that "it is not possible to
determine whether or not Ms. Nield was MRSA or pseudomonas colonized as of the time she was
admitted to [PCRC]. This conclusion speaks volumes to support that Dr. Coffinan offers nothing
but speculation, which is not admissible on summary judgment.
CONCLUSION
Based on the foregoing, Plaintiff respectfully requests that the Court grant her Motion to
Strike the Affidavit of Dr. Coffinan.

DATED this 29 th day of November, 2010.
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CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this 29 th day of November, 2010, I served a true and correct
copy of the above and foregoing document to the following person(s) as follows:

[1

Keely Duke
Chris D. Comstock
HALLFARLEY OBERRECHT &BLANTON
P.O. Box 1271
Boise, ID 83701

[]

f}

U.S. Mail/Postage Prepaid
Hand Delivery
Overnight Mail
Facsimile /208-395-8585
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Reed W. Larsen, ISB # 3427
Javier L. Gabiola, ISB # 5448
COOPER & LARSEN, CHARTERED
151 North 3 rd Avenue, 2 nd Floor
P. O. Box 4229
Pocatello, ID 83205-4229
Telephone: (208) 235-1145
Facsimile: (208) 235-1182

Attorneys for Plaintiff

IN THE DISTRICT COURT OF THE SIXTH mDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,
Plaintiff,
vs.
POCATELLO HEALTH SERVICES, INC.,
a Nevada corporation, d/b/a
POCATELLO CARE AND
REHABILITATION CENTER, and
JOHN DOES I-X, acting as
agents and employees of POCATELLO
HEALTH SERVICES, INC., d/b/a
POCATELLO CARE AND
REHABILIT A nON CENTER,
Defendants.

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

Case No. CV-09-3869-PI

MOTION TO CONTINUE HEARING
ON SUMMARY JUDGMENT OR IN
THE ALTERNATIVE ADDITIONAL
TIME TO SUPPLEMENT THE
RECORD

COMES NOW Plaintiff Judy Nield, by and through the undersigned counsel, and pursuant
to I.R.c.P. 56(f), requests the Court either continue the hearing on Defendants' Motion for Summary
Judgment, or allow, pursuant to I.R.c.P. 6(b), additional time in which to allow Plaintiffto
supplement the record so she can procure the affidavit of Suzanne Frederick, one of her experts
disclosed and identified in this case, additional time to procure and file with the Court the deposition
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of Derrick Glum, a former administrator at Defendants' facility, and additional time to obtain an
affidavit from her expert, Dr. Shockley.
This Motion is supported by the record herein and the Affidavit of Javier L. Gabiola in
Support of Plaintiffs' Motion to Continue the Hearing on SUITl.!!1ary Judgment filed concurrently
herewith.
Oral argument is requested.
DATED this

J2!L day of November, 2010.
COOPER & LARSEN, CHARTERED

CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this ~7 day of November, 2010, I served a true and correct
copy of the above and foregoing document to the following person(s) as follows:
Keely E. Duke
Chris D. Comstock
Hall, Farley, Oberrecht & Blanton
P.O. Box 1271
Boise, ID 83701

ff
[]
[]
~

U.S. Mail/Postage Prepaid
Hand Delivery
Overnight Mail
Facsimile: 208-395-8585
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Reed W. Larsen, ISB # 3427
Javier L. Gabiola, ISB # 5448
COOPER & LARSEN, CHARTERED
151 North 3rd Avenue, 2nd Floor
P. O. Box 4229
Pocatello, ID 83205-4229
Telephone: (208) 235-1145
Facsimile: (208) 235-1182

Pf-l
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Attorneys for Plaintiff

IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

Plaintiff,
vs.
POCATELLO HEALTH SERVICES, INC.,
a Nevada corporation, d/b/a
POCATELLO CARE AND
REHABILITATION CENTER, and
JOHN DOES I-X, acting as
agents and employees of POCATELLO
HEALTH SERVICES, INC., d/b/a
POCATELLO CARE AND
REHABILITATION CENTER,
Defendants.

Case No. CV-09-3869-PI

MEMORANDUM IN SUPPORT OF
PLAINTIFF'S MOTION TO
CONTINUE HEARING ON SUMMARY
JUDGMENT OR IN THE
ALTERNATIVE ADDITIONAL TIME
TO SUPPLEMENT THE RECORD

COMES NOW Plaintiff Judy Nield, by and through the undersigned counsel, and submits
this Memorandum in Support of Plaintiff s Motion to Continue Hearing on Summary Judgment.
ARGUMENT
Plaintiff requests a continuance on Defendants' Motion for Summary Judgment, pursuant
to I.R.C.P. 56(f). Rule 56(f) provides as follows:
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When affidavits are unavailable in summary judgment proceedings. Should
it appear from the affidavits of a party opposing the motion that the party
cannot for reasons stated present by affidavit facts essential to justify the
party's opposition, the court may refuse the application for judgment or may
order a continuance to permit affidavits to be obtained or depositions to be
taken or discovery to be had or may make such other order as is just.
Plaintiffhas made several attempts to obtain an affidavit from Suzanne Frederick, one of her
experts in this matter. See Affidavit ofJavier L. Gabiola in Support ofPlaintiff's Motion to Continue
Hearing on Summary Judgment ("Gabiola AjJ. ''). For an unknown reason, Ms. Frederick has not

been available, nor has she been reached by Plaintiff or her attorneys to procure her affidavit to file
in support of Plaintiffs opposition to Defendants' Motion for Summary Judgment. Id.
Additionally,on November 1&,2010, Plaintiffs counsel took the deposition of Defendants ,
former administrator, Derrick Glum, in St. George, Utah. On November 24

th,

2010, Plaintiffs

counsel was notified for the first time that they would not be allowed to obtain an electronic
transcript by email from the reporting firm that reported Mr. Glum's deposition without first paying
for and ordering the transcript. See Gabiola Ajf., Exh. 1.

On November 26 til, 2010, Plaintiff s

counsel sent a request to the reporting firm that reported Mr. Glum's deposition requesting that an
e-transcript of that deposition be provided as soon as possible. See Gabiola AjJ., Exh. 2.
Additionally, Plaintiff requests a continuance, or in the alternative, additional time to
supplement the record with the affidavit of her infectious disease expert Dr. Shockley. Plaintiffs
counsel has been working diligently to procure an affidavit from Dr. Shockley since approximately
October 29 th , 2010. Gabiola AjJ., ~ 4. Due to a miscommunication, Dr. Shockley's assistant did not
provide him with appropriate documents for his review in order to prepare an affidavit and submit
his opinions in opposition to Defendants' Motion for Summary Judgment. Id.
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Pursuant to Rule 56(f), Plaintiff requests the Court to continue the hearing or allow Plaintiff
to supplement the record with the affidavits of Ms. Frederick and Dr. Shockley and deposition
testimony transcript of Derrick Glum in order to more fully and completely respond and support
Plaintiffs opposition to Defendants' Motion for Summary Judgment.
DATED this ~ day of November, 2010.
COOPER & LARSEN, CHARTERED

~~
-

By'

~

. REEriw.LRSEN

----

CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this pJy day of November, 2010, I served a true and correct
copy of the above and foregoing document to the following person(s) as follows:
Keely E. Duke
Chris D. Comstock
Hall, Farley, Oberrecht & Blanton
P.O. Box 1271
Boise, ID 83701

[--r-[]
[]
[--}---

U.S. Mail/Postage Prepaid
Hand Delivery
Overnight Mail
Facsimile: 208-395-8585
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Reed W. Larsen, ISB # 3427
Javier L. Gabiola, ISB # 5448
COOPER & LARSEN, CHARTERED
151 North 3rd Avenue, 2nd Floor
P. O. Box 4229
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Attorneys for Plaintiff

IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,
Plaintiff,
vs.
POCATELLO HEALTH SERVICES, INC.,
a Nevada corporation, d/b/a
POCATELLO CARE AND
REHABILITA TION CENTER, and
JOHN DOES I-X, acting as
agents and employees of POCATELLO
HEALTH SERVICES, INC., d/b/a
POCATELLO CARE AND
REHABILITATION CENTER,
Defendants.

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

Case No. CV-09-3869-PI

AFFIDAVIT OF JAVIER L. GABIOLA
IN SUPPORT OF PLAINTIFF'S
MOTION TO CONTINUE HEARI~
ON SUMMARY JUDGMENT OR IN
THE ALTERNATIVE ADDITIONAL
TIME TO SUPPLEMENT THE
RECORD

ST ATE OF IDAHO )
: ss.
County of Bannock )
JAVIER L. GAB lOLA, being first duly sworn upon oath, deposes and states as follows:
1.

I am one ofthe attorneys representing Plaintiffin this matter and make this Affidavit

upon my own personal knowledge and information.
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2.

My office and its staff have been attempting and trying to obtain an affidavit from

Suzanne Frederick, one of Plaintiffs healthcare and nursing experts, disclosed in this matter. Since
November 8, 2010, I and my staff have been attempting to contact Ms. Frederick to obtain her
signature on an affidavit, a copy of which is attached hereto as Exhibit 1, to file in opposition to
Defendants' Motion for Summary Judgment. As of the date of this affidavit, for unknown reasons,
neither I nor my office staff have been able to contact or get a hold of Ms. Frederick;
3.

Attached hereto as Exhibit 2 is a copy of an email my paralegal received from the

deposition firm that reported the deposition of Derrick Glum, the former administrator at
Defendants' facility, which was taken on November 16th , 2010. On November 24h, 2010 I was first
informed that an e-transcript of Mr. Glum's deposition would not be available until it was ordered
and paid for. Thereafter, on November 2~, 2010 I sent a request to the reporting firm that reported
Mr. Glum's deposition, providing a credit card to obtain an e-transcript of Mr. Glum's deposition.
See Exhibit 3 attached hereto;
4.

On approximately October 28 th , 2010 I endeavored to obtain and procure an affidavit

from Dr. Shockley an infectious disease expert that I wanted to retain on behalf of Plaintiff, and to
obtain opinions to submit to the Court in opposition to Defendants' Motion for Summary Judgment.
The documents that Dr. Shockley would need to review to prepare his opinions and affidavit, due
to a miscommunication between my office and Dr. Shockley's assistant, Dr. Shockley was not given
documents to review until November 19t h, 2010. Based upon this, I was unable to obtain any
affidavit or opinions from Dr. Shockley to file an opposition to Defendants' Motion for Summary
Judgment.
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FURTHER SAITH AFFIANT NAUGHT.
DATED this..2:1.- day of November, 2010.
COOPER & LARSEN, CHARTERED

"~//

/

BY:~~L
.

-

A VIER L. GABIOLA

SUBSCRIBED AND SWORN TO before me this:J 'i ~day of November, 2010.

NOTARY PUBLIC FOR IDAHO
Residing at Pocatello
My Commission Expires: \ l- J. /., - 13

CERTIFICATE OF SERVICE

~

I HEREBY CERTIFY that on this
day of November, 2010, I served a true and correct
copy of the above and foregoing document to the following person(s) as follows:

M
[]

Keely E. Duke
Chris D. Comstock
Hall, Farley, Oberrecht & Blanton
P.O. Box 1271
Boise, ID 83701

~

U.S. MaillPostage Prepaid
Hand Delivery
Overnight Mail
Facsimile: 208-395-8585
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Reed W. Larsen, ISB # 3427
Javier L. Gabiola, ISB # 5448
COOPER & LARSEN, CHARTERED
151 North 3rd Avenue, 2nd Floor
P. O. Box 4229
Pocatello, ID 83205-4229
Telephone: (208) 235-1145
Facsimile: (208) 235-1182
Attorneys for Plaintiff

IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,

)

Case No. CV-09-3869-PI

)

Plaintiff,

)
)

vs.

)
)

POCATELLO HEALTH SERVICES, INC.,
a Nevada corporation, d/b/a
POCATELLO CARE AND
REHABILITATION CENTER, and
JOHN DOES I-X, acting as
agents and employees of POCATELLO
HEALTH SERVICES, INC., d/b/a
POCATELLO CARE AND
REHABILITATION CENTER,
Defendants.

)
)
)
)
)
)
)
)
)
)
)

AFFIDA VIT OF SUZANNE
FREDERICK

)

STATE OF TEXAS
County of

)
: ss
)

I, SUZANNE FREDERICK, being first duly sworn on oath, depose and state as follows:
1.

That I am over the age of 18 and am competent to testify as to the facts set forth

below.
EXHIBIT
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2.

That I am a Registered nurse licensed in the State of Texas. I have been practicing

as a registered nurse since 1983. Attached hereto is a copy of my CV.
3.

Attached hereto is a copy of my reports dated April 19,2010, and June 10,2010.

Said reports are incorporated by reference. Attached thereto is a list of all the documents I reviewed
in preparing my opinions in this matter.
4.

It is my opinion that Pocatello Nursing and Rehabilitation Center nursing staff, as

well as the Director of Nursing and Administrator, acted negligently and recklessly with regard to
Mrs. Nield and were indifferent to her health and well-being. The nursing staff knew that their
failure to meet the standards of care put Mrs. Nield at extreme risk ofharrn and that their failure to
meet the standards would likely cause injuries to Mrs. Nield but despite this knowledge, Pocatello
Nursing and Rehabilitation Center and its nursing staff still failed to meet the standard of care which
caused her to develop MRS A which caused her many subsequent injuries and prolonged suffering.
5.

From my review ofthe records, the records show that Mrs. Nield did not have MRS A

or Pseudomonas when she entered Pocatello Care and Rehabilitation Center. Mrs. Nield was seen
at the Wound Care & Hyperbaric Center on November 8, 2008. A physician's note on November
20, 2007 showed that a wound culture taken November 13, 2007 was positive for MRSA and
pseudomonas.
6.

It is also my opinion that Pocatello Nursing and Rehabilitation Center failed to follow

proper infection control procedures to prevent Mrs. Nield's MRSA and pseudomonas infection. As
stated above, Mrs. Nield did not have MRSA and pseudomonas when she was admitted to Pocatello
Nursing and Rehabilitation Center on August 25,2007. However, the records clearly show that she
did develop MRS A and pseudomonas while she was a resident of Pocatello Nursing and
Rehabilitation Center.
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7.

It is my professional nursing opinion that Mrs. Nield's contraction of MRSA and

pseudomonas was caused by substandard nursing practice regarding infection control.
FURTHER SAITH AFFIANT NAUGHT.
DATED this _ _ day of November, 2010.

SUZANNE FREDERICK

SUBSCRIBED AND SWORN TO before me this _ _ day of November, 2010.

(SEAL)

NOTARY PUBLIC FOR TEXAS
Residing at:
My Commission expires:

CERTIFICATE OF SERVICE
I HEREBY CERTIFY that on this
day of November, 2010, I served a true and correct
copy of the above and foregoing document to the following person(s) as follows:
(]
[]
[]
[]

Keely E. Duke
Chris D. Comstock
Hall, Farley, Oberrecht & Blanton
P.O. Box 1271
Boise, ID 83701
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U.S. Mail/Postage Prepaid
Hand Delivery
Overnight Mail
Facsimile: 208-395-8585

Page 1 of 1

Liz
From:

Sherry Longo [sherry@toddolivas.com]

Sent:

Wednesday, November 24, 2010 11 :11 AM

To:

Liz

Subject:

Deposition of Derrick Glum

Attachments: DepoOrderForm_O+1.pdf
Good morning Liz,
I have received the final transcript of the above mentioned deponent in my office for production. I have
attached an order form if you would like to fill out the order form and return it to me signed I will be happy
to forward you an e-transcript right away.
Best regards,
Sherry Longo
Todd Olivas & Associates. Inc.
41690 Enterprise Circle North
Suite 200CC
Temecula, CA 92590
(951) 296-0114 Main Line:
(951) 848-0789 Fax
http://www.toddolivas.com
sherrv@toddolivas.com
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Attorneys for Plaintiff

IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,
Plaintiff,
vs.
POCATELLO HEALTH SERVICES, INC.,
a Nevada corporation, d/b/a
POCATELLO CARE AND
REHABILITATION CENTER, and
JOHN DOES I-X, acting as
agents and employees of POCATELLO
HEALTH SERVICES, INC., d/b/a
POCATELLO CARE AND
REHABILITATION CENTER,
Defendants.

)
)
)

Case No. CV-09-3869-PI

)
)
)

MEMORANDUM IN OPPOSITION TO
DEFENDANTS' MOTION FOR
SUMMARY JUDGMENT

)
)
)
)
)
)
)
)
)
)
)
)

COMES NOW Plaintiff Judy Nield ("Judy"), by and through the undersigned counsel,
submits this Memorandum in Opposition to Defendants Pocatello Care and Rehabilitation Center's
(PCRC) Motion for Summary Judgment.

INTRODUCTION
Judy is a 68 year old long-time resident of Chubbuck. For over three years, Judy has been
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bed bound, as she has no leg below her left knee, nor does she have any right hip bone below her hip.
Judy's situation is entirely due to PCRC's negligence and breach ofthe standard of care. PCRC's
conduct is best described as reckless and a gross violation of the type of care a health care giving
facility should have given Judy, which PCRC did not do. PCRC infected andlor colonized Judy with
Methicillin-Resistant Staphylococcus Aureus ("MRSA") and pseudomonas aeruginosa ("P A"). It
is not disputed that prior to her admission to PCRC, Judy tested negative for MRSA and P A.
Apporixmately 3 months after her admission, Judy contracted MRSA and PA, based on tests done
November 9 th, 2007. Judy was infected andlor colonized with MRSA and PA at PCRC as a result
of its negligent, reckless conduct and its breach of the standard of care in failing to prevent the spread
of MRS A and P A to Judy.
PCRC's request for summary judgment is improper, as it based on speculation, nothing more.
PCRC asserts Judy could have been a carrier of MRS A or P A or that someone other than PCRC may

have exposed her to MRSA and P A and that there is no evidence Judy contracted MRSA or P A due
to PCRC"s negligence or breach of the standard of care. The lynchpin of PCRC's speculative
motion is their expert, Dr. Coffman, who, in his deposition testified, when asked whether he could
rule out Judy contracted MRSA at PCRC: "I can't rule out where she got it from" and "Well, 1
don't think we can tell." Dr. Coffman also, as to PA, concluded he does not know where, when or
how Judy acquired it.
On the other hand, Judy's treating physician and expert, Dr. Hugh Selznick, opined that to
a reasonable degree of medical probability, Judy contracted MRSA and P A from PCRC. Dr.
Selznick concluded "the etiology of [Judy's MRSA infection] was poor infection control measure
by the staff at Pocatello Care & Rehabilitation Center. . . and it is my opinion Ms. Nield also
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sustained left lower extremity pseudomonas wound infection while hospitalized at Pocatello Care

& Rehabilitation Center as evident per 1119/07 culture results." Further, Judy's other experts,
reviewed this matter, Sid Gerber, an expert in healthcare administration, as well a residential care
nurse, Suzanne Frederick, both opined that Judy contracted MRSA and PA due to PCRC's breach
of the standard of care from its failure to prevent the transmission of disease and infection. Mr.
Gerber characterized PCRC's conduct as "gross violations", "reckless" and "unjustifiable." Further
Ms. Frederick concluded PCRC's failures to provide adequate care and prevent the spread of MRS A
and PA to Judy "increas[ed] the risk of harm, causing injury and unnecessary pain and suffering to
Mrs. Nield, as well as MRSAlPseudomonas infection."
PCRC is not entitled to summary judgment, as there is a genuine issue of material fact Judy
contracted MRSA and PA due to the negligence and breach of the standard of care committed by
PCRC.

STATEMENT OF FACTS
1. On August 21 S\ 2007, Judy was taken to the ER department at PortneufMedical Center
("PMC"). At the time, Judy was suffering from four open wounds on her left leg, as well as
cellulitis, and other medical conditions. See Affidavit 0/Reed W Larsen ("Larsen Aff. 'j, Exhibit

A {history and physical/rom PMC}. While at PMC, Judy was tested for MRSA and PA, and the test
results were negative for those infections. Larsen £lff., Exh. B. (Test results August 21-23, 2007).
2. Judy was admitted to PCRC on August 25 t h, 2007, to recuperate enough to have surgery
as her medical providers planned to operate on her hip so that she could have a hip replacement, as
well as other prosthetic procedures done. Larsen £lff., Exh. C (PCRC admission records).
3. Upon admission to PCRC, PCRC' s wound care nurse knew Judy's physician ordered that
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Judy have daily wound assessments. Larsen Af[., Exh., D (PCRC record-Maxfield). Despite this,
PCRC's nurses did not do daily skin assessments Larsen Af[., Exh. E (weekly skin assessment and

ulcer pressure sore sheets). PCRC's medical staff generated cryptic medical records, which did not
identify or document accurately Judy's four open wounds in her left leg. Larsen Af[., Exh. F

(Suzanne Frederick 4-19-1 0 Report, pp. 9-13; Affidavit o/Sid Gerber~~ 4-5, Gerber Report, pp. 6-7.
In fact, Judy's weekly skin assessments, which certainly were not daily, were started upon her
admission and then ended on September 18th, 2007, such that all documentation on two of Judy's
wounds stopped at that time, and the largest wound on her left leg stopped on October 22nd , 2007,
three weeks prior to her being positively cultured for MRS A and P A. Larsen Af[., Exh. F (Frederick

Report, pp. 9-10; Gerber Report, p. 7,

~

3.

This deficiency was admitted to by one of Judy's

wound care nurses, Joyce Maxfield, who testified Judy's wound care records could have been more
accurate. Larsen Af[., Exh. G (Joyce Maxfield Deposition), p. 77, ll. 12-22.
4. On November 13 th , 2007, Judy's left leg wounds were cultured. Larsen Af[., Exh. H

(November 13, 2007 test reports). The test results showed Judy was positive with infections of
MRSA and PA. Id. This was a trivial matter, to PCRC's former administrator, Derrick Glum, who
testified that "it was not warranted" for PCRC to conduct an investigation as to how Judy acquired
MRSA and P A while she was at PCRC. 1
5. PCRC did not do any testing or screening for MRSA or P A of Judy prior to her admission
to its facility, nor during her stay there.
6. PCRC had in place, while Judy was a resident, an "Infection Control Policy and Procedure

lJudy has requested a copy of Mr. Glum's deposition transcript, from his deposition on
November 16, 2010, which will be produced to the Court upon receipt.
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Manual (Manual)." Larsen Aff., Exh. 1. However, not everyone at PCRC was given a copy of the
policy, which PCRC's directors of nursing and staff developer admitted. Larsen Aff., Exh. G
(Maxfield Depo.), p. 21, ll. 18 to p. 22, I. 2; Exh. J (LaRee Dunn Deposition), p. 26, I. 10-15.

PCRC's manual required that its staff do a self evaluation to insure its employees were following
policies regarding infection control practices. Larsen Aff., Exh. L p. 992. Further, PCRC's manual
had "Compliance Rounds Forms" which were to be filled out to monitor universal precautions and
documentation of infections. Id., pp. 1118-1119. However, the Director of Nursing during Judy's
residency, testified that she "did not recall" using the Compliance Rounds Forms at PCRC and
"didn't recall ever seeing this [compliance rounds forms] before." Larsen Aff., Exh. K (Marjorie
Brim Deposition),p. 25, l. 21 to p. 26, I. 5. Further, as to the staffselfevaluation form PCRC's staff

were required to perform every six months, the Director of Nursing testified those forms did not look
familiar to her. Id., Exh. K,p. 26, l. 12-19. PCRC's Director of Nursing was in charge of monitoring
its staff to ensure they complied with its infection control prevention procedures. Id., Exh. K, p. 24,
I. 22 to p. 25, I. 1.

7. PCRC's failure to monitor its medical caregivers, to see if they were following basic
infection prevention procedures, such as handwashing, is evident from the testimony of Ms.
Maxfield, one of Judy's nurses who provided wound care, who admitted that she did not wash her
hands prior to gloving, itself a violation of PCRC's manual.

PCRC's manual required that, to

prevent the spread of infection, the caregiver was first required to obtain gloves, open the package,
without touching the gloves, and wash hands and then put on the gloves. Larsen Aff., Exh. L p. 991.
Ms. Maxfield did not do this, which the Department of Health and Welfare documented in its survey
on January 24,2008. LarsenAff., Exh. M (January 24,2008 survey o/PCRC). In that report, DHW
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documented nurse, LN(A), which was Ms. Maxfield, prior to putting on her gloves, did not wash her
hands, did not remove contaminated gloves, did not wash a wound guide prior to treating a resident
who had MRSA. Id., Exh. G (Maifzeld Deposition), p. 46, I. 20, I. 25; p. 49, I. 14 to p. 50, I. 5; p.
53, l. 13 to p. 55, I. 20; Exh. M, p. 82-86.

DHW found PCRC failed to follow its policies on

preventing infection and the spread of infection.Id., Exh. M, p. 85. Further, DHW sent a letter to
PCRC's then adminstrator, Derrick Glum, notifYing him PCRC was cited for improper infection
control, for failure to provide proper wound care using proper clean technique and universal
precautions on a resident who had MRSA. Larsen AjJ., Exh. N (DHW 2-19-10 Letter to Derrick
Glum), p. 3. PCRC did not follow its own hand washing policy, which it characterized as "the most

important single procedure for preventing nosocomial infections." Larsen AjJ., Exh.I, p. 1002.
8. Judy testified in her deposition that her room was not clean, smelled of urine, there was
mold in the bathroom, and feces in the bed and sink, for weeks. Larsen AjJ., Exh. 0 (Judy Nield
Deposition), p. 127, I. 21 to p. 128, 1.13. Judy also witnessed the nurses failing to wash their hands,

and did not have gloves on, before they came into her room. Id., p. 131, 1.14 to p. 132, I. 9. The
nurses admitted to Judy that it was too hard to put on gloves or wash their hands, and Judy witnessed
that 60% of the time, the nurses were not washing their hands or putting on gloves. Id., p. 131, I.
10 to p. 132, l. 9. [Emphasis added].

9. Judy testified she was housed next to a resident who had MRSA, and witnessed him
walking in the hallway. Id., p. 139, I. 3-p. 140, I. 12. Judy was also told by CNAs at PCRC that
PCRC was "working us to death" and that "[t]here's not even enough of us to cover." Id., p. 161,
ll. 18 to 21. Judy also recounted that she would be left in a wheelchair for eight straight hours to get

a pain pill. Id., p. 161, I. 22 to p. 162, I. 17.
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10. Judy's observations of the MRSA resident are confinned by the DHW 2-19-2008 letter
it sent to Mr. Glum. Larsen AjJ., Exh. N, p. 3, '3. That letter confinned, by PCRC's admission, that
while Judy was at PCRC, there were residents diagnosed with MRSA. See also, Affidavit of Dr.

Selznick, September 19, 2009 report, p. 13, , 5.
11. Further, as for PA, the DHW 1-24-2008 survey report noted that in August of 2007,
there was a patient at PCRC who was treated for wound care and "pseudomonas cellulitis of both
knees." Larsen AjJ., Exh. M, p. 32; Affidavit of Dr. Selznick, September 17, 2009 report, p. 13, ,
4. [Emphasis added].
12. Judy's observation, and the PCRC nurses saying that they did not always wash or glove
is copacetic with PCRC's expert, Dr. Coffinan's opinion that:
And when it's [hand washing] done-it's interesting, when people do self-evaluation,
self-reporting on hand washing, it's always close to 100 percent. But when they're
actually observed doing it, yeah, 70, 72 percent, 60 percent, at some facilities
50 percent.

Larsen AjJ., Exh. P (Dr. Coffman Deposition),p. 64, II. 17-22 [Emphasis added].
13. More telling from Dr. Coffinan is that, during his deposition testimony, he admitted that
he could not rule out where Judy contracted MRSA. Specifically, Dr. Coffinan testified:
Q.

So ifPCRC didn't follow infection control procedure, how are you able to rule out
that Judy Nield did not contract MRSA at PCRC?

A.

Well, I don't think we can tell....And we don't know where it came from. It
had a susceptibility pattern that was sort of more consistent with the communityacquired strain than a hospital strain. So it makes you think it might have come from
outside. But we just don't know.
Well, if PCRC is being cited for not following infection control procedure, so I
mean they didn't follow that, would you be able to rule out that Judy didn't
contract MRSA from PCRC?
I can't rule out where she got it from.

Q.

A.

***
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Larsen AjJ., Exh. P (Dr. Coffman Deposition), p. 69,

t. 18 to p. 3. [Emphasis added]. Further, Dr.

Coffinan's own affidavit amplifies that he cannot determine when Judy contracted MRS A or PA:

"[IJt is not possible to determine when, where or how Ms. Nield became infected with MRSA
or pseudomonas." See Affidavit of Thomas J. Coffman, MD in Support of Defendant Pocatello
Health Services, Inc. DBA Pocatello Care and Rehabilitation Center's Motion for Summary
Judgment, ,-r 28.
14. On the other hand, Dr. Hugh Selznick, Judy's treating physician, opined that, to a
reasonable degree ofmedical probability, Judy contracted MRSA and PA from PCRC. Dr. Selznick
concluded "the etiology of [Judy's MRSA infection] was poor infection control measure by the staff
at Pocatello Care & Rehabilitation Center... and it is my opinion Ms. Nield also sustained left lower
extremity pseudomonas wound infection while hospitalized at Pocatello Care & Rehabilitation
Center as evident per 1119107 culture results." Affidavit of Hugh Selznick, September 17, 2009

Report, p. 17, 3rd and 4th Paragraphs.
15. Further, Judy's other experts who have reviewed this matter, Sidney Gerber, an expert
in healthcare administration, as well as Suzanne Frederick, a residential care nurse, both opined that
PCRC failed to comply with state and federal regulations and standard of care to prevent the
transmission of disease and infection, leading to Judy's contracting of MRS A and PA. Both Mr.
Gerber and Ms. Frederick reviewed the January 24th, 2008 survey ofPCRC by the Department of
Health & Welfare, which found that the staff at PCRC failed to follow proper infection control
prevention procedures, such as hand washing, which was the result of PCRC failing to properly
instruct and train its employees on infection control and prevention measures. Larsen AjJ., Exh. Q

(1-24-10 Survey report from the Idaho Department of Health and Welfare, pp. 82-86); Exh. R
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(Suzanne Frederick 4-19-10 & 6-10-10 Reports, pp. 9-13; Affidavit o/Sid Gerber" 4-5, Gerber
Report, pp. 6-7. Further, Ms. Frederick concludes that the January 24th, 2008 Department of Health
& Welfare review established that the nurses at PCRC, during wound care failed to follow the

professional practice standards and facility policies to prevent infections, as nurses repeatedly failed
to wash their hands at appropriate times during wound care procedures and follow proper precautions
with a resident that had MRSA. See Larsen Ajf, Exh. R, pp. 10-11. Mr. Gerber also concluded that
PCRC failed to provide an adequate and sufficient, in addition to competent, nursing staff to provide
necessary care to prevent Judy from contracting MRSA and PA from PCRC. According to Mr.
Gerber, the nursing staff at PCRC "were not compliant with the ordinary standard of care and
protocols established to prevent the spread of infection and in [Mr. Gerber's expert opinion], were
reckless in not complying with essential and fundamental precautions established universally when
nursing staff are in physical contact with all patients or residents i.e. routine had washing regardless
of predisposition or risk factors involving MRSA." See Affidavit o/Sid Gerber, Gerber Report, p.
8. Mr. Gerber further characterized PCRC's conduct as
[G]ross violations and significant deviations from the standard of care that
they were responsible and obligated to provide to Ms. Nield, .. resulting in
Ms. Nield's injuries and causing her deterioration and needless suffering....
Furthermore, under these circumstances, such conduct in my opinion is
unjustifiable.

Gerber Ajf, Gerber Report, p.9.
Ms. Frederick further opined that
[T]he Director of Nursing and nursing staff of Pocatello Nursing and Rehabilitation
Center and its owners, managers, and agents failed to adhere to applicable standards
of care and violated state and federal nursing home regulations in addition to facility
policies and procedures in their care and treatment of Mrs. Nield thereby increasing
the risk of harm, causing injury and unnecessary pain and suffering to Mrs. Nield, as
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well as MRSA infection.

Larsen AjJ., Exh. R, p. 10-11.

16. Additionally, Dr. Selznick concluded that due to PCRC's actions and omissions in
transmitting MRSA and PA to Judy, Judy had to have her left legmnputated below the knee, surgery
on her right hip. See Dr. Selznick AjJ.,

~~

4-10.

ARGUMENT
A.

JUDY CONTRACTED MRSA AND
PRECLUDING SUMMARY JUDGMENT.

PA FROM PCRC THEREBY

1.

Standard of review in medical malpractice cases.

Pursuant to IRCP 56( c), summary judgment is appropriate, "if the pleadings, affidavits, and
discovery documents on file with the court, read in a light most favorable to the nonmoving party,
demonstrate no material issue of fact such that the moving party is entitled to a judgment as a matter
oflaw." Cramer v. Slater, 146 Idaho 868, 873, 204 P.3d 508,513 (2009)(citation omitted). "The
burden of proving the absence of a material fact is upon the moving party. Id. All disputed facts are
to be construed liberally in favor ofthe nonmoving party, and all reasonable inferences that can be
drawn from the record are to be drawn in favor of the nonmoving party. Id. (Citation omitted). "If
reasonable people might reach a different conclusion from conflicting inferences based on the
evidence then the motion must be denied." Id. "If the evidence is conflicting on material issues or
supports conflicting inferences, or if reasonable minds could reach different conclusions, summary
judgment must be denied." !d. (Citation omitted).
As to the issue of proximate cause, the court in Cramer, supra, a medical malpractice case, stated
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the following:
The question of proximate cause is one of fact and almost always for the jury....
[P]roximate cause is one of fact to be submitted to the jury and not a question of law
for the court; if, upon all the facts and circumstances, there is a reasonable
chance or likelihood of the conclusions of reasonable (people) differing, the question
is one for the jury.

Cramerv. Slater, supra, 146 Idaho at 875, 204 P.3d at 515 (2009(citing, Sisters a/the Holy Cross,
126 Idaho 1036, 1041,895 P.2d. 1229, 1234 (Ct. App. 1995)).
A plaintiff is not required, in a medical malpractice action, to prove proximate cause beyond
a reasonable doubt or that such must be proven by expert testimony.

As stated by the court in

Sheridan v. St. Luke's Reg 'I Med. Ctr., 135 Idaho 775, 25 P.3d 88 (2001)
Unlike the elements of duty and breach of duty, there is no statutory requirement
explicitly stating proximate cause in medical malpractice cases must be shown
by direct expert testimony. Therefore, testimony admissible to show proximate
cause in a medical malpractice case, like any other case, is governed by the rules
of evidence regarding opinion testimony by lay witnesses and experts under Idaho
Rules of Evidence 701 and 702.

Sheridan, supra. Further, the court held:
Furthermore, according to our precedent, proximate cause can be shown from
a "chain of circumstances from which the ultimate fa<:::! required to be
established is reasonably and naturally inferable.

***

[A plaintiff] was not required to prove his case beyond a reasonable doubt, nor
by direct and positive evidence. It was only necessary that he show a chain of
circumstances from which the ultimate fact required to be established is
reasonably and naturally inferable. "If the rule oflaw is as contended for by
defendant and appellant, and it is necessary to demonstrate conclusively and
beyond the possibility of a doubt that the negligence resulted in the injury, it would
never be possible to recover in a case of negligence in the practice of a profession
which is not an exact science. [Internal citations omitted].

Sheridan, supra.
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2.

Judy can and has established she did not have MRSA or P A prior to her
admission to PCRC.

As the expert opinions of Dr. Selznick, Dr. Gerber, and Suzanne Frederick clearly establish,
Judy contracted MRSA and PA from PCRC. As a reminder, summary judgment is not appropriate
where there are affidavits or opinions from which reasonable minds could conclude or reach different
conclusions. Further, under the summary judgment standard, the court is precluded from weighing
the evidence and is to accept all facts offered by Judy, as well as the opinions from her experts, as
true, and to look at the facts posed by and opinions held by PCRC experts as not true. Given that
Judy's treating doctor and expert, Dr. Selznick, concluded that Judy contracted MRS A and PA from
PCRC, PCRC is not entitled to summary judgment.

3.

PCRC's motion is based on speculation as to whether Judy "could" have been
MRSA or PA positive/carrier when she was admitted to its facility, that she may
have had the infections in her wounds or contracted it from another source

PCRC offers the speculative opinions from their key expert, Dr. Coffinan, who testified that
he could not rule out where Judy contracted MRSA, and in his affidavit that he did not know when,
where or how Judy acquired MRSA and PA. Summary Judgment is not allowed based on the
supposition of Dr. Coffinan. 2
PCRC offers no evidence showing it they tested Judy to determine ifshe was colonized with
MRSA or P A prior to or during her stay at its facility. PCRC offers no evidence to show that the
screening done prior to her admisstion to its facility "may" have proven a false negative or fails to
show that each wound was tested. PCRC fails to offer any evidence in the record to support its
supposition that Judy "could" have acquired MRSA or PA from a visitor or from PortneufMedical

2Judy incorporates herein by reference her Memorandum in Support of Motion to Strike
Affidavit of Dr. Coffman, filed concurrently with this Memorandum.
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Center. Again, PCRC certainly had the ability to screen or test Judy to rule out whether she was
MRS AlP A colonized or positive upon her admission to its facility but did not do so.
It is axiomatic that the defendant asserting an affirmative defense has the burden of proving

the defense. See, Chandler v. Hayden, 147 Idaho 765, 771, 215 P.3d 485, 491 (2009)(nonmoving
defendant has the burden of supporting a claimed affirmative defense on a motion for summary
judgment). Further, as IRCP 56(e) requires evidence be admissible before the court can consider
such in deciding a motion for summary judgment. IRE 401 and 402 preclude the Court's
consideration ofPCRC's speculation and supposition.

IRE 401 provides:

"Relevant Evidence" means evidence having any tendency to make the existence
of any fact that is of consequence to the determination of the action more probable
or less probable than it would be without the evidence.
Further, IRE 402 requires the exclusion of irrelevant evidence:
All relevant evidence is admissible except as otherwise provided by these rules or
by other rules applicable in the courts of this state. Evidence which is not relevant
is not admissible.
Here, PCRC asserts its affirmative defense, albeit based on pure speculation, that Judy may have
been MRSA/P A positive or colonized or acquired MRSA and PA from other people or entities.
PCRC offers no evidence Judy was MRSA or PA colonized prior to her admission there, nor any
evidence Judy acquired the infections elsewhere. PCRC's administrator admitted in deposition that
PCRC did not do an investigation as to how Judy acquired MRSA or PA. PCRC did not test Judy
at any time prior or during her stay. All ofthis was confirmed by PCRC' s own expert, Dr. Coffinan,
who admitted he cannot determine "when, where or how Judy became infected with MRSA or
pseudomonas. "
The evidence in the record, as concluded by Dr. Selznick and Mr. Gerber and Ms. Frederick
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supports the conclusion Judy contracted MRSA and PA due to PCRC's conduct and/or omissions.
Her preadmission testing showed her to be negative for MRSA and PA. The evidence shows PCRC
and its nursing staff did not follow proper infection prevention procedures. The evidence shows
Judy was housed near MRSA and PA infected residents while she was there. At the very least,
summary judgment is not appropriate.
Again, taking as true what Judy and her experts' facts and opinions are, which the court must
do under summary judgment, it is clear summary judgment should not be allowed. It is up to the jury
to decide the issue ofwhether Judy contracted MRSA and PA from PCRC and as a result ofPCRC's
negligence and breach of the standard of care.

B.

JUDY HAS ESTABLISHED SHE WAS INFECTED AND/OR COLONIZED
WITH MRSA AND PA DUE TO PCRC'S NEGLIGENCE AND BREACH OF
THE STANDARD OF CARE.

Again, as all of Judy's experts opined, Dr. Selznick, Mr. Gerber, and Ms. Frederick, Judy
contracted MRSA and P A from PCRC. See Dr. Selznick Affidavit, September 18, 2009 report, pp.
13-18; Gerber AfJ., Gerber Report, pp. 6-9, and Frederick Reports, Exhibit R to the Larsen AfJ., pp.

9-13. Mr. Gerber and Ms. Frederick concluded, PCRC failed to provide adequately trained staff, and
an adequate number of staff, which resulted in Judy contracting MRSA and PA from PCRC. Again,
Judy's initial requirements at peRC were to have daily wound assessments. PCRC did them weekly
and also incompetently as they failed to properly document the size of the wound, what the wound
looked like, and any other identification of the wound and in the weekly skin assessments and the
ulcer sore sheets. PCRC completely stopped documentation of two ofthe wounds on September 18,
2007, and the largest wound on October 22,2007, a few weeks prior to Judy testing positive for
MRSA and P A. Furthermore, PCRC was found in violation of state and federal standards by the
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Department of Health and Welfare on January 24, 2008. The Department of Health and Welfare
found that the staff at PCRC could not demonstrate proper infection control policies and procedures
when handling patients that had MRSA. Moreover, there is evidence Judy was housed in a room
next to a patient that had MRS A and that there was a P A infected patient at PCRC while Judy was
there. Larsen Affidavit, Exhibits M and N. Judy also testified that she witnessed nurses exiting the
MRSA patient's room without any gloves on or washing their hands. Larsen AjJ., Exh. 0, p. 127,

l. 21 top. 128, t. 13;p. 131, t.14 top. 132, t. 9; p.131, l.10top. 132, l. 9.

Asaresult,summary

judgment must be denied.

C.

DR. SELZNICK OPINED JUDY'S PA INFECTION RESULTED IN HER
RIGHT HIP INFECTION.

Contrary to PCRC's unfounded conclusion, Judy has retained experts, more specifically her
treating physician, Dr. Hugh Selznick, who unequivocally opined that she contracted MRSA and PA
from PCRC. Also, Dr. Selznick concluded that Judy's pseudomonas infection resulted in her right
prosthetic hip infection requiring surgery in May and June of 2008. In that regard, Dr. Selznick
concluded:
It is also my opinion that the right hip joint aspiration confirms pseudomonas which
is also related to Pocatello Care & Rehabilitation Center. It is my opinion
that the colonization of pseudomonas took place during her hospitalization and stay at
Pocatello Care & Rehabilitation Center. It is my opinion the aspiration confirmed
pseudomonas infection of the right hip was indeed related as well to
pseudomonas colonization during her hospitalization at Pocatello Care &
Rehabilitation Center. Again, the 1119/07 left lower extremity would cultures
did grow out moderate pseUdomonas aeruglnosa. It is my opinion that her right hip
two-stage revision surgery should be attributed to Pocatello Care & Rehabilitation
Center hospitalization, colonization and subsequent infection with pseudomonas.
After the two stage revision, she developed recurrent prosthesis right hip infection
and all of that treatment for that condition should be related to her stay and
subsequent infection while at Pocatello Care & Rehabilitation Center.
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Affidavit ofDr. Selznick,

D.

~

6. As a result, PCRC is not entitled to summary judgment.

JUDY HAS PRESENTED EXPERT TESTIMONY ESTABLISHING CAUSATION.
PCRC asserts it is entitled to summary judgment because Judy has no expert testimony from

an infectious disease expert to show PCRC' s conduct or omissions caused her to contract MRSA and
P A. PCRC cites to no case supporting this unfounded position that Judy needs expert testimony
from an infectious disease expert. As stated earlier by the court in Sheridan v. St. Luke's Reg 'I Med.

Clr., 135 Idaho 775, 25 P.3d 88 (2001)
Unlike the elements of duty and breach of duty, there is no statutory requirement

explicitly stating proximate cause in medical malpractice cases must be shown
by direct expert testimony. Therefore, testimony admissible to show proximate
cause in a medical malpractice case, like any other case, is governed by the rules
of evidence regarding opinion testimony by lay witnesses and experts under Idaho
Rules of Evidence 701 and 702.

Sheridan, supra. [Emphasis added]. Further, the court held:
Furthermore, according to our precedent, proximate cause can be shown from

a "chain of circumstances from which the ultimate fact required to be
established is reasonably and naturally inferable.

***

[A plaintiff] was not required to prove his case beyond a reasonable doubt, nor
by direct and positive evidence. It was only necessary that he show a chain of

circumstances from which the ultimate fact required to be established is
reasonably and naturally inferable. "If the rule of law is as contended for by
defendant and appellant, and it is necessary to demonstrate conclusively and
beyond the possibility of a doubt that the negligence resulted in the injury, it would
never be possible to recover in a case of negligence in the practice of a profession
which is not an exact science. [Internal citations omitted].

Sheridan, supra.
Additionally, there is no requirement that Judy have an infectious disease expert. See, Fosler
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v. Traul, 145 Idaho 24,29, 175 P .3d 186, 191 (2007)(there is no requirement that an expert witness
be board-certified in the same specialty as the defendant in a malpractice action)).
PCRC's position is belied by the fact that Dr.

Selznic~a medical

physician who has been

practicing in Idaho since 1993, concluded Judy contracted MRSA and PA from PCRC. PCRC's
position is also ironic, since its expert, Dr. Coffman concluded he does not know where Judy
contracted MRSA or PA and admitted he could not rule out where she got it. The record shows that
Judy has met her burden on summary judgment, and that PCRC's motion should be denied.

CONCLUSION
Based on the foregoing, plaintiff Judy Nield respectfully requests the Court deny PCRC's
Motion for Summary Judgment.
DATED thiSci1f- day of November, 2009.
COOPER &

.!".A~E;;J

,CHARTERED
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Reed W. Larsen, ISB # 3427
Javier L. Gabiola, ISB # 5448
COOPER & LARSEN, CHARTERED
151 North 3rd Avenue, 2nd Floor
P. O. Box 4229
Pocatello, ID 83205-4229
Telephone: (208) 235-1145
Facsimile: (208) 235-1182
Attorneys for Plaintiff

IN THE DISTRICT COURT OF THE SIXTH JUDICIAL DISTRICT OF THE
STATE OF IDAHO, IN AND FOR THE COUNTY OF BANNOCK
JUDY NIELD,
Plaintiff,
vs.
POCATELLO HEALTH SERVICES, INC.,
a Nevada corporation, d/b/a
POCATELLO CARE AND
REHABILITATION CENTER, and
JOHN DOES I-X, acting as
agents and employees of POCATELLO
HEAL TH SERVICES, INC., d/b/a
POCATELLO CARE AND
REHABILITATION CENTER,
Defendants.

)
)
)
)
)

Case No. CV-09-3869-PI

)
)
)
)
)

AFFIDAVIT OF REED W. LARSEN IN
SUPPORT OF PLAINTIFF'S
OPPOSITION TO DEFENDANTS'
MOTION FOR SUMMARY
JUDGMENT

)
)
)
)
)
)
)
)

STATE OF IDAHO )
: ss
County of Bannock )
I, REED W. LARSEN, being first duly sworn on oath, depose and state as follows:
1.

I am Plaintiff Judy Nield's attorney and make this affidavit upon my own personal

knowledge and information.
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2.

Attached hereto as Exhibit A is a copy of Judy Nield's discharge summary and

medical records from PortneufMedical Center from August 21 to 25,2007.
3.

Attached hereto as Exhibit B is a copy of wound cultures and tests taken of Judy

Nield at PortneufMedical Center on August 21,2007.
4.

Attached hereto as Exhibit C is a copy of Pocatello Care and Rehabilitation Center's

records of admission.
5.

Attached hereto as Exhibit D is a copy of Resident Care Plan Skin Integrity, Actual

or Potential records from Pocatello Care and Rehabilitation Center.
6.

Attached hereto as Exhibit E are Non-Pressure Ulcer Site Sheets and weekly skin

assessment records of Judy Nield from Pocatello Care and Rehabilitation Center.
7.

Attached hereto as Exhibit F is a copy ofthe reports of Suzanne Frederick dated April

19,2010, and June 10,2010.
8.

Attached hereto as Exhibit G is a copy of the transcript of the deposition of Joyce

Maxfield.
9.

Attached hereto as Exhibit H is a copy cultures tests from PortneufMedical Center

dated November 9,2007.
10.

Attached hereto as Exhibit I is a copy of Pocatello Care and Rehabilitation Center's

Infection Control Policy and Procedure Manual.
11.

Attached hereto as Exhibit J is a copy of the deposition transcript of LaRee Dunn.

12.

Attached hereto as Exhibit K is a copy ofthe deposition transcript of Marjorie Brim.

13.

Attached hereto as Exhibit L is a copy of excerpts from the Department of Health and

Human Service's survey dated January 24, 2008.
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14.

Attached hereto as Exhibit M is a copy of a letter from the Idaho Department of

Health and Welfare to Derrick Glum, former Administrator of Pocatello Care and Rehabilitation
Center dated February 19,2008.
15.

Attached hereto as Exhibit N is a copy of a deposition transcript of Judy Nield.

16.

Attached hereto as Exhibit 0 is a copy of a deposition transcript of Dr. Jeffrey

Coffman.
FURTHER SAITH AFFIANT NAUGHT.

------

"

SUBSCRIBED AND SWORN TO before me this

(SEAL)

J.1if

day of November, 2010.

NOTARY PUBLIC FOR IDAHO
Residing at: t3cvvvvu-ti. C-o
My Commission expires: t I - 0. Is, , 13
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day of November, 2010, I served a true and correct
copy of the above and foregoing document to the following person(s) as follows:
Keely E. Duke
Chris D. Comstock
Hall, Farley, Oberrecht & Blanton
P.O. Box 1271
Boise, ID 83701

rr-

[]
[]
[]

u.s. Mail/Postage Prepaid
Hand Delivery
Overnight Mail
Facsimile: 208-395-8585
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PORTNEUF MEDICAL CENTER
651 Memorial Drive
Pocatello, Idaho 83201
(208) 239-1000
DISCHARGE SUMMARY
PT NAME: NIELD, JUDY
PT AGE: 65Y
PT DOB:
ADMIT:
08/21/2007
DISCH:
08/25/2007
ATTN PHYS: JONATHAN CREE, M.D.

ATTENDING PHYSICIAN:

ROOM:
MR:
ACCT:
DD:
TD:
DT:

MS-0003-1
125192
3865462
08/25/2007
1235
08/27/2007

DR. DAN JONES; DR. JONATHAN CREE

PRIMARY CARE PHYSICIAN:

None.

DISCHARGE DIAGNOSES
1.
Left lower extremity cellulitis.
2.
Right hip pain.
3.
Left hip dislocation.
4.
Newly diagnosed diabetes.
5.
Hypothyroidism.
6.
Hypertension.
PAST MEDICAL HISTORY
1.
DVT one year ago in the left leg.
2.
Bilateral hip replacements.
ALLERGIES
No known drug allergies.
DISCHARGE MEDICATIONS
1.
Colace 100 mg p.o. two times daily for constipation.
2.
Synthroid 0.05 mg p.o. daily for hypothyroidism.
3.
Lovenox 40 mg subcutaneously daily for DVT prophylaxis.
4.
Naprosyn 500 mg p.o. two times daily p.r.n. pain.
5.
Lantus 20 units subcutaneously every night for diabetes.
6.
Cephazolin 1000 mg IV every 8 hours times six weeks for cellulitis.
7.
Morphine 2 to 4 mg IV every 2 hours p.r.n. pain.
8.
Phenergan 6.25 mg IV every 4 hours p.r.n. nausea.
9.
Metformin 500 mg p.o. every night for diabetes.
FOLLOWUP INSTRUCTIONS
Orthopedics consult for applying definitive management of prosthetic
joints. M.D. will call.
CONSULTATIONS
Dr. Newhouse, Orthopedics
PROCEDURES
Fluoroscopic-guided right hip arthrocentesis.
EXHIBIT

A

CONTINUED
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DISCHARGE SUMMARY
NAME:
ADMIT:

NIELD, JUDY

MR: 125192

08/21/2007

DD: 08/25/2007
DT: 08/27/2007

PAGE 2

CONTINUED

DIAGNOSTIC TESTS
X-ray AP pelvis and lateral right hip show shallow acetabular
configuration with uncovering of the lateral stent component
arthroplasty.
No acute fracture or dislocation involving right hip.
AP
film which also reveals a fracture dislocation involving the left hip
with superior dislocation of the femoral component and displacement at
the level of the acetabular fracture.
HISTORY OF PRESENT ILLNESS
This pleasant 65-year-old Caucasian female presents to the Emergency
Room with worsening oozing and redness of her left lower extremity.
She
had a history of a DVT in this left leg approximately one year ago.
She
states that she had an ulceration over this leg and that she had popped
it approximately three months ago. Apparently this leg is swollen at
this time, but it is normally swollen seconaary to this history of DVT
that she had.
The patient took Coumadin for six months and then stopped
for treatment of DVT. The patient denies any fevers or chills. She
basically has no pain in this area, but she attributes that to she has
no feeling in the left lower extremity at alL secondary to her hip
replacement in the past. She also does report a little bit of back
pain, but this is nothing new.
HOSPITAL COURSE
The patient was admitted to Med-Surg overflow and placed on contact
isolation in case she had MRSA. She was placed on IV antibiotics and
improved considerably. She had her pain controlled with morphine and
Naprosyn.
Wound culture of the left lower extremity grew out klebsiella
sensitive to Ancef; this is the IV medication that she will be placed on
long-term for this infection. Also, an aspiration of the right hip
showed only white blood cells but did not grow any bacteria.
Blood
cultures were negative for any organisms times two. The patient had a
hemoglobin Ale that showed an elevated level of 6.6%. I did start her
on Lantus and a mild sliding scale of NovOLog, and her sugars improved.
I believe that she is an undiagnosed diabetic and will start her on
metformin for her time over at the skilled nursing facility.
I believe
Lantus and metformin will be a good combination for her to control her
blood sugars.
She does need to have her left and right hip
arthroplasties revised as they are unstable, and actually her left hip
is completely dislocated. She is non-weightbearing at this time, and
she does need revision of these types of arthroplasties at the
University of Utah as we are not able to do those here.
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DISCHARGE SUMMARY
NAME:
ADMIT:

NIELD, JUDY
08/21/2007

MR:

125192

DD; 08/25/2007
BT: 08/27/2007

CONTINUED

PAGE 3

We will get a hold of Orthopedics here to help us to make this referral
happen. f'V(\S P; S ~~d1'.re..

----~MMERMANN, MD

\

:

fx;

lh

/:
374
JOB: 278354

KENNETH E. NEWHOUSE, M.D.

(00975)

>

565

566

3:36 08/£2/2007
POFTNEUF MEDICAL CENTER
651 Memorial Drive
Pocatello, Idaho 83201
(208)

239-1000

HISTORY AND PHYSICAL

----------------------------------------------------------------------PT NAME: NIELD, JUDY
FOOM: MS-0003-1
ADMIT:
08/21/2007
DISCH:
ATTN PHYS: JONATHAN CREE, M.D.
PT DOB:
PT AGE: 65Y

MR:
ACCT:
PT TYPE:
DD:
TD:
DT:

125192
3865462
I
08/21/2007
1924
08/22/2007

CHIEF "COMPLAINT
Left leg infection.
HISTORY OF PRESENT ILLNESS
The patient is a 65-year-old female with a previous history of DVT with
.chronic edema and some ulceration in her left lower extremity as well as
being insensate from the knee down, who presents to the Emergency Room
with worsening oozing and redness in her left lower extremity.
The
patient reports that approximately three months ago, she had a clear
blister posteriorly of her distal lett lower extremity.
They popped the
ulceration, and since then that araa has been getting progressively
worse and has proceeded to move around toward the front.
The patient
reports that her leg is normally incredib,ly swollen.
Today it is much
better as she was on her back with per leg elevated all day yesterday.
The swelling has been going on since the DVT she had approximately one
year ago in this left leg.
The patient was on Coumadin for six months
and then requested not to be on it any longer. The patient denies any
fevers.
The patient has no pain in this area, so denies any pain.
Again she has no feeling, so no numbness or tingling in that area.
The
patient denies any weakness, any weight changes.
The patient has a
bilateral hip prosthesis and does report increased pain in her right hip
prosthesis and that is why she was actually on her back yesterday was
because of the pain in this right hip.
The patient has been having Home Health come for the last week or so to
help with dressing changes and the patient reports that approximately
four to five weeks ago, she was on antibiotics for a few days.
They
were leftover antibiotics that she had from a dental procedure
previously.
PAST MEDICAL HISTORY
Remarkable for the DVT as stated above, hypothyroidism, and the patient
has had bilateral hip replacements.
The patient has not had any
colonoscopies or colon cancer screening.
SOCIAL HISTORY
The patient is widowed. She lives alone.
She has about a 15 pack/year
history of tobacco in the distant past and has occasional alcohol use.
CODE STATUS
DNR/DNI.
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MEDICATIONS
The patient is on.
1.
Hydrocodone 10/325 p.o. every 4 hours p.r.n. pain.
2.
Diclofenac 50 mg p.o. every day for pain.
3.
Levothyroxine 50 mcg p.o. daily.
FAMILY HISTORY
No blood clots in the family history. The patient reports that her
mother had colon cancer in her mid-30's.
ALLERGIES
No known drug allergies.
REVIEW OF SYSTEMS
The p\atient has been in a wheelchair for approximately the last three
months due to the swelling and pain and difficulty walking due to the
feel~ng in this left leg and weakness and pain in the right leg.
The
patient denies any weight changes.
The patient denies any night sweats,
any weakness, any chest pain, any shortness of breath, no cough.
/

PHYSICAL EXAMINATION
VITAL SIGNS; Temperature 98.8, pulse 96, blood pressure 165/83,
respirations 20 and the patient was satting 95% on room air.
GENERAL: The patient is in no acute distress.
She is awake, alert, and
oriented. She is pleasant and cooperative during the exam.
HEENT:
Pupils are equal, round, and reactive to light and
accommodation.
Sclerae and conjunctivae are normal.
Mouth and pharynx
are without lesions or exudate.
Tympanic membranes were unable to be
visualized bilaterally due to cerumen. Hearing to finger rub was
intact.
NECK:
Soft and supple, no lymphadenopathy, no thyromegaly, no carotid
bruits.
HEART:
Regular rate and rhythm, no murmurs, rubs, or gallops.
LUNGS: Clear to auscultation, no wheezes, rales or rhonchi.
ABDOMEN:
Abdomen appeared to be mildly distended, was nontender, no
peritoneal signs.
EXTREMITIES; The patient had trace pitting edema in the left lower
extremity.
The patient was insensate from approximately the knee down.
The patient from the mid-shin down had erythema, but no warmth. There
was superficial ulcerations around much of the distal lower leg. The
largest being posteriorly, approximately 6 to 7 cm.
There was
granulation tissue and vascular tissue on all of these. There were some
areas of oozing and it was a clear to yellowish serous discharge.
Pulses were present bilaterally at the posterior fibula and posterior
tibia and dorsalis pedis. Sensation was intact everywhere other than
this left lower extremity.
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LABORATORY
White count was 7.6, hemoglobin 13.7, hematocrit 40.6, platelets 229.
BMP revealed a glucose of 177, creatinine 1.0, and electrolytes were
fine.
The patient's albumin was a little bit lbw at 3.1.
The rest of
her liver function tests were otherwise normal.
The patient had a venous and arterial ultrasound of her left extremity.
The arterial ultrasound showed an abnormal wave form consistent with
proximal arterial disease, likely at the iliacs or distal abdominal
aorta.
The venous ultrasound showed disease in the common femoral vein
.consistent with a chronic DVT.
ASSESSMENT AND PLAN
1. Left lower extremity cellulitis. I believe that there is a
cell~litic component to the patient's infection.
However, I believe
tha~ is not the greatest component.
The patient has chronic edema
ulcerations on and off, most recently-for the last three months.
The patient has arterial and venous disease and so this is more of a
picture of arterial and venous disease. However, given the
pat{ent's poor circulation, she is at high risk for infectious
disease and I suspect that there is some component of infectious
disease here. The patient also has elevated sugar, so it is a worry
that the patient may be a diabetic or borderline diabetic and also
has bilateral artificial hips. Given all of this, I feel that it
would be in the patient's best interest to be admitted for IV
antibiotics at least until cultures are back. We will admit the
patient on Primaxin 500 mg every 8 hours IV, as well as Vancomycin 1
gram every 24 hours IV.
Wound and blood cultures were sent in the
Emergency Room.
The patient h~s been seen in the past by
hyperbarics. Hyperbarics will be consulted for further evaluation
of this wound and in preparation for further outpatient treatment.
2.
Right hip pain.
It is unlikely being that the patient is afebrile
and has a normal white count that the patient has seeded one of the
artificial joints. However, I will check an ESR and a CRP.
If
these are normal. that will be very reassuring.
I will also check
an x-ray of this right hip to look for any signs and symptoms of
inflammation or instability there.
3. Elevated sugars.
If the patient had more signs of this being a
systemic infection, could easily be ascribed to that.
However,
those were not present.
If the ESR is normal, it makes these sugars
more worrisome.
I will check a hemoglobin Alc and check a fasting
glucose in the morning with a BMP for further evaluation of this.
4. Hypothyroidism.
The patient will continue on her outpatient dose
and a TSH will be checked in the a.m.
5.
Hypertension. The patient does not have a diagnosis of
hypertension, but had blood pressure up to 165/83. This will
continue to be followed in the hospital and if it continues to be
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antihypertensive at discharge or possibly with fol10wup as an
outpatient.
Prophylaxis. The patient is at high risk for deep venous thrombosis
havi~g had a previous deep venous thrombosis and has poor flow in
this left leg. The patient will be given Lovenox 40 mg subcu daily.
The patient is low risk for gastrointestinal prophylaxis, so a
proton pump inhibitor will not be prescribed.
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CONSULTATION REPORT

PT NAME: NIELD, JUDY
PT DOB:
ADMIT:
DISCH:

--_._-----------------------ROOM: t4S-0QC3-1
KP.. : :.25192
ACCT ..: 3865462

PT AGE: 65Y

08/21/2007

PT TYPE:

~

08/23/2007
TD: 1441
DT : 0 8 / 2 3 12 0 0 7
DD:

CONSULTING PHYSICIAN: KENNETH E. NEWHOUSE, M.D.
REQUESTING PHYSICIAN:
_.. _ _ _ ._. .DATE OJ" CONSULTATIObJ:

08123/2007

IDENTIFICATION
A 65-year-old female.
"

CHIEF'COMPLAINT
Cellulitis and right hip pain.
HISTO~Y

The patient does have a fairly long complicated history in .which she h.c..d
bilateral total hip replacements done! approximats~.y.: 1.3. yea.rs age done by
Dr. William Mott, now deceased.
., ....
The
hip
has
and

patient evidently had some sort of sciatic nerv~ injury to the left
at or around the time of surgery and since the time of surgery she
had difficulty with feeling in her left leg and moving her ankle up
down.

The patient was ambulatory until about two years ago when she evidently
Iell coming out of a grocery store.
She was at that point seen and
evaluated by Dr. B.J. Blair.
The patient states she had radiographs of
her spine.
She is not $ure if she had radiographs of her hip but was at
any rate given a reasonably clean bill of health and did reasonably well
until about three month$ ago when, without any type of insult or ir.jury
whatsoever, she lost che ability to ambulate.
She has evidently been dealing with chronic cellulitis in he= lower
extremities, treated with hyperbarics, p.o. antjbiotics and the like.
She presented to the hospital approximately 36 hours ago with increasipg
pain and soreness in her right hip as well as increasing ce!l~~itis.
She was admitted to the hospital and started on IV antibiotics.
I was
consulted approximately 21 hours after her admission b¢cause of right
hip pain.
Radiographs had been obtaineo (they were not evaluated by a
clinician at that point).
I waS asked to see her, wondering whether or
not her right hip could be infected.
The patient'~ past medical history is well documented in the clinic
notes but from an orthopedic standpoint again, she says she has not
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ambulated for approximately three months and she states she really is
not having no pain at all in her left leg.
Examination of her left leg shows the left leg is at least 2 inches
shorter contrary to her right leg and general range of motion causes her
very little discomfort.
She has a fair amount of cellulitis and open
blistering of her left lower extremity.
It should also be noted she has
essentially no sensation in her left foot and calf area.
Examination of the right leg shows she is grossly neurovascular intact.
She has much less cellulitis and open areas on the right leg but has
fair amount of pain both laterally and anteriorly with range of motion
of her hip.
Radiographs were reviewed.
The radio~raphs consist of an AP pelvis. The
patient has a fracture dislocation of her left total hip replacement.
The cup has been disassembled from the native acetabulum and there is a
central acetabular fracture.
The hip is dislocated with the femoral
h~d slttlng at least two~nches proximal to the native acetabulum.
There also appears to be some loosening of the right hip acetabular
component but the hip is grossly~located, the cup is somewhat vertical.
This is a difficult problem that I believe the patient has what appears
to be a Charcot left leg and at least a chronic dislocation and intury
to this w[thout any evidence of trauma whatsoever.
The patient could also have seeded both of her hips, the left and the
right, with her cellulitis and is now complaining of pain and loosening
of the right hip.
On the other hand, she simply could have a loose
acetabulum which could be causing her discomfort.
Antibiotics are started prior to any type of aspiration and therefore
any aspiration studies we get are equivocal.
On a positive note, the patient is not septic at this point.
I think medical management at this point should consist of continuing
with antibiotics but I have recommended last evening, when I saw the
patient, aspiration of her hip. At the time of this dictation this
still has not been done yet.
This is scheduled.
Unfortunately the results of this aspiration are going to be compromised
because of starting the antibiotics.
However, if we obtain a
considerable amount of white blood cells we can assume that the hip is
infected.
Unfortunately, if the hip is infected I think the only option would be~
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the other side and the fracture is noted in the disassembly of the
components, this would basically give her no lower extremity on which
she can stand.
with respects ~o operative treatment for the left leg this would be
difficult.
Revision could be performed but given the fact that she has
a Charcot leg she very likely may end up with similar circumstances in
the future.
In any event, I think this should probably be done by a total joint
revision specialist. We will await the aspiration results and discuss
this further.
I have discussed this case at length with Dr. Routson as well as Dr.
Zimmerman and they concur wi th this plan. "

--------------~-------------

KENNETH E. NEWHOUSE, M.D.
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LABORA.TORY
~Thite count was 7.6, hemoglobin 13.7, hematocrit 40.6, platelets".229.
aMP revealed a glucose of 177, creatinine 1.0, and £lectrol~te~ we~e
fine. The patient's albumin was a little bit l'ow at 3.1. The res.t c:':
her liver function tests were otherwise normal.
The pati£nt had a venous and arterial ultrasound of her left e~tremity.
The arterial ultrasound showed an abnormal wave form consistent with
proximal arterial disease, likely at the ~liacs. or distal abdominal
..
aorta. The venous ul trasound Showed disease .in the .common :: ell'~l': '.l ~
. .
.. consistent with a chronic DVT.
. .- ...-."
ASSESSMENT AND PLAN
1.
Left lower extremity cellulitis. I believe that there 'is a
cellulitic component ~(l the patient's infection. How·eve'!··; I :;:"e::'ie'le
that is not the grea~est component. The patient has chronic edema
ulcerations on and off, most recently for th.e last three months.
The patient has arterial and venous disease and so this is more of a
picture of arterial and venous disease. However, given the
patient's poor circulation. she is at high risk for infectious
disease and ! suspect that there is some component of infectious
disease here. The patient also has clevated sugar, so it is a wo~~y
that the patient may be a diabetic or borderline diabetic and e~so
has bilateral artificial hips. Given all of this, I feel that it
would be in the patient's best interest to be admitted for IV
antibiotics at least until cultures are back. We will admit the
patient on Pr.imaxin 500 mg every 8 hours IV, as well as vancomycin 1
gram every 24 hours IV. Wound and hlood cultures we=e sent in :h~
Emergency Room.
The patient has been seen in the pes.:: by
hyperbarics. Hyperbarics will be consulted fo::: fu:::!::he.r ~val\l.<!t.:'~,:
of this wound and in preparation for further outpatient treatment.
2. Right hjp pain. it is unlikely being that the patient is afebrile
and hus it normal white count that the patient has seeded one of the
artificial joints. However, I will check an ESR and a CRP. If
these are normal, that will be very reassuring.
I will also check
an x-ray of this right hip to look for any signs and symptoms of
inflammation or instability there.
3. Elevated sugars. If the patient had more signs of this being a
systemic infection, could casi.1y be ascribed t.o that. However,
those were not prosent. 2f the ESR is normal, it makes these sugars
more worrisome. I will check a hemoglobin Alc and check a fasting
glucose in the morning with a BMP for further evaluation of this.
4. Hypothyroidism. The patient will continue on her outpatient dose
and a TSH will be checked in the a.m.
5. Hypertension. The patient does not have a diagnosis of
hyp~Ttension, but had blood pressur~ up to 165/83. This will
continue to be followed in the hospital and if it contin~es ~c ~e
elevated, the pain will likely need to be started on a~
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antihypertensive at discharge or possibly with followl.:p as a:'.
6.

ou tpa tient.
Prophylaxis.

The patient is at high risk for deep venous thrombosis
having had a previous deep venous thrombosis and has poor flow in
this left leg. The patient will be given Lovenox 40 mg subcu daily.
The patient is low risk for gastrointestinal prophylaxis. so a
proton pump inhibitor will not be prescribed.
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MS-OOU3-1
125192
386 S4 62
I
08/21/2007
1924.
08/22/2007

CHIEF COMPl,A:tNT

Left leg infection.
','

/

HISTORY OF PRESENT ILLNESS
The patient is a 65-year-old female with a previous history of DVT with
chronic edema and some ulceration in ber left lower extremity' as "/el: as
being insensate from the knee down. who presents to the Emergency th)pm
with worsenipg oozing and redness in ber. left lower extrem:ty, The
patient reports that app.oximately three months ago. she had e clea=
blister posteriorly of her distal left lower extremity.
They popp~d the
ulceration, and since tben that area has been getting progressive~y
worse ana. has proceeded to move around toward the front.
The patient
reports that her leg is normally incredib~swollen.
Today it is muer.
better as she was on her back with her leg elevated all day yesterday.
The swelling has been going on since the DVT she had approximately one
year ago in this left leg. The patient was on Coumadin for six months
and then requested not to be on it any longer. The patient denies any
fevers.
The patient has no pain in this area, so denies any pain.
Again she has no feeling, so no numbness or tingling in that area.
The
patient denies any weakness. any weight changes.
The patient has a
bilateral hip prosthesis and does report increased pain in her right hip
prosthesis and that is why she was actually on ber back y~sterday was
because of the pain in this right hip.
The patient has been having Home Health come for the last week 0= so to
help with dressing changes and the patient reports that approximately
four to five weeks ago, she was 00 antibiotics for a few days. -:'.hey
were leftover antibiotics that she had from a dental
previously.

procedu~€

PAST MEDICAL HISTORY
Remarkable for the DVT as stated above. hypothyroidism. and the patient
has had bilateral hip replacements.
The patient ha~ not had any
colonoscopic~ or colon cancer screening.
SOCIAL HISTORY
The patient is widowed. She lives alone.
She has about a 15 pack/yca=
history of tobacco in the distant past and has occasional alcohol use.
CODE STATUS
DNR/DN1.
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CONTINUED
MEDICATIONS
The patient is on.
1.
Hydrocodone'10/325 p.o. every 4 hours p.r.n,. pain.
2.
Diclofenac SO mg p.o. every day for pain:.:"', "
3.
Levothyroxifie 50 mcg p.o. daily.
~~ ~
:. ,'::

':;..:;

FAMILY HISTORY
No b).ood clots in the family history.
The patient reports that her
mother had colon cancer in her mid-30's.
ALT..ERGIES
No known drug allergies.

REVIEW OF SYSTEMS
The patient has been in a wheelchair for approximately the last three
months due to the swelling and pain and difficulty walking diie to ,th-s
feeling in this left leg and weakness and pain in the right leg.
The
patient denies any weight changes.
The patient denies any night swea~s.
any weakness. any chest pain. any shortness of breath, no coug~.
PHYSICAL EXAMINATION
VITAL SIGNS: Temperature 98.8. pulse 96, blood pressur'e 165/83,
respirations 20 and the patient was satting 95% on room air.
GENERAL: The patient is in nO acute distress.
She is awake, alert, ana
oriented. She is pleasant and cooperative during the ~~am.
HEEN~:
Pupils are equal. round, and reactive to light and
accommodation. Sclerae and conjunctivae are normal.
Mouth and pharynx
are without lesions or exudate. Tympanic membranes were unable to be
visuali~ed bilaterally due to cerumen.
Hearing to fi,nger rub was
intact.
NECK:
Soft and supple, no lymphadenopathy, no thyromegaly, no carotid
bruit.s.
HEART:
Regular rate and rhythm. no murmurs. rubs. or gallops.
LUNGS: Cl~ar to auscultation, no wheezes. rales or rhonchi.
ABDOMEN: Abdomen appeared to be mildly distended. was nontende~, no
peritoneal signs.
EXTREMITIES: The patient had tr~ce pitting edema in the left lower
extremity. The patient was insensate from approximately the knee dO"'/~.
The pat.ient from the mid-sh:i.n down had erythema, but no warmtb. The:::-~
WaS superficial ulcerations around much of the distal lowe= leg. The
Itlrgest being posteriorly. approximately 6 to 7 em.
The:::"€: was
granulation tissue and vascular tissue on all of these. ~bere ~e=9 &~~~
areas of oozing and it was a clear to yellowish serous dis=har~i.
Pulses W€re present bilaterally at the posterior fibula a~d pos~eric=
tibia and dorsalis pedis.
Sensation was intact. everywhere other than in
this left lower extremity.
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NIELD, JUDY
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MR:
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PAGE 2

ambulated for. approximately three months and she states she really is
not having no pain at all in her. left leg.
Examination of her left leg shows the left leg is at least 2 inches
shorter contrary to her right leg and general range of motion"" cau.s~s ~e~
very little discomfort.
She has a fair amount of cellulitis and open
blistering of heT. left lower extremity,
It should also be no~ed ste h~5
essentially no sensat.ion in her left foot and calf area.
Examinat.ion of the right leg shows she is grossly neurovascular intact".
She has much less cellulitis and open areas on the right leg but has
fair amount of pain both 1a terally and anteriorly wi th range of motion
of her hip.
Radi.ographs weX'e reviewed.
Th~ radiograph~ consist of an AI' pelvi~:. T~";'i:
patient has a fracture dislocation of her~left total hip r~placcmR=t.
The cup has been disassembled from the native acetabul~m a~d there is a
central acetabular fracture. The hip is dislocated with the =emo=al
head sitting at least two inches proximal/to the native acetabulum.
There also appears to be some loosening of the right hip acetabular
component but the hip is grossly located, the cup is somewhat vertical.
This is a difficult problem that! believe the patient has what appears
to be n Charcot left leg and at least a chronic dislocation and injury
to this without any evidence of trauma whatsoever.
The patient could also have seeded both of her hips, the left and the
right. with her cellulit:is and. is now complaining of pain and loosening
of the right hip,
On the other hand; she simply could ha"e a loosg
acetabulum which. could be causing her discomfort.
Antibiotics are started prior to Qny type of aspiration
any aspiration studies we get a.re equivocal.
On a positive note,

a~d

theT€f~~e

the patient is not septic at this point.

I think medical management at this point should consist of continuing
with antibiotics but I hav~ recommended last ev~ning, when I saw the
patient, aspiration of her hip. At the time of this dictation this
still has not been done yet.
This is scheduled.
Unfortunately the results of this asoi~ation are going to be compromis~d
because of starting the antibiotics,- However, if we obtain a
considerable amount of white blood cells we can assume that the hip i5
i.nfected.
Unfortunately, if the hip is infected I think the only option would be a
two stage exchange. Given the fact that the patient has Charcot h!p o~
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ADMIT:

NIELD, J'UDY
08/21/2007

MR: 125192
DO: 08/23/2007
D'1': 08123/2007

DISCH:
CONTINUED

PAGE 3

the other side and the fracture is noted i.n the disassembly of t!1e
components. this would basically give her no lower extremi ty on whid:
she can stand.
with respects 'to operative treatment for the left leg thi:; would De
difficult. Revision could be performed. but given the fact that she ;"",5
a Cha.rcot leg she very likely may end up with similar CirC'I.lffistances in
the future.

In any event, r. think this should probably be done by a total joint
.__...._____.... __ revision specia.list. We will await the aspiration results and d.iscuss
this further_
I have discussed this case CI.t length with Dr. Routson as well as D!:'.
Zimmerman and they cor-cur with this plan.
I,
~

------------_._--

.~(-----

KENNETH E. NEWHOUSE, M.D.

\ :

fx:
>

db

/:
JOB:

KENNETU E.

ID: 001409310
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278063

TUrF.:

NEWHOUSE, M.D.
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'fiPortneuf
MEDICAL CENTER

EAST CAMPUS
777 HOSPITAL WAY

E5TCAMPVS
,iEMORIAl DR!VE
A..ATELtO, IDAHO 83;>01

CLINICAL LABORA:
COLLEGE OF AMERICAN PATHOLOGISTS CERTIFIED

DOC NO I BOO.)I! (11106)
© I.ITHO PRINT'NG

COpy TO MEDICAL RECORDS

f'OCATELLO, IOArIO SJ2Cl

ATTENDING PHYS:
CREE, JONATHAN

PATIIOI-OGIST:
S.M. SKOUMAL. M.D.

*~

FINAL** REPORTED:
NIELD, JUDY
OS/26/1942(65Y F}

ORDERED BY: MICKELSEN, BRANDON FP-RES
COLLECTED ON: 08/21/2007 @ 21:00

08/~1/2007

23:52 PAGE: 1
MR 125192
BN 3865462
MS

ACCESSION: L0847973

ACC #: L0847973
ANAEROBE CULTURE
Set-up: 08/21/2007 2345
Source: WOUND,LEFT LEG
Status: FINAL
RESULTS
NO ANAEROBES ISOLATED IN 46 HOURS

i

EXHIBIT

i

B

I
H·H1GH

L·LOW

It·SIGNIFlCANT CHANCE FROM PREVIOUS RF.5ULT

UNK·UNKNOWN

582

NA·NOT APPLICABLE

ND·NOT DONE

PND·PENDINC

*·FOOTNDTE
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'8Portneuf
MEDICAL CENTER

WEST CAMPUS

1 MeMORIAL DRIVE
_ATELLO, IDAHO 83201

EAST CAMPUS
777 HOSPITAL WAY
POCATELLO. IDAHO 83201

ATTENDING PHYS:
CREE, JONATHAN

RY

CLINICAL LABO

PAI"HOLOGlST:
S.M. SI<OUMAL. M.D

COLLEGE Of AMERICAN PATHOLOGISTS CERTIFIED

DOC. NO. LB!XXll1 /lllO6l
LITHO PRINTING

COPY TO MEDICAL RECORDS
~*

e

FINAL** REPORTED: 08/21/2007 23:53 PAGE: 1
NIELD/JUDY
MR 125192
OS/26j1942(65Y F)
BN 3865462
MS

ORDERED BY: BRADBURY, ANDREW
COLLECTED ON: 08/21/2007 @ 21:00

ACCESSION: L0847960
............

ACC #: L0847960
WOUND CULTURE
Set-up: 08/21/2007 2345
Source: WOUND, LEFT LEG
Status: FINAL
GRAM STAIN
1+ WBC1S - 1+ GRAM NEGATIVE RODS
1+ GRAM POSITIVE COCCI
RESULTS
MODERATE GRAM POSITIVE COCCI

MODERATE COAG-NEG STAPH SPECIES
MODERATE BETA HEMOLYTIC STREPTOCOCCI, NOT GROUP A,B OR D
(NO FURTHER IDENTIFICATION)
LIGHT GRAM NEGATIVE RODS
LIGHT KLEBSIELLA PNEUMONIAE
ANTIMICROBICS

AMOXICILLIN!K CLAVULANATE
AMPICILLIN
AMPICILLIN/SULBACTAM
AZTREONAM
CEFAZOLIN
CEFTAZIDIME
CEFTRIAXONE
CEFUROXIME
CIPROFLOXACIN
ERTAPENEM
GENTAMICIN
IMIPENEM
LEVOFLOXACIN

PIPERACILLIN/TAZABACTAM

KLEBSIELLA PNEUMONIAE
MIC uG/ML BLD UR
<-=8(4

16
<=8/4
<=8
<=8
<=1
<=8
<=4

<=1
<=2
<=1

<=4
<=2

<=16

TETRACYCLINE
~RIMETHOPRIM/SULFAMETHOX

<=4

<=2/38

S
I
S

S
S
S
S
S
S
S
S
S
S
S
S
S

REPORT CONTINUED ON NEXT FORM

H-HIGH

t·LOW

"·SIGNIFICANT CHANGE FROM PREVIOUS RESULT

UNK-UNKNOWN

584

NA-NOT APPLICABLE

NO-NOT DONE

PND·PENDING

*·FOOTNarE

585

:ONTINUED REPORT

'fiPortneuf
MEDICAL CENTER

NEST CAMPUS

~E

RY

S.M. SKOUMA1.. M.D.

EAST CAMPUS

MEMORIAL DRIVE
IDAHO 83701

r~_ATELLO.

CLINICAL

777 HOSPITAl WAY
POCATELLO. IDAHO 83201

CREE, JONATHAN

DOC NO. LBOCOll (111()6)
C LITHO PRINTING

**~~~~__~~~~~~~~/2007

23:53 PAGE: 2
MR 125192
BN 3865462
MS

NIELD,JUDY
OS/26/1942(65Y F)
..'.::

.~. :~;-r:

ORDERED BY: BRADBURY, ANDREW
COLLECTED ON: 08/21/2007 @ 21:00

ACCESSION: L0847960

Ace

#: L0847960
Set-up: 08/21/2007 2345

WOUND CULTURE
Source: WOUND, LEFT LEG
Status: FINAL

S=Susceptible
I=Intermediate R=Resistant N/R=Not Reported
BLANK=Drug not advisable BLAC=Beta Lac Pos TFG=Thymidine dependant
INTERPRETATIONS BASED ON APPROX. ADULT ATTAINABLE BLOOD/URINE LEVELS.
IB APPEARS IN PLACE OF INTERP W/ORG'S W/KNOWN INDUCIBLE B-LACTAMASES.
S.aureus and Coag neg Staph species tested for Inducible Resistance
to Clindamycin, results reported as MIC interpretation

H·HICH

L·LOW

#·SlGNlfICANT CHANGE FROM PREVlOUS RESULT

UNK·UNKNOWN

586

NA·NOT APPLlCABLE

ND-NOT DONE

PND·PENDING

*·FOOTNOfE
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·Portneuf
MEDICAL CENTER

weST CAMPUS
MEMORIAl. DKIV!:
.••,,1 ellO. IDAHO 03201

EAST CAMPUS
77 J HOSPITAl. WAY

CLINICAL LABORATORY
COLLEGE OF AMERICAN PATHOLOGISTS CERTIFIED

COpy TO MEDlCAL RECORDS

POCATELLO, IDAHO 83201

ATTENDING PHYS:
CREE, JONATHAN

*~

FINAL** REPORTED:
NIELD,JUDY
OS/26!1942(65Y F)

ORDERED BY: CREE, JONATHAN
COLLECTED ON: 08/23/2007 @ 13;30

MISC FLUID CELL COUNT
FLUID TYPE
VOLUME
APPEARAl~CE

**

H-HIGH

#-SIGNIFICANT CHANGE FROM PREVIOUS RF.5ULT

DOC NO LB@n (11106
C LITHO PRINTING

08/~3/2007

ACCESSION:

18:47 PAGE: 1
MR 125192
BN 3865462
MS

L0848712

SYNOVIAL
3

mL

CLEAR

YELLOW, CLOUDY
10250

RBC count
WBC'S
Test performed at: WEST

["·LOW

PATHOLOGIST:
S_M_ SKOUMAI., M.D

3

UNK·UNKlIIowN

588

per uL
uL

NA·NOT APPLICABLE

NO-NOT DONE

(O-25)

PND·PENDING

*-FOOTNOTE

589

'ilPortneuf

CLINICAL LABO

MEDICAL CENTER
ST CAMPUS

EAST CAMPUS

iMORIAL DmvE
POL ....! ELLO. IDAHO 83201

777 IIOSPITAL WAY
POCATELLO, IDAHO 83201

ATTENDING PHYS:
CREE, JONATHAN

RY

COLLEGE. OF AMERICAN PATHOLOGISTS CERTIFIED

COpy TO MEDICAL RECORDS

PATHOI.OGIST;

S,M. SKOLJMAL, M,D.
DOC. NO. L8()(:Oll t lI/Q6J
~ WHO FRINTING

** FINAL**

REPORTED: 08/23/2007 06:59 PAGE: 1
MR 125192
NIELD/JUDY
65Y F}
BN 3865462
MS

ORDERED BY: ZIMMERMANN, RYAN, FP--RES
COLLECTED ON: 08/23/2007 @ 06:00

ACCESSION: L0848159

[If[!~;[l:;.:[:I::.'I'~::;,;:?,i'.• '::';:::.:'::'.':::;~:;l::tr~iji&IS~¥?1~~[,1.!,::::·~;;:j:(:",;~;:.;;::;:::::,:i::;:XW::N:;:;i:i:;~;:iij:~~:;,:,.:,:;
17 . 1
file:?;: mg / dL
(0 . 1 - 0 . 9 )
The assay used in FMC lab has an extended rarig'e. It is therefore
useful for assessing both high sensitive CRP (hsCRP) AND
traditional less sensitive CRP. High sensitivity assays for CRP
may add to the predictive value of other markers used to assess the
risk of cardiovascular and peripheral vascular disease. Low
sensitive CRP may be useful for the detection and evaluation of
infection, tissue injury, inflammatory disorders and associated
diseases.
.
Separate reference ranges are listed with hsCRP and CRP·results.
**- Test performed at: WEST
:';:<-

CRP

H-H1GH

L,LOW

a·SIGNIFICANT CHANGE FROM PREVIOUS RfSULT

UNK·UNKNOWN

590

NA·NOT APPLICABLE

NO·NOT DONE

PND-PENDING

*·FOOTNOTE
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'8Portneuf
MEDICAL CENTER

EAsrCAMpUs

,ST CAMPUS
,[MORtAl DRIVE

po""rEUO. IDAHO R:J201

117 HOSPITAL WAY
POCA1ELLO,IDAH083:>01

ATTENDING PHYS:
CREE, JONATHAN

COLLEGE OF AMERICAN PATHOLOGISTS CERTIFIED

** FINAL**

REPORTED:
NIELD,JUDY
OS/26/1942(65Y F)

'·SlCN1F1CANT CHANGE FROM PREVIOUS RESULT

08/23/2007 17:38 PAGE: 1
MR 125192
BN 3865462
MS

ACCESSION: L084870B

BODY FLUID CULTURE
Source: BODY FLUID, SYNOVIAL
Status: FINAL
GRAM STAIN
2+ WBelS - NO ORGANISMS SEEN
RESULTS
SOURCE IS RT HIP
NO GROWTH IN 24 HOURS
NO GROWTH IN 48 HOURS

L·LOW

DOC NO l6UOOIl (11!116)
@ LITHO PRINTING

COpy TO MEDICAL RECORDS

ORDERED BY; CREE, JONATHAN
COLLECTED ON: 08/23/2007 @ 13:30

H-HiGH

PATHOLOGIST:
S.M. SKOUMAL. M.D.

RY

CLINICAL LA

UNK-UNKNOWN

592

ACC #: L0848708
Set-up: 08/23/2007 1736

NA-NaT APPLICABLE

ND·NaT DONE

PND-PENDING

*-FOOTNOTE
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'8Portneuf
MEDICAL CENTER

EAST CAMPUS

'EST CAMPUS
A£MORIAi. Dl'liVF

PlKATELlO. IDAHO 11,7.01

777 HOSPITAl. WAY
83201

POO.TE:L~O.IDAHO

ATTENDING PHYS:
CREEl JONATHAN

CLINICAL LABORATORY

PATHOLOGIST:

S.M. SKOUMAI.. M.D

COLLEGE Of AMERICAN PATHOLOGISTS CERTIFIED

DOC. NO.lB(XX)11111106

COpy TO MEDICAL RECORDS

Q LITHO PRINTING

** FINAL** REPORTED: 08/23/2007 17:38 PAGE: 1
MR 125192
NIELD, JUDY
OS/26/1942(65Y F)
BN 3865462
MS

ORDERED BY: ZIMMERMANN, RYAN, FP--RES
COLLECTED ON: 08/23/2007 @ 16:05

ACCESSION: L0848620

ANAEROBE CULTURE
ACC #: L0848620
Set-up: 08/23/2007 1736
Source: JOINTIHIP
Status: FINAL
RESULTS
SOURCE IS RT HIP
NO GROWTH ANAEROBICALLY IN 48 HOURS

I-HIGH

L·I.OW

"·SICNIFICANT CHANGE FROM PREVIOUS RESULT

UNK·UNKl\OWN

594

NA-NOT APPLICABLE

NO-NOT DONE

PND,PENDING

*·FOOTNOTE
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PO

~LLO

CARE & REHAB CEN

Date: 08/31/07
Time: 10 =53: 15

Record of Admission
Middle Last Name
NIELD

First Name
JUDY
Admit # 1

Gen F

Age 65

BirthDate

Race White

Insert

M/S M

Phone (208)237-4079

Address
260 ADAMS STREET
City

ST Zip Code
ID 83202
-

CHUBBUCK

Soc.Sec.1t

Admit Date
08/25/07 14:00

ReAdm.i.t Date
:
/ /

Payor
MEDICARE A

edicaid 1/

PLACE OF BIRTH:

PRIOR STAY

RELIGION

OTHER INSURANCE

OCCUPATION

POLICY ft

ADMIT FROM:
PMC

AUTHORIZATION It

QUALIFYING STAY
08/21/2007
08/25/2007
Phone
(208)282-4700
F(208) 282-4696

Return Date

/

:

/

:

Care Level
Skilled

MCR PART D

-

Attending Physician
JONES, DANIEL
~ternate Physician

Photo

M/R #
223538

Address
465 Memorial Dr

St.

City
Pocatello

Zip_
83201
ID

.

Hospital
Funeral Hom.e

/

Dentist
Pha:rm.acy
Ambulance
Prim.ary Contact
Barbara Larson
Friend

H(208) 232-5320

Financial Contact
Judy Nield
Self

H(208) 237-4079

260 ADAMS STREET

ID 83202

Chubbuck

Contact

~dmitting

Diagnosis
682.6 - CELLULITIS OF LEG *** 835.00 - DISLOCAT HIP NOS-CLOSED *** 719.7 DIFFICULTY IN WALKING *** 250.00 - DIABETES MELLITUS WITHOUT MENTION OF
COMPLICATION, *** 244.9 - HYPOTHYROIDISM NOS *** V57.1 - PHYSICAL THERAPY NEC ***
VS7.21 - ENCNTR OCCUPATNAL THRPY ***
."
Allergies
EXHIBIT
81
'9
NKDA
!3
6
~

I

PDP Carrier:

C,

w
a.

PDP Plan:
Building: Memorial

Floor:Floor 1

Hall:Hall A

596

Room: Room 01

Bed: Room 01a

:

dAB
POCATELLO CARE &
Resident Diagnosis Listing

Page:
28
Date: 12127/2007
Time: 09:30:27

~~a~m~e~:~J_U_D_Y__N_IE_LD______________~R~M~/~B_E~D__I__~A~D~M~#_1~~______M~.~R~.#~22_3_5_38____~)
ICD9: 682.6

Type: Admission

Date: 08/25/2007

PIS Primary

Date: 08/25/2007

PIS Secondary

Description: CELLULITIS OF LEG
ICD9: 835.00

Type: Admission

Description: DISLOCAT HIP NOS-CLOSED
ICD9:719.7

Type: Admission

Date: 08/25/2007

PIS

Date: 08/25/2007

PIS

Description: DIFFICULTV IN WALKING
ICD9: 250.00

Type: Admission

Description: DIABETES MELLITUS WITHOUT MENTION OF
COMPLICATION,
ICD9: 244.9

Type: Admission

Date: 08/2512007

PIS

Date: 08/2512007

PIS

Resolved: 09/2412007

Date: 08/2512007

PIS

Resolved: 09/1212007

Description: HYPOTHYROIDISM NOS
ICD9: V57.1

Type: Admission

Description: PHYSICAL THERAPY NEC
ICD9: V57.21

Type: Admission

Description: ENCNTR OCCUPATNAL THRPY

/
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~ p \(Q (RegL Ir~:g _) R-llo- SiP..J1ll...J.1.O... Weis;ht 1<i(p H:igh:: .:L~.!l in
""At:encin.;:pr.,/sici3nr,otifiedCfaCr.1issicn:{1Yc5 [[No lir.-,e 1400
Ai\A/PM Data: tl~"()7
;.lIergies (with r=ac~icnl: Mccica,icr,s
Allergies: Focc ___\'...,l""D....N..,....L::..-____________________________
Othar_________________

en

I

-------------------------------------------

Oat: of last

c~cst

x·ray or P?D: _ _, ___,_ _ P.esults fer 18: [ I Positive ( I Ne~a:il/e

Skin Condition: Indicac.; c-eiow all tocy marks such as oCe or recant scars (Surgical am! ether) bruises.
disc%rations. a~rasions. pressure ulcers cr ar.'1 C;l!es:jGr.a~/e r;-;arkin~s. Ir.cica~e si:e. ce:;th (ir.t. Crtis). color and
crair.a~e.

....

.

.

,-..

,C OI7.r.1elits:_

V.::}'

R:C;1I1

(~
\\tf~Jr .~ ,';: ~'
~. ~~

. 1.1 ~
1
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La::
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:Ufl

So~ciar li:atr:-.erits

e. Fr~ce~ur;s:

)je;.~Je4 5RDD ~e $ to O~!{> Q,,~5
o.,:~.-. l.J. l?,wvC \£:5 ~ }P1)1:: -

11
.\::l.. 3,. 5t--'" <\C-'"
7
~ -q
~t.-..,.:;2.0<"'Ger.era~kjn Ccncitjcn: [ l Recccr.ed [J Fale [ I Jaur:ciced ICya;;ctic ( J Ashen [.(Dry [ IMcist [ I
Oily. [-1 Warm f J Cold [ ! Ecema { J Site cfE~er..a
.,
Paraly.sistPar.asis: site: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _--:-_ _ _ _ _ __
Cont.act!1re: site:-:-_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
'1 .
J

Con~e:-jtat

.

r

a:lCmOlieS~.

_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ____:_ _ _ _ _ _ _ _ _ _ _ __

Prcs:hesis: ( I Glasses r I Dentures - Upr:;er { I Dentures - Lower
Other. _ _ _ _ _...;..;~_
Functional Status
Trarysf~rs:. -:: a.ble to ti3r.sfer

r ! Inc~::er.C entty

W=!~ht

r I Hearin; Aice r I

bearing - able to

{ I 1: perscn assis:

[ I Full weight
r I Par:iaf wei~r.t

( ! 2 perscr. assisi

(r(c"01i~wej~ht bearing

c-:;a.

[.{Total assis!

':',:nt·ula:icn -

a::'/~ 10

ar.:bv(a:::

[ llnd=p-enCer.tly
[ I I ;:;.erscn assis.

( I Etas.ic has;

( I 8~d cradle

{. I '....,en d':'/lc::. _ _ _ _ _.

( I Shce;:·sr:in
! I Ha:-.d rells
[ I Siing

( I It'lha;lc:-.air on Iy
( I \."!r.=-=-lch::irlr-·ror.::.I<: s::.ff

'/'Jh~;;

( I:;:

p~;sc:r.

assis:

(4c~-;=s:-'"

~-'- ~.

Tra::icr.: :N'r.i:f::
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crat~

r I Tra~€:;

-----------_______________
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9t~ Y2u!.c!,";,3·pO~/J

[ I Footbcarc
{ I ;.,ir martr~ss

R••d.nts N,meo

JI!.~ Nidd

Admitting Physician:

D~ ~'mmtrf1\4f\

Attending Physician: -1'.D.LC~• ...I.~WQ.D_..u.s
......"_ _ _ __
Primary Diagnosis: 1_)::::U=O=I4i=w::;..'n:....:...·\1...-_ _ _ __
Secondary Diagnosis: 1.) Q't\.ip ch:l>lpadt'o VI ~

®~p PCVO'"'

Admit to:

I~tl~~f'f. O(·~

Skilled

Certificatio

Facility Standing Orders

I certify that post-hospital skilled nursing services

·2 Step PPD Test

are required to be given on an inpatient basis are

• Pneumovax on admission if indicated

required because of the above named patient's

• Annual influenza vaccine

need for skilled nursing care on a continuing basis

• Follow Bowel and Bladder protocol

for the condition(s) for which he/she was receiving

• Follow Skin protocol

inpatient hospital services prior to hislher transfer

• Follow facility protocol 10 discontinue orders for

or discharge to the facIY'

medication or treatments not used in 60 days.
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: ~~~$==!!eJ. DentalNision/Podiatry consults PRN
• Tylenol 325 1-2 tabs every four hours PRN for mild
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Rehab Potential:
Diet:
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Allergies:

Fair ·
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post-op chronic pain: moderate or severe pain use
other pain meds per M.D.
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• May go off premises with Family and/or Staff
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CPR Status: 0 N
I
Labs: _ _ _ _o-;_ _ _ _ _ _ _ _ __
Oxygen at
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Nasal canCa
Dressing Changes:

Associated Diagnosis:
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Mask

Other
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Treatments:
Associated Diagnosis:

Therapy (please check all applicable therapies)

~ PT Eval & Tx
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wt bearing status MW,&

OT Eval & Tx .

o ST Eval & Tx
o

Swallow Evaluation
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